FINLAY
EDICIONES

BOLETÍN VACCIENCIA

No. 2 (16-24 marzo/2020)

VaCyT

SiViFinlay

IFV INSTITUTO FINLAY DE VACUNAS

...vacunar es prevenir.

Análisis bibliométrico: Meningococos

Base de Datos utilizada:

PUBMED/MEDLINE

Estrategia de búsqueda:

"*Meningococcal Vaccines"[Mesh], "Meningococcal Infections"[Mesh] AND "Meningitis, Meningococcal"[Mesh]*

Las variables utilizadas en el análisis fueron:

⇒ Productividad científica por años.

⇒ Autores con mayor productividad científica.

⇒ Revistas con mayor número de publicaciones sobre el tema.

⇒ Países a la vanguardia sobre el tema.

⇒ Términos usados con mayor frecuencia.

EN ESTE NÚMERO




Autores más productivos sobre meningococo
Cantidad de artículos
0 5 10 15 20 25 30 35 40 45 50 55 60
Autores
Borrow, R. 55
Pollard, A. J. 33
Taha, M. K. 23
Caugant, D. A. 22
Preziosi, M. P. 22
Rappuoli, R. 21
LaForce, F. M. 17
Pizza, M. 16
Djingarey, M. H. 14
Granoff, D. M. 14
Trotter, C. L. 14
Findlow, J. 12
Nicolas, P. 12
Findlow, H. 11
Giuliani, M. M. 11
Greenwood, B. 11
Maiden, M. C. 11
Stuart, J. M. 11
Hassan-King, M. 10
Snape, M. D. 10
Vazquez, J. A. 10
Viviani, S. 10


Revistas con mayor número de publicaciones sobre el tema
Cantidad de artículos
0 10 20 30 40 50 60 70 80 90 100
Vaccine
Lancet
Clin Infect Dis
Expert Rev Vaccines
PLoS One
Lancet Infect Dis
Hum Vaccin Immunother
Bmj
Clin Vaccine Immunol
Pediatr Infect Dis J
Wkly Epidemiol Rec
Emerg Infect Dis
Med Trop (Mars)
Hum Vaccin
Infect Immun
Euro Surveill
Science
Revistas


Producción científica por países
Cantidad de artículos
300
250
200
150
100
50
0
253
200
122
83
50
47
41
36
35
30
29
26
23
22
18
17
12
12
11
9
9
Reino Unido
Estados Unidos de América
Italia
Francia
Canadá
España
Burkina Faso
Suiza
Holanda
Noruega
Brasil
China
Nigeria
Australia
Cuba
India
Nueva Zelanda
Alemania
Bélgica
Nigeria
Suecia
Países


Términos con mayor frecuencia de aparición
Términos
methods 101
blood 102
Young Adult 104
Antibodies, Bacterial 106
therapeutic use 107
Disease Outbreaks 124
Adult 125
Female 133
Child, Preschool 170
Adolescent 181
administration & dosage 183
immunology 187
Humans 211
Meningococcal Vaccines 230
240
250
263
263
291
293
302
336
456
504
759
834
866
869
0
100
200
300
400
500
600
700
800
900
1000
Cantidad de artículos en los que aparecen

Noticias en la Web

Gobierno salvadoreño comprará antiviral cubano que fue usado en China para recuperación de pacientes con coronavirus

16 mar. "El Salvador ya está en lista de espera para cuando salga la vacuna desarrollada", aseguró la directora ejecutiva de la DNM Mónica Ayala Guerrero.

El Gobierno salvadoreño informó este lunes que solicitó al embajador de Cuba en el país René Ceballos Prats la compra de tres mil unidades del medicamento Interferón alfa 2-B, un antiviral "que ha sido utilizado en China y ha sido asociado con la recuperación de pacientes enfermos de Covid-19".

Las "gestiones de compra" se están haciendo con BioCubaFarma, un grupo de industrias de biotecnología y farmacéutica en La Habana.

La solicitud se hizo mediante una carta enviada "la semana pasada" por la ministra de Salud Ana Orellana y este lunes se enviará "un nuevo pedido de otras 3,000 unidades".

Cuba reserva suficiente antiviral

Cuba asegura tener reservas de Interferón Alfa 2B -uno de los medicamentos con los que se ha tratado el Covid-19 en China- para cubrir no solo la demanda del país en caso de expandirse el virus, sino también la de parte de la comunidad internacional.

"Estamos recibiendo solicitudes de un grupo grande de países que nos están pidiendo ofertas. Tenemos la capacidad para suministrárselo sin poner en riesgo las cantidades que se requieren para el país", declaró en rueda de prensa este viernes Eduardo Martínez, presidente del grupo estatal de medicamentos BioCubaFarma.

Esta empresa fabrica tanto en Cuba como en China - a través de una empresa mixta- el Interferón Alfa 2B recombinante (IFNrec), un antiviral que combinado con otros fármacos está ayudando a tratar el coronavirus, especialmente en el gigante asiático.

Producido desde enero de este año en la planta chino-cubana ChangHeber de la provincia china de Jilin, el Interferón es uno de los productos estrella de la biotecnología de Cuba y también se usa contra infecciones virales provocadas por el VIH, el virus del papiloma humano y las hepatitis tipos B y C.

Las autoridades de BioCubaFarma especificaron este viernes que 15 países de América Latina, Europa, África y Asia ya han solicitado a Cuba información o suministro de este medicamento.

"ESTAMOS RECIBIENDO SOLICITUDES DE UN GRUPO GRANDE DE PAÍSES QUE NOS ESTÁN PIDIENDO OFERTAS. TENEMOS LA CAPACIDAD PARA SUMINISTRÁRSELO SIN PONER EN RIESGO LAS CANTIDADES QUE SE REQUIEREN PARA EL PAÍS"

Fuente: La Prensa Gráfica. Disponible en: https://bit.ly/3dqUtgV

EEUU prueba la primera vacuna experimental para coronavirus

16 mar. Investigadores de Estados Unidos aplicaron el lunes la primera vacuna experimental contra el coronavirus, colocándose al frente de una carrera mundial mientras se extiende la pandemia.

"Ahora somos el equipo coronavirus", dijo la doctora Lisa Jackson, líder del estudio. "Todos quieren hacer lo que puedan en esta emergencia".

El hito del lunes marcó sólo el inicio de una serie de estudios en personas necesarios para demostrar si las vacunas son seguras y podrían funcionar. Incluso si la investigación es exitosa, la vacuna no estaría disponible para su uso extenso hasta dentro de 12 a 18 meses, dijo el doctor Anthony Fauci de los Institutos Nacionales de la Salud de Estados Unidos (NIH).

No es la única posible vacuna en el horno. Decenas de grupos de investigación en el mundo se apresuran para crear una vacuna contra COVID-19. Se prevé que otro candidato, elaborado por Inovio Pharmaceuticals, comience el próximo mes sus propios estudios de seguridad en Estados Unidos, China y Corea del Sur.

La pandemia del coronavirus ha infectado a más de 169000 personas y matado a más de 6500 en todo el mundo.

Fuente: Chicago Tribune. Disponible en https://bit.ly/3dqDPhs

Falta probar efectividad de Cloroquina para tratar coronavirus: Investigador

21 mar. En entrevista, Omar Carrasco, jefe del Departamento de Farmacología en la Facultad de Medicina de la UNAM, explicó que "falta probar, qué tan efectivo es para tratar esta variedad de coronavirus".

La Cloroquina anunciada por el Presidente Donald Trump para el tratamiento del Covid -19, es un medicamento empleado para la malaria desde hace 70 años.

En entrevista con Yuriria Sierra para Grupo Imagen, Omar Carrasco, jefe del Departamento de Farmacología en la Facultad de Medicina de la UNAM, explicó que del fármaco se conoce su efectividad, la dosis que se debe de utilizar, "pero lo que falta probar es, qué tan efectivo es para tratar esta variedad de coronavirus".

Explicó que el pasado mes de febrero se publicó un trabajo donde se utilizaba en terapia combinada del antiparasitario cloroquina y la hidroxicloroquina acompañado con el antibiótico azitromicina, que se utiliza para el tratamiento de infecciones respiratorias altas.

"Lo que hace falta implementar son protocolos de estudio e investigación en pacientes que tienen la enfermedad y que están expuestos, y observar la tasa de efectividad".

El investigador comentó que desde la Facultad de Medicina de la UNAM el Departamento de Farmacología ha propuesto al sector salud implementar algunos protocolos terapéuticos, definir los escenarios que podrían favorecerse más a los pacientes y probarlas con rigor científica.

Es bien importante que si hay sintomatología acudir al médico, el médico, si la catalogar como leve que se vayan a sus casas medicados bajo supervisión, o si se van a un hospital o requieren de otro tipo de tratamiento" concluyó.

Fuente: Excelsior. Disponible en https://bit.ly/39hTnk6

China prueba en humanos su primer candidato vacunal contra la COVID-19

22 mar. Analistas coinciden en que completar el proceso tomaría al menos un año antes del lanzamiento oficial del producto.

El presidente chino Xi Jinping visita la Academia de Ciencias Médicas, que busca una vacuna contra el coronavirus.

China da otro paso en la búsqueda de una vacuna contra el nuevo coronavirus al conocerse que científicos militares probaron al primer candidato del país en 108 personas sanas de Wuhan, epicentro del brote de la enfermedad.

Reportes de prensa detallan que los voluntarios se dividieron en tres grupos de 36, sus edades oscilan entre los 18 y 60 años de edad, y ahora están bajo observación médica por 14 días.

Pasado ese período, los expertos le darán seguimiento por seis meses a fin de identificar posibles reacciones adversas.

Se trata de una vacuna recombinante desarrollada por un equipo médico del Ejército Popular de Liberación comandado por la principal experta en bioguerra del país, Chen Wei, y se aplicó a esos individuos tras recibir aprobación del Gobierno el lunes pasado para el ensayo en humanos.

China dio luz verde al proceso 19 horas después que Estados Unidos anunció que administraría a un grupo de ciudadanos el mRNA-1273, su propio candidato de inyección contra la Covid-19.

El medicamento del gigante asiático se obtuvo sobre la base del proceso seguido para crear el del ébola y, según los creadores, cumple con las leyes nacionales, estándares internacionales y saldrá pronto al mercado si resulta exitosa.

Según la prensa local, a diferencia de otras pruebas clínicas los voluntarios no requirieron infectarse con el nuevo coronavirus que provoca la Covid-19 y los investigadores buscarán determinar si la sustancia produce anticuerpos y los vuelve inmune a la afección respiratoria.

Analistas coinciden en que completar el proceso tomará al menos un año antes del lanzamiento oficial del producto.

Aunque científicos dentro y fuera de China trabajan a contrarreloj en múltiples proyectos para obtener una inyección efectiva contra la enfermedad, la Organización Mundial de la Salud indicó que demoraría unos 18 meses en ver la luz alguna realmente efectiva y segura porque el patógeno es nuevo.

"...A DIFERENCIA DE OTRAS PRUEBAS CLÍNICAS LOS VOLUNTARIOS NO REQUIRIERON INFECTARSE CON EL NUEVO CORONAVIRUS QUE PROVOCA LA COVID-19."

Fuente: Juventud Rebelde. Disponible en https://bit.ly/33TnhKN

CIGB trabaja en diseño de vacuna contra el coronavirus SARSCoV-2

23 mar. Científicos del Centro de Ingeniería Genética y Biotecnología cuentan con un diseño de vacuna que pudiera utilizarse contra el nuevo coronavirus Sars-CoV-2 causante de la COVID-19.

El Centro de Ingeniería Genética y Biotecnología (CIGB) de Cuba cuenta este jueves con un diseño de vacuna que pudiera utilizarse contra el nuevo coronavirus Sars-CoV-2 causante de la COVID-19.

El director de investigaciones biomédicas del CIGB, Gerardo Guillén, dijo que actualmente se trabaja en la parte metodológica y de diseño del medicamento.

La ventaja de esta vacuna, radica en que se utiliza la plataforma que tiene desarrollada el CIGB, donde trabajamos con partículas semejantes a virus con gran capacidad de estimular el sistema inmune, subrayó el investigador cubano.

Otra plataforma, precisó Guillén, es por inmunización a través de la vía nasal, tiendo en cuenta que Cuba tiene experiencia pues cuenta con una vacuna ya registrada.

Agregó que al ser la COVID-19 una enfermedad que tiene entre las vías de transmisión la nariz, la referida plataforma posee ventajas para el desarrollo de un medicamento contra el nuevo coronavirus.

El científico detalló sobre la propuesta a las autoridades de China para realizar la vacuna en conjunto con el centro de investigación y desarrollo mixto, ubicado en el gigante asiático.

Dicho centro se ubica en la ciudad de Yongzhou, provincia Hunan, y según Guillén, a raíz de la pandemia, la institución tiene experiencia en el trabajo con el nuevo virus, además de contar con laboratorios de alto nivel de contención.

El investigador cubano también se refirió al nivel de mutaciones del nuevo coronavirus. En tal sentido, comentó que al mutar, la virulencia puede aumentar o disminuir.

De igual modo destacó la influencia de las etnias, en la que diferentes grupos pueden reaccionar distintos a la enfermedad y a tratamientos.

Las altas temperaturas climáticas no eliminan el virus

Sobre las especulaciones referidas a cómo el calor puede disminuir la trasmisión de la infección, el también miembro de la Academia de Ciencias de Cuba, dijo que si bien algunas publicaciones afirman que las altas temperaturas afectan al virus, eso no significa que se elimine.

Hay que hablar con rigor científico, y no se pude especular diciendo que el clima va evitar el contagio de la enfermedad, sentenció el especialista.

Por tal motivo reiteró la importancia de la contribución de la población y observar las medidas de vigilancia y aislamiento para contener la transmisión de la COVID-19.

"...La ventaja de esta vacuna, radica en que se utiliza la plataforma que tiene desarrollada el CIGB, donde trabajamos con partículas semejantes a virus con gran capacidad de estimular el sistema inmune."

Fuente: Extranet CIGB. Disponible en https://bit.ly/2WCBs5b

VaCyT SiViFinlay IFV INSTITUTO FINLAY DE VACUNAS

Nuevo compuesto químico bloquea la capacidad de replicación del coronavirus

23 mar. Los científicos han mejorado las alfa-cetoamidas, que interrumpen la actividad de la proteasa principal del virus SARS-CoV-2. Para esto, la estructura cristalina de la proteína viral y su complejo fueron obtenidos con el inhibidor. Las inhalaciones de alfa-cetoamidas no causaron efectos secundarios y se puede desarrollar una cura para el nuevo virus en base a estas sustancias. El artículo fue publicado en Science.

Contexto

El SARS-CoV-2 es similar al coronavirus causante del primer SARS, que causó la epidemia en 2003. Ni durante el brote ni después de él, se realizó un ensayo clínico con un medicamento que destruiría el virus, y en 2020, la humanidad volvió a enfrentar la necesidad de proponer un tratamiento.

Para crear una sustancia que suprima la actividad del virus, es necesario determinar el objetivo: la molécula y su parte, que el medicamento podría atacar. La proteasa principal está bien estudiada en los coronavirus: esta proteína divide largas cadenas de aminoácidos en piezas más cortas, de las cuales se obtienen proteínas virales.

Si la proteasa principal está bloqueada, el virus no podrá producir nuevas proteínas y, por lo tanto, multiplicarse. Las propias proteasas humanas cortan otras secuencias de aminoácidos, por lo que un inhibidor de proteínas virales no interferirá con su trabajo y el medicamento no será tóxico.



Las nuevas pruebas

En febrero de 2020, un grupo de científicos creó una serie de alfa-cetoamidas que inhibían las principales proteasas de los coronavirus de diversos géneros. Ahora, científicos de Alemania y China, liderados por Linlin Zhang de la Universidad de Lübeck, han aumentado la viabilidad de estas moléculas en las células humanas.

Para esto, cambiaron la estructura de la sustancia moviendo partes importantes de la molécula a una posición en la que serán inaccesibles para las proteasas celulares y aumentando la solubilidad de las cetoamidas.

Luego, los investigadores determinaron la estructura cristalina tridimensional de la proteasa principal de SARS-CoV2 para probar si la nueva alfa-cetoamida es espacialmente compatible con su objetivo. La molécula se modificó para que la inhibición específica de los coronavirus del SARS se maximizara con la vida útil más larga de la sustancia en la célula.



Estructura óptima alfa-cetoamida

Fuente: N + 1. Disponible en https://bit.ly/2wo3d6V

Potencial vacuna contra el COVID-19 será desarrollada por Pfizer y BioNTech

23 mar. Las empresas Pfizer y BioNTech anunciaron el pasado 17 de marzo que han acordado una carta de intención en relación con el desarrollo conjunto y la distribución (excluida China) de una posible vacuna contra el coronavirus, basada en ARNm (ácido ribonucleico), con el objetivo de prevenir la infección por COVID-19.

Las compañías han ejecutado un Acuerdo de Transferencia de Materiales y Colaboración para que las partes comiencen a trabajar juntas de inmediato.

"La alianza apunta a acelerar el desarrollo del potencial programa de vacuna de ARNm COVID-19 de BioNTech, el primero en su clase, BNT162, que se espera que sea sometido a pruebas clínicas a finales de abril de 2020", dice Pfizer en un comunicado.

"Estamos orgullosos de que nuestra relación continua y exitosa con BioNTech lebrinde a nuestras compañías la capacidad de movilizar nuestros recursos colectivos con una velocidad extraordinaria frente a este desafío mundial", expresa

Mikael Dolsten, presidente de investigación de Pfizer.

En cambio, Ugur Sahin, cofundador y CEO de BioNTech, señala que"es una pandemia global, que requiere una iniciativa global. Al unir fuerzas con nuestro socio Pfizer, creemos que podemos acelerar nuestros esfuerzos para llevar una vacuna COVID-19 a las personas de todo el mundo que la necesitan".

Las empresas esperan utilizar múltiples sitios de investigación y desarrollo de ambas compañías, incluso en Estados Unidos y Alemania.

El 13 de marzo de 2020, Pfizer emitió un plan de cinco puntos en el cual solicitaba a la industria biofarmacéutica que se uniera a la compañía para comprometerse a una colaboración sin precedentes para combatir el COVID-19.

> **"LA ALIANZA APUNTA A ACELERAR EL DESARROLLO DEL POTENCIAL PROGRAMA DE VACUNA DE ARNM COVID-19 DE BIONTECH, EL PRIMERO EN SU CLASE, BNT162, QUE SE ESPERA QUE SEA SOMETIDO A PRUEBAS CLÍNICAS A FINALES DE ABRIL DE 2020"**

Fuente: El Universo. Disponible en https://bit.ly/2WDTt2S



...vacunar es prevenir.

Francia realiza primeras pruebas clínicas de una vacuna contra el nuevo coronavirus

24 mar. Un grupo de investigadores franceses ha anunciado los resultados exitosos de las primeras pruebas clínicas de una vacuna contra el coronavirus SARS-CoV-2, que ha causado una pandemia que afecta a decenas de países.

Los especialistas del hospital universitario Méditerranée Infection, en Marsella, plantean que el nuevo coronavirus podría curarse con una combinación de dos medicamentos existentes: la antimalárica hidroxicloroquina y el antibiótico de amplio espectro azitromicina.

Estos fármacos fueron administrados conjuntamente y por separado a un grupo de pacientes en un experimento que involucró a 36 personas con COVID-19, aunque parte de ellas no mostraban síntomas.

De esas 36 personas, 16 formaron el grupo de control al que no se le suministraron las sustancias mencionadas, mientras que los restantes 20 pacientes recibieron 200 mg de sulfato de hidroxicloroquina tres veces al día. Seis de ellos también tomaron 500 mg de azitromicina al día los primeros dos días y 250 mg los siguientes cuatro.

Los seis integrantes de este último grupo resistieron bien la combinación de los dos medicamentos, dando negativo en la prueba de coronavirus ya el quinto día, mientras que aquellos que tomaron solo hidroxicloroquina mostraron un nivel de recuperación del 50% en el quinto día, frente al 18,8% del grupo de control.

Curiosamente, una paciente que siguió dando positivo tras ser tratada solo con hidroxicloroquina, a partir del octavo día se le suministró azitromicina y el día siguiente dio negativo.

En su informe publicado en International Journal of Antimicrobial Agents, los investigadores califican los resultados de “prometedores”, aunque admiten el limitado número de los participantes del estudio y la necesidad de continuar las pruebas clínicas.

"...Los especialistas plantean que el nuevo coronavirus podría curarse con una combinación de dos medicamentos existentes: la antimalárica hidroxicloroquina y el antibiótico de amplio espectro azitromicina."

Fuente: Cubadebate. Disponible en https://bit.ly/2WMAweJ

FINLAY EDICIONES

VACCI MONITOR

VacciMonitor es una revista con más de 25 años de difundir los resultados científicos sobre vacunas de instituciones nacionales e internacionales y así coadyuvar a la visibilidad de este sector de la ciencia en Cuba y otros países, principalmente de Hispanoamérica. **http://vaccimonitor.finlay.edu.cu**

Está dedicada a la Vacunología y se incluyen temáticas de Inmunología, Adyuvantes, Infectología, Microbiología, Epidemiología, Programas de Vacunaciones, Estudios Preclínicos y Clínicos, Biología molecular, Bioinformática, Biomodelos Experimentales, Inmunodiagnosticadores, Tecnologías de Producción, Validación, Aseguramiento de la Calidad y Aspectos regulatorios.

Arbitrada, de acceso abierto y bajo la Licencia Creative Commons está indexada en:

EBSCO Information Services

Scopus

DOAJ DIRECTORY OF OPEN ACCESS JOURNALS

SciELO

redalyc.org

WEB OF SCIENCE™

HINARI Research in Health

latindex Sistema Regional de Información en Línea para Revistas Científicas de América Latina, el Caribe, España y Portugal

SeCiMed

Artículos científicos publicados en Medline

Filters activated: Publication date from 2020/03/16 to 2020/03/24. Keyword “Vaccine”.

Preparation for Possible Sustained Transmission of 2019 Novel Coronavirus: Lessons From Previous Epidemics.

Swerdlow DL, Finelli L.

JAMA. 2020 Mar 24;323(12):1129-1130. doi: 10.1001/jama.2020.1960. No abstract available.

PMID: 32207807

Leading HIV **Vaccine** Trial Stopped for Ineffectiveness.

Slomski A.

JAMA. 2020 Mar 24;323(12):1124. doi: 10.1001/jama.2020.2813. No abstract available.

PMID: 32207795

Antenatal **vaccine** uptake: A cross-sectional study investigating factors influencing women's choices in pregnancy.

Moir D, Gunter K, Lynch LA, Vogrin S, Said J.

Aust N Z J Obstet Gynaecol. 2020 Mar 23. doi: 10.1111/ajo.13146. [Epub ahead of print]

PMID: 32207153

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.

Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, Niu G, Su T, Zhu G, Lu G, Zhang L, Chen X.

Sci Adv. 2020 Mar 18;6(12):eaaw6071. doi: 10.1126/sciadv.aaw6071. eCollection 2020 Mar.

PMID: 32206706

H7N9 Influenza Virus in China.

Li C, Chen H.

Cold Spring Harb Perspect Med. 2020 Mar 23. pii: a038349. doi: 10.1101/cshperspect.a038349. [Epub ahead of print]

PMID: 32205415

T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy.

Smith S, Honegger JR, Walker C.

Cold Spring Harb Perspect Med. 2020 Mar 23. pii: a036954. doi: 10.1101/cshperspect.a036954. [Epub ahead of print]

PMID: 32205413

Updated approaches against SARS-CoV-2.

Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J.

Antimicrob Agents Chemother. 2020 Mar 23. pii: AAC.00483-20. doi: 10.1128/AAC.00483-20. [Epub ahead of print] Review.

PMID: 32205349

Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication.

Zhao Y, Yan K, Wang Y, Cai J, Wei L, Li S, Xu W, Li M.

Microb Pathog. 2020 Mar 20:104169. doi: 10.1016/j.micpath.2020.104169. [Epub ahead of print]

PMID: 32205210

Genetic signatures of the immune-escaping type 2 porcine reproductive and respiratory syndrome virus in farms with a robust vaccination program.

Saenglub W, Jantafong T, Mungkundar C, Romlamduan N, Pinitkiatisakul S, Lekcharoensuk P.

Microb Pathog. 2020 Mar 20:104166. doi: 10.1016/j.micpath.2020.104166. [Epub ahead of print]

PMID: 32205207

Epitope-based **vaccine** design: a comprehensive overview of bioinformatics approaches.

Parvizpour S, Pourseif MM, Razmara J, Rafi MA, Omidi Y.

Drug Discov Today. 2020 Mar 20. pii: S1359-6446(20)30113-6. doi: 10.1016/j.drudis.2020.03.006. [Epub ahead of print]

PMID: 32205198

IPVS statement on "Temporary HPV **vaccine** shortage: Implications globally to achieve equity".

Garland SM, Stanley M, Giuliano AR, Moscicki AB, Kaufmann A, Bhatla N, Woo YL; IPVS Policy Committee.

Papillomavirus Res. 2020 Mar 20:100195. doi: 10.1016/j.pvr.2020.100195. [Epub ahead of print] No abstract available.

PMID: 32205196

Virus isolation and full-length genome sequencing of a representative Canine Distemper Virus wild type strain of the South America 2 clade.

Romanutti C, Keller L, La Torre J, Panzera Y, Fuques E, Pérez R, Gallo CM.

J Virol Methods. 2020 Mar 20:113857. doi: 10.1016/j.jviromet.2020.113857. [Epub ahead of print]

PMID: 32205180

A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus.

Balelli I, Pasin C, Prague M, Crauste F, Effelterre TV, Bockstal V, Solforosi L, Thiébaut R.

J Theor Biol. 2020 Mar 20:110254. doi: 10.1016/j.jtbi.2020.110254. [Epub ahead of print]

PMID: 32205143

Immunologic Dysfunction Contributes to the Otitis Prone Condition.

Pichichero ME.

J Infect. 2020 Mar 20. pii: S0163-4453(20)30147-X. doi: 10.1016/j.jinf.2020.03.017. [Epub ahead of print]

PMID: 32205139

Dendritic cell therapy in cancer treatment; the state-of-the-art.

Sadeghzadeh M, Bornehdeli S, Mohahammadrezakhani H, Abolghasemi M, Poursaei E, Asadi M, Zafari V, Aghebati-Maleki L, Shanehbandi D.

Life Sci. 2020 Mar 20:117580. doi: 10.1016/j.lfs.2020.117580. [Epub ahead of print] Review.

PMID: 32205087

Assessment of the long-term efficacy of a dengue **vaccine** against symptomatic, virologically-confirmed dengue disease by baseline dengue serostatus.

Dayan GH, Langevin E, Gilbert PB, Wu Y, Moodie Z, Forrat R, Price B, Frago C, Bouckenooghe A, Cortes M, Noriega F, DiazGranados CA.

Vaccine. 2020 Mar 20. pii: S0264-410X(20)30384-4. doi: 10.1016/j.**vaccine**.2020.03.029. [Epub ahead of print]

PMID: 32204943

Molecular characterization of Latin American invasive Streptococcus pneumoniae serotype 19A isolates.

Moreno J, Duarte C, Cassiolato AP, Chacón GC, Alarcon P, Sánchez J, Martín YNS, Valenzuela C, Castillo W, Gabarrot GG; SIREVA II Group.

Vaccine. 2020 Mar 20. pii: S0264-410X(20)30385-6. doi: 10.1016/j.**vaccine**.2020.03.030. [Epub ahead of print]

PMID: 32204942

Impact of media reports regarding influenza **vaccine** on obstetricians' vaccination practices.

O'Leary ST, Cataldi JR, Lindley MC, Hurley LP, Riley LE, Brtnikova M, Crane LA, Beaty B, Stokley S, Fisher A, Kempe A.

Vaccine. 2020 Mar 21. pii: S0264-410X(20)30263-2. doi: 10.1016/j.**vaccine**.2020.02.051. [Epub ahead of print]

PMID: 32204941

Impact of a 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, 2011-2017.

Suo L, Lu L, Zhao D, Pang X.

Vaccine. 2020 Mar 20. pii: S0264-410X(20)30140-7. doi: 10.1016/j.**vaccine**.2020.01.087. [Epub ahead of print]

PMID: 32204940

Bovine immune response to leptospira antigen in different novel adjuvants and **vaccine** delivery platforms.

Wilson-Welder JH, Boggiatto P, Nally JE, Wafa EI, Alt DP, Hornsby RL, Frank A, Jones DE, Olsen SC, Bowden NB, Salem AK.

Vaccine. 2020 Mar 20. pii: S0264-410X(20)30333-9. doi: 10.1016/j.**vaccine**.2020.02.086. [Epub ahead of print]

PMID: 32204939

Determinants of geographical inequalities for DTP3 **vaccine** coverage in sub-Saharan Africa.

Ikilezi G, Augusto OJ, Sbarra A, Sherr K, Dieleman JL, Lim SS.

Vaccine. 2020 Mar 20. pii: S0264-410X(20)30338-8. doi: 10.1016/j.**vaccine**.2020.03.005. [Epub ahead of print]

PMID: 32204938

Rejuvenating conventional dendritic cells and T follicular helper cell formation after vaccination.

Stebegg M, Bignon A, Hill DL, Silva-Cayetano A, Krueger C, Vanderleyden I, Innocentin S, Boon L, Wang J, Zand MS, Dooley J, Clark J, Liston A, Carr E, Linterman MA.

Elife. 2020 Mar 24;9. pii: e52473. doi: 10.7554/eLife.52473.

PMID: 32204792

The Effects of Glucosylation and O-Acetylation on the Conformation of *Shigella Flexneri* Serogroup 2 O-Antigen **Vaccine** Targets.

Hlozek J, Ravenscroft N, Kuttel MM.

J Phys Chem B. 2020 Mar 23. doi: 10.1021/acs.jpcb.0c01595. [Epub ahead of print]

PMID: 32204588

Mosquito Cell-Derived Japanese Encephalitis Virus-Like Particles Induce Specific Humoral and Cellular Immune Responses in Mice.

Chang YH, Chiao DJ, Hsu YL, Lin CC, Wu HL, Shu PY, Chang SF, Chang JH, Kuo SC.

Viruses. 2020 Mar 19;12(3). pii: E336. doi: 10.3390/v12030336.

PMID: 32204533

Commensal *Neisseria* Are Shared between Sexual Partners: Implications for Gonococcal and Meningococcal Antimicrobial Resistance.

Van Dijck C, Laumen JGE, Manoharan-Basil SS, Kenyon C.

Pathogens. 2020 Mar 19;9(3). pii: E228. doi: 10.3390/pathogens9030228.

PMID: 32204480

Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-ω Proteins.

Wang X, Li F, Han M, Jia S, Wang L, Qiao X, Jiang Y, Cui W, Tang L, Li Y, Xu YG.

Viruses. 2020 Mar 19;12(3). pii: E335. doi: 10.3390/v12030335.

PMID: 32204464

Stability of the HSV-2 *US-6* Gene in the del II, del III, *CP77*, and *I8R-G1L* Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells.

Atukorale VN, Weir JP, Meseda CA.

Vaccines (Basel). 2020 Mar 19;8(1). pii: E137. doi: 10.3390/vaccines8010137.

PMID: 32204367

Vaccination Perception and Attitude among Undergraduate Medical and Teacher Education Students at Charles University, Prague, Czech Republic.

Šálek J, Čelko AM, Dáňová J.

Vaccines (Basel). 2020 Mar 19;8(1). pii: E136. doi: 10.3390/vaccines8010136.

PMID: 32204313

Intratumoral Gene Electrotransfer of Plasmid DNA Encoding shRNA against Melanoma Cell Adhesion Molecule Radiosensitizes Tumors by Antivascular Effects and Activation of an Immune Response.

Kranjc Brezar S, Mrak V, Bosnjak M, Savarin M, Sersa G, Cemazar M.

Vaccines (Basel). 2020 Mar 19;8(1). pii: E135. doi: 10.3390/vaccines8010135.

PMID: 32204304

Association between Bacillus Calmette-Guerin (BCG) vaccination and lymphoma risk: A systematic review and meta-analysis.

Salmon C, Conus F, Parent MÉ, Benedetti A, Rousseau MC.

Cancer Epidemiol. 2020 Mar 20;65:101696. doi: 10.1016/j.canep.2020.101696. [Epub ahead of print] Review.

PMID: 32203929

Lipophosphoglycan-3 recombinant protein **vaccine** controls hepatic parasitism and prevents tissue damage in mice infected by Leishmania infantum chagasi.

Bastos DSS, Miranda BM, Fialho Martins TV, Guimarães Ervilha LO, Souza ACF, de Oliveira Emerick S, Carneiro da Silva A, Novaes RD, Neves MM, Santos EC, de Oliveira LL, Marques-da-Silva EA.

Biomed Pharmacother. 2020 Mar 20;126:110097. doi: 10.1016/j.biopha.2020.110097. [Epub ahead of print]

PMID: 32203891

Respiratory syncytial virus treatment and the respiratory microbiome.

Mejias A, Ramilo O.

Lancet Respir Med. 2020 Mar 20. pii: S2213-2600(20)30106-5. doi: 10.1016/S2213-2600(20)30106-5. [Epub ahead of print] No abstract available.

PMID: 32203713

Rational use of face masks in the COVID-19 pandemic.

Feng S, Shen C, Xia N, Song W, Fan M, Cowling BJ.

Lancet Respir Med. 2020 Mar 20. pii: S2213-2600(20)30134-X. doi: 10.1016/S2213-2600(20)30134-X. [Epub ahead of print] No abstract available.

PMID: 32203710

In silico design of a T-cell epitope **vaccine** candidate for parasitic helminth infection.

Zawawi A, Forman R, Smith H, Mair I, Jibril M, Albaqshi MH, Brass A, Derrick JP, Else KJ.

PLoS Pathog. 2020 Mar 23;16(3):e1008243. doi: 10.1371/journal.ppat.1008243. [Epub ahead of print]

PMID: 32203551

Contribution of Leishmania braziliensis antigen-specific CD4+ T, CD8+ T, NK and CD3+CD56+NKT cells in the immunopathogenesis of cutaneous leishmaniasis patients: Cytotoxic, activation and exhaustion profiles.

Cunha CF, Ferraz-Nogueira R, Costa VFA, Pimentel MIF, Chometon TQ, Lyra MR, Schubach AO, Da-Cruz AM, Bertho AL.

PLoS One. 2020 Mar 23;15(3):e0229400. doi: 10.1371/journal.pone.0229400. eCollection 2020.

PMID: 32203546

Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.

Setiawan D, Andrijono, Hadinegoro SR, Meyta H, Sitohang RV, Tandy G, Perwitasari DA, Postma MJ.

PLoS One. 2020 Mar 23;15(3):e0230359. doi: 10.1371/journal.pone.0230359. eCollection 2020.

PMID: 32203527

Comparison of anti-Vi IgG responses between two clinical studies of typhoid Vi conjugate **vaccines** (Vi-DT vs Vi-TT).

Lee EY, Park JY, Kim DR, Song M, Sahastrabuddhe S, Kim H, Chon Y, Yang JS.

PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008171. doi: 10.1371/journal.pntd.0008171. [Epub ahead of print]

PMID: 32203521

Leptospira interrogans and Leptospira kirschneri are the dominant Leptospira species causing human leptospirosis in Central Malaysia.

Philip N, Bahtiar Affendy N, Ramli SNA, Arif M, Raja P, Nagandran E, Renganathan P, Taib NM, Masri SN, Yuhana MY, Than LTL, Seganathirajah M, Goarant C, Goris MGA, Sekawi Z, Neela VK.

PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0008197. doi: 10.1371/journal.pntd.0008197. [Epub ahead of print]

PMID: 32203511

Inhibition of Invasive Salmonella by Orally Administered IgA and IgG Monoclonal Antibodies.

Richards AF, Doering JE, Lozito SA, Varrone JJ, Willsey GG, Pauly M, Whaley K, Zeitlin L, Mantis NJ.

PLoS Negl Trop Dis. 2020 Mar 23;14(3):e0007803. doi: 10.1371/journal.pntd.0007803. [Epub ahead of print]

PMID: 32203503

Coronavirus **vaccines**: five key questions as trials begin.

Callaway E.

Nature. 2020 Mar 18. doi: 10.1038/d41586-020-00798-8. [Epub ahead of print] No abstract available.

PMID: 32203367

An imperfect **vaccine** reduces pathogen virulence.

York A.

Nat Rev Microbiol. 2020 Mar 17. doi: 10.1038/s41579-020-0358-3. [Epub ahead of print] No abstract available.

PMID: 32203298

The function and clinical application of extracellular vesicles in innate immune regulation.

Zhou X, Xie F, Wang L, Zhang L, Zhang S, Fang M, Zhou F.

Cell Mol Immunol. 2020 Mar 19. doi: 10.1038/s41423-020-0391-1. [Epub ahead of print]

PMID: 32203193

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and **vaccine**.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L.

Cell Mol Immunol. 2020 Mar 19. doi: 10.1038/s41423-020-0400-4. [Epub ahead of print]

PMID: 32203189

Host receptors: the key to establishing cells with broad viral tropism for **vaccine** production.

Dai X, Zhang X, Ostrikov K, Abrahamyan L.

Crit Rev Microbiol. 2020 Mar 23:1-22. doi: 10.1080/1040841X.2020.1735992. [Epub ahead of print]

PMID: 32202955

Innovation in AMR - the CARB-X Perspective.

Alm R, Gallant K.

ACS Infect Dis. 2020 Mar 23. doi: 10.1021/acsinfecdis.0c00026. [Epub ahead of print]

PMID: 32202756

Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.

Bonate PL, Van Sant C, Cho K, Zook EC, Smith LR, Boutsaboualoy S, Ye M, Wang X, Wu R, Koester A, Rammelsberg D, Goldwater R, Marbury TC.

Clin Pharmacol Drug Dev. 2020 Mar 23. doi: 10.1002/cpdd.792. [Epub ahead of print]

PMID: 32202705

Barriers and facilitators to seasonal influenza vaccination uptake among nurses: A mixed methods study.

Flanagan P, Dowling M, Gethin G.

J Adv Nurs. 2020 Mar 23. doi: 10.1111/jan.14360. [Epub ahead of print]

PMID: 32202315

Superior adjuvanticity of the genetically fused D1 domain of Neisseria meningitides Ag473 lipoprotein among three Toll-like receptor ligands.

Lu H, Zhang X, Wang Y, Zong Y, Wang Y, Zhang X, Xia X, Sun H.

Biosci Rep. 2020 Mar 23. pii: BSR20193675. doi: 10.1042/BSR20193675. [Epub ahead of print]

PMID: 32202301

Evaluation of the immune response of a H7N9 candidate **vaccine** virus derived from the fifth wave A/Guangdong/17SF003/2016.

Dong J, Chen P, Wang Y, Lv Y, Xiao J, Li Q, Li Z, Zhang B, Niu X, Li C, Pan W, Chen L.

Antiviral Res. 2020 Mar 19:104776. doi: 10.1016/j.antiviral.2020.104776. [Epub ahead of print]

PMID: 32201204

Molecular Characterization of Human Lung and Liver Cystic Echinococcus Isolates in Van Province, Turkey.

Beyhan YE, Çobanoğlu U, Çelik S, Yılmaz H, Halidi AG.

Acta Trop. 2020 Mar 19:105451. doi: 10.1016/j.actatropica.2020.105451. [Epub ahead of print]

PMID: 32201196

HPV infections among young MSM visiting sexual health centers in the Netherlands: Opportunities for targeted HPV vaccination.

Woestenberg PJ, van Benthem BHB, Bogaards JA, King AJ, van der Klis FRM, Pasmans H, Leussink S, van der Sande MAB, Hoebe CJPA; Medical Microbiological Laboratories, the Public Health Services.

Vaccine. 2020 Mar 19. pii: S0264-410X(20)30330-3. doi: 10.1016/j.**vaccine**.2020.03.002. [Epub ahead of print]

PMID: 32201140

Corrigendum to "Impact of the pediatric 13-valent pneumococcal conjugate **vaccine** on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal **Vaccine** Effectiveness Study (J-PAVE)" [**Vaccine** 37 (2019) 2687-2693].

Sando E, Suzuki M, Furumoto A, Asoh N, Yaegashi M, Aoshima M, Ishida M, Hamaguchi S, Otsuka Y, Morimoto K.

Vaccine. 2020 Mar 19. pii: S0264-410X(20)30397-2. doi: 10.1016/j.**vaccine**.2020.03.031. [Epub ahead of print] No abstract available.

PMID: 32201139

Adverse events following immunization with typhoid conjugate **vaccine** in an outbreak setting in Hyderabad, Pakistan.

Qamar FN, Yousafzai MT, Khaliq A, Karim S, Memon H, Junejo A, Baig I, Rahman N, Bhurgry S, Afroz H, Sami U.

Vaccine. 2020 Mar 19. pii: S0264-410X(20)30383-2. doi: 10.1016/j.**vaccine**.2020.03.028. [Epub ahead of print]

PMID: 32201138

Shaping humoral immunity to **vaccines** through antigen-displaying nanoparticles.

Irvine DJ, Read BJ.

Curr Opin Immunol. 2020 Mar 19;65:1-6. doi: 10.1016/j.coi.2020.01.007. [Epub ahead of print] Review.

PMID: 32200132

Tetanus, diphtheria and acellular pertussis (Tdap) **vaccine** for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis.

Cho BH, Acosta AM, Leidner AJ, Faulkner AE, Zhou FJ.

Prev Med. 2020 Mar 18:106066. doi: 10.1016/j.ypmed.2020.106066. [Epub ahead of print]

PMID: 32199910

An Immunocompromised Woman with a Brain Lesion.

Hauser N, Luethy PM, Rapaka RR.

Am J Med. 2020 Mar 18. pii: S0002-9343(20)30206-0. doi: 10.1016/j.amjmed.2020.02.021. [Epub ahead of print] No abstract available.

PMID: 32199814

Low rates of influenza vaccination uptake among healthcare workers: Distinguishing barriers between occupational groups.

Durovic A, Widmer AF, Dangel M, Ulrich A, Battegay M, Tschudin-Sutter S.

Am J Infect Control. 2020 Mar 18. pii: S0196-6553(20)30097-3. doi: 10.1016/j.ajic.2020.02.004. [Epub ahead of print]

PMID: 32199740

Tailored Messages Addressing Human Papillomavirus Vaccination Concerns Improves Behavioral Intent Among Mothers: A Randomized Controlled Trial.

Panozzo CA, Head KJ, Kornides ML, Feemster KA, Zimet GD.

J Adolesc Health. 2020 Mar 18. pii: S1054-139X(20)30052-5. doi: 10.1016/j.jadohealth.2020.01.024. [Epub ahead of print]

PMID: 32199723

Characterization of invasive Neisseria meningitidis isolates recovered from children in Turkey during a period of increased serogroup B disease, 2013-2017.

Ceyhan M, Ozsurekci Y, Lucidarme J, Borrow R; Meningitis Surveillance Group.

Vaccine. 2020 Mar 18. pii: S0264-410X(20)30377-7. doi: 10.1016/j.**vaccine**.2020.03.024. [Epub ahead of print]

PMID: 32199701

Effectiveness Analysis of the Immunization Against Hepatitis B in Liver Transplantation Patients.

Rodrigues IC, Ferreira da Silva R, de Cássia Martins Alves da Silva R, Camarero de Felício HC.

Transplant Proc. 2020 Mar 18. pii: S0041-1345(19)31413-7. doi: 10.1016/j.transproceed.2019.12.053. [Epub ahead of print]

PMID: 32199649

Chimpanzee adenovirus type 3 vectored Ebola **vaccine**: expanding the field.

Bavari S, Iversen PL.

Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30065-7. doi: 10.1016/S1473-3099(20)30065-7. [Epub ahead of print] No abstract available.

PMID: 32199495

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola **vaccine** in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

Tapia MD, Sow SO, Mbaye KD, Thiongane A, Ndiaye BP, Ndour CT, Mboup S, Keshinro B, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Gobert P, Hogrefe WR, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group.

Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30019-0. doi: 10.1016/S1473-3099(20)30019-0. [Epub ahead of print]

PMID: 32199492

Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola **vaccine** in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.

Tapia MD, Sow SO, Ndiaye BP, Mbaye KD, Thiongane A, Ndour CT, Mboup S, Ake JA, Keshinro B, Akintunde GA, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Hogrefe WR, Günther S,

Naficy A, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F; Zaire EBola Research Alliance group.

Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30016-5. doi: 10.1016/S1473-3099(20)30016-5. [Epub ahead of print]

PMID: 32199491

Profiling inflammatory response in lesions of cutaneous leishmaniasis patients using a non-invasive sampling method combined with a high-throughput protein detection assay.

Taslimi Y, Agbajogu C, Brynjolfsson SF, Masoudzadeh N, Mashayekhi V, Gharibzadeh S, Östensson M, Nakka SS, Mizbani A, Rafati S, Harandi AM.

Cytokine. 2020 Mar 17;130:155056. doi: 10.1016/j.cyto.2020.155056. [Epub ahead of print]

PMID: 32199248

Enhanced efficacy of a multi-epitope **vaccine** for type A and O foot-and-mouth disease virus by fusing multiple epitopes with Mycobacterium tuberculosis heparin-binding hemagglutinin (HBHA), a novel TLR4 agonist.

Lei Y, Shao J, Ma F, Lei C, Chang H, Zhang Y.

Mol Immunol. 2020 Mar 18;121:118-126. doi: 10.1016/j.molimm.2020.02.018. [Epub ahead of print]

PMID: 32199211

Identification of novel HLA-A0201-restricted T-cell epitopes against thyroid antigens in autoimmune thyroid diseases.

Cai Y, Xu X, Zhang Z, Wang P, Hu Q, Jin Y, Wang Z, Liu X, Yang T.

Endocrine. 2020 Mar 20. doi: 10.1007/s12020-020-02264-x. [Epub ahead of print]

PMID: 32198668

Variability in the Management of Adults with Pulmonary Nontuberculous Mycobacterial Disease.

Abate G, Stapleton JT, Rouphael N, Creech B, Stout JE, El Sahly HM, Jackson L, Leyva FJ, Tomashek KM, Tibbals M, Watson N, Miller A, Charbek E, Siegner J, Sokol-Anderson M, Nayak R, Dahlberg G, Winokur P, Alaaeddine G, Beydoun N, Sokolow K, Kown NP, Phillips S, Baker AW, Turner N, Walter E, Guy E, Frey S.

Clin Infect Dis. 2020 Mar 21. pii: ciaa252. doi: 10.1093/cid/ciaa252. [Epub ahead of print]

PMID: 32198521

CYD-TDV dengue **vaccine** performance by baseline immune profile (monotypic/multitypic) in dengue seropositive individuals.

DiazGranados CA, Langevin E, Bonaparte M, Sridhar S, Machabert T, Dayan G, Forrat R, Savarino S.

Clin Infect Dis. 2020 Mar 21. pii: ciaa304. doi: 10.1093/cid/ciaa304. [Epub ahead of print]

PMID: 32198515

Prevalence of Measles Antibodies in São José do Rio Preto, São Paulo, Brazil: A serological survey model.

Estofolete CF, Milhim BHGA, França CCG, Silva GCDD, Augusto MT, Terzian ACB, Zini N, Durigon EL, Oliveira DBL, Massad E, Nogueira ML.

Sci Rep. 2020 Mar 20;10(1):5179. doi: 10.1038/s41598-020-62151-3.

PMID: 32198469

Dissecting the role of PfAP2-G in malaria gametocytogenesis.

Josling GA, Russell TJ, Venezia J, Orchard L, van Biljon R, Painter HJ, Llinás M.

Nat Commun. 2020 Mar 20;11(1):1503. doi: 10.1038/s41467-020-15026-0.

PMID: 32198457

Effects of lipid metabolism on mouse incisor dentinogenesis.

Kurotaki Y, Sakai N, Miyazaki T, Hosonuma M, Sato Y, Karakawa A, Chatani M, Myers M, Suzawa T, Negishi-Koga T, Kamijo R, Miyazaki A, Maruoka Y, Takami M.

Sci Rep. 2020 Mar 20;10(1):5102. doi: 10.1038/s41598-020-61978-0.

PMID: 32198436

The case for assessing the full value of new tuberculosis **vaccines**.

Gebreselassie N, Hutubessy R, Vekemans J, den Boon S, Kasaeva T, Zignol M.

Eur Respir J. 2020 Mar 20;55(3). pii: 1902414. doi: 10.1183/13993003.02414-2019. Print 2020 Mar. No abstract available.

PMID: 32198269

Characterization of the inflammasome component SmASC in turbot (Scophthalmus maximus).

Wang W, Tan J, Wang Z, Zhang Y, Liu Q, Yang D.

Fish Shellfish Immunol. 2020 Mar 18;100:324-333. doi: 10.1016/j.fsi.2020.03.032. [Epub ahead of print]

PMID: 32198069

Toxicity of thimerosal in biological systems: Conformational changes in human hemoglobin, decrease of oxygen binding capacity, increase of protein glycation and amyloid's formation.

de Magalhães Silva M, de Araújo Dantas MD, da Silva Filho RC, Dos Santos Sales MV, de Almeida Xavier J, Leite ACR, Goulart MOF, Grillo LAM, de Barros WA, de Fátima Â, Figueiredo IM, Santos JCC.

Int J Biol Macromol. 2020 Mar 17. pii: S0141-8130(19)40191-8. doi: 10.1016/j.ijbiomac.2020.03.156. [Epub ahead of print]

PMID: 32198046

Higher education associated with better national tetanus vaccination coverage: A population-based assessment.

Rencken CA, Dunsiger S, Gjelsvik A, Amanullah S.

Prev Med. 2020 Mar 17:106063. doi: 10.1016/j.ypmed.2020.106063. [Epub ahead of print]

PMID: 32197975

E. coli production process yields stable dengue 1 virus-sized particles (VSPs).

Hirsch J, Faber BW, Crowe JE Jr, Verstrepen B, Cornelissen G.

Vaccine. 2020 Mar 17. pii: S0264-410X(20)30332-7. doi: 10.1016/j.**vaccine**.2020.03.003. [Epub ahead of print]

PMID: 32197924

Effects of the thermal denaturation of Sabin-derived inactivated polio **vaccines** on the D-antigenicity and the immunogenicity in rats.

Murakami K, Fujii Y, Someya Y.

Vaccine. 2020 Mar 17. pii: S0264-410X(20)30380-7. doi: 10.1016/j.**vaccine**.2020.03.027. [Epub ahead of print]

PMID: 32197923

Eosinophils are the main cellular targets for oral gene delivery using Lactic acid bacteria.

Takahashi K, Orito N, Yanagisawa D, Yano A, Mori Y, Inoue N.

Vaccine. 2020 Mar 17. pii: S0264-410X(20)30329-7. doi: 10.1016/j.**vaccine**.2020.02.084. [Epub ahead of print]

PMID: 32197922

Epidemiologic study of Haemophilus influenzae causing invasive and non-invasive disease in Paraguay (1999-2017).

León ME, Kawabata A, Nagai M, Rojas L, Chamorro G, Zárate N, Gómez G, Leguizamón M, Irala J, Ortellado J, Franco R, Segovia N.

Enferm Infecc Microbiol Clin. 2020 Mar 17. pii: S0213-005X(20)30054-9. doi: 10.1016/j.eimc.2020.02.020. [Epub ahead of print] English, Spanish.

PMID: 32197798

"What will my child think of me if he hears I gave him HIV?": a sequential, explanatory, mixed-methods approach on the predictors and experience of caregivers on disclosure of HIV status to infected children in Gombe, Northeast Nigeria.

Wariri O, Ajani A, Raymond MP, Iliya A, Lukman O, Okpo E, Isaac E.

BMC Public Health. 2020 Mar 20;20(1):373. doi: 10.1186/s12889-020-08506-x.

PMID: 32197648

Systematic review of statistical methods for safety data in malaria chemoprevention in pregnancy trials.

Patson N, Mukaka M, Otwombe KN, Kazembe L, Mathanga DP, Mwapasa V, Kabaghe AN, Eijkemans MJC, Laufer MK, Chirwa T.

Malar J. 2020 Mar 20;19(1):119. doi: 10.1186/s12936-020-03190-z.

PMID: 32197619

Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children.

Falcón-Lezama JA, Saucedo-Martínez R, Betancourt-Cravioto M, Alfaro-Cortes MM, Bahena-González RI, Tapia-Conyer R.

BMC Infect Dis. 2020 Mar 20;20(1):240. doi: 10.1186/s12879-020-4948-5.

PMID: 32197591

Rapid and Broad Immune Efficacy of a Recombinant Five-Antigen **Vaccine** against *Staphylococcus Aureus* Infection in Animal Models.

Zeng H, Yang F, Feng Q, Zhang J, Gu J, Jing H, Cai C, Xu L, Yang X, Xia X, Zeng N, Fan S, Zou Q.

Vaccines (Basel). 2020 Mar 18;8(1). pii: E134. doi: 10.3390/vaccines8010134.

PMID: 32197534

Pervasive Differential Splicing in Marek's Disease Virus can Discriminate CVI-988 **Vaccine** Strain from RB-1B Very Virulent Strain in Chicken Embryonic Fibroblasts.

Sadigh Y, Tahiri-Alaoui A, Spatz S, Nair V, Ribeca P.

Viruses. 2020 Mar 18;12(3). pii: E329. doi: 10.3390/v12030329.

PMID: 32197378

Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring.

Cullen LM, Boukhvalova MS, Blanco JCG, Morrison TG.

Vaccines (Basel). 2020 Mar 18;8(1). pii: E133. doi: 10.3390/vaccines8010133.

PMID: 32197348

Epidemiological Features and Risk Factors for Acquiring Hepatitis B, Hepatitis C, and Syphilis in HIV-Infected Patients in Shaanxi Province, Northwest China.

Zhang C, Ren Q, Chang W.

Int J Environ Res Public Health. 2020 Mar 18;17(6). pii: E1990. doi: 10.3390/ijerph17061990.

PMID: 32197326

Safety and immunogenicity of a tetravalent dengue **vaccine** in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.

Tricou V, Sáez-Llorens X, Yu D, Rivera L, Jimeno J, Villarreal AC, Dato E, Saldaña de Suman O, Montenegro N, DeAntonio R, Mazara S, Vargas M, Mendoza D, Rauscher M, Brose M, Lefevre I, Tuboi S, Borkowski A, Wallace D.

Lancet. 2020 Mar 17. pii: S0140-6736(20)30556-0. doi: 10.1016/S0140-6736(20)30556-0. [Epub ahead of print]

PMID: 32197107

Evaluation of a tetravalent dengue **vaccine** by serostatus and serotype.

Wilder-Smith A.

Lancet. 2020 Mar 17. pii: S0140-6736(20)30603-6. doi: 10.1016/S0140-6736(20)30603-6. [Epub ahead of print] No abstract available.

PMID: 32197106

Efficacy of a tetravalent dengue **vaccine** in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.

Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, López-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D; TIDES study group.

Lancet. 2020 Mar 17. pii: S0140-6736(20)30414-1. doi: 10.1016/S0140-6736(20)30414-1. [Epub ahead of print]

PMID: 32197105

Disease X: accelerating the development of medical countermeasures for the next pandemic.

Simpson S, Kaufmann MC, Glozman V, Chakrabarti A.

Lancet Infect Dis. 2020 Mar 17. pii: S1473-3099(20)30123-7. doi: 10.1016/S1473-3099(20)30123-7. [Epub ahead of print] Review.

PMID: 32197097

How hypoxia regulate exosomes in ischemic diseases and cancer microenvironment?

Yaghoubi S, Najminejad H, Dabaghian M, Karimi MH, Abdollahpour-Alitappeh M, Rad F, Mahi-Birjand M, Mohammadi S, Mohseni F, Sobhani Lari M, Teymouri GH, Rigi Yousofabadi E, Salmani A, Bagheri N.

IUBMB Life. 2020 Mar 20. doi: 10.1002/iub.2275. [Epub ahead of print] Review.

PMID: 32196941

Next-Generation Sequencing of the Intrahepatic Antibody Repertoire Delineates a Unique B-Cell Response in HBV-Associated Acute Liver Failure.

Chen Z, Shen CH, Engle RE, Zamboni F, Kwong PD, Purcell RH, Farci P.

J Viral Hepat. 2020 Mar 20. doi: 10.1111/jvh.13290. [Epub ahead of print]

PMID: 32196859

Characterization of Aeromonas salmonicida and A. sobria isolated from cultured salmonid fish in Korea and development of a **vaccine** against furunculosis.

Lim J, Hong S.

J Fish Dis. 2020 Mar 20. doi: 10.1111/jfd.13158. [Epub ahead of print]

PMID: 32196710

Assessing the virulence of Cryptococcus neoformans causing meningitis in HIV infected and uninfected patients in Vietnam.

Thanh LT, Toffaletti DL, Tenor JL, Giamberardino C, Sempowski GD, Asfaw Y, Phan HT, Van Duong A, Trinh NM, Thwaites GE, Ashton PM, Chau NVV, Baker SG, Perfect JR, Day JN.

Med Mycol. 2020 Mar 20. pii: myaa013. doi: 10.1093/mmy/myaa013. [Epub ahead of print]

PMID: 32196550

Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice.

Kang JG, Jeon K, Choi H, Kim Y, Kim HI, Ro HJ, Seo YB, Shin J, Chung J, Jeon YK, Kim YS, Lee KH, Cho NH.

PLoS Negl Trop Dis. 2020 Mar 20;14(3):e0007813. doi: 10.1371/journal.pntd.0007813. [Epub ahead of print]

PMID: 32196487

PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.

Wippold JA, Wang H, Tingling J, Leibowitz JL, de Figueiredo P, Han A.

Lab Chip. 2020 Mar 20. doi: 10.1039/c9lc01165j. [Epub ahead of print]

PMID: 32196032

Perioperative Management of Patients Infected with the Novel Coronavirus: Recommendation from the Joint Task Force of the Chinese Society of Anesthesiology and the Chinese Association of Anesthesiologists.

Chen X, Liu Y, Gong Y, Guo X, Zuo M, Li J, Shi W, Li H, Xu X, Mi W, Huang Y; Chinese Society of Anesthesiology, Chinese Association of Anesthesiologists.

Anesthesiology. 2020 Mar 19. doi: 10.1097/ALN.0000000000003301. [Epub ahead of print]

PMID: 32195699

Sero-prevalence of rubella among pregnant women in Sub-Saharan Africa: a meta-analysis.

Kassa ZY, Hussen S, Asnake S.

Hum Vaccin Immunother. 2020 Mar 20:1-7. doi: 10.1080/21645515.2020.1729027. [Epub ahead of print]

PMID: 32195620

Ten years of experience with the pneumococcal non-typeable *Haemophilus influenzae* protein D-conjugate **vaccine** (*Synflorix*) in children.

Lecrenier N, Marijam A, Olbrecht J, Soumahoro L, Nieto Guevara J, Mungall B.

Expert Rev **Vaccines**. 2020 Mar 20:1-19. doi: 10.1080/14760584.2020.1738226. [Epub ahead of print]

PMID: 32195602

Progresses on bacterial secretomes enlighten research on Mycoplasma secretome.

Zubair M, Khan FA, Menghwar H, Faisal M, Ashraf M, Rasheed MA, Marawan MA, Dawood A, Chen Y, Chen H, Guo A.

Microb Pathog. 2020 Mar 17:104160. doi: 10.1016/j.micpath.2020.104160. [Epub ahead of print] Review.

PMID: 32194181

Recombinant ubiquitin-conjugating enzyme of Eimeria maxima induces immunogenic maturation in chicken splenic-derived dendritic cells and drives Th1 polarization in-vitro.

Lakho SA, Haseeb M, Huang J, Hasan MW, Naqvi MA, Zhou Z, Song X, Yan R, Xu L, Li X.

Microb Pathog. 2020 Mar 17:104162. doi: 10.1016/j.micpath.2020.104162. [Epub ahead of print]

PMID: 32194180

Early cytokine response to lethal challenge of Klebsiella pneumoniae averted the prognosis of pneumonia in FyuA immunized mice.

Kumar A, Harjai K, Chhibber S.

Microb Pathog. 2020 Mar 17:104161. doi: 10.1016/j.micpath.2020.104161. [Epub ahead of print]

PMID: 32194179

Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China.

Li W, Wang Y, Yu B, Tan Q, Zhou J, Hu J, Wu Y, Wang B, Li H.

Virus Res. 2020 Mar 16:197937. doi: 10.1016/j.virusres.2020.197937. [Epub ahead of print]

PMID: 32194139

Genetic Characterization of Mumps Viruses Associated with the Resurgence of Mumps in the United States: 2015-2017.

McNall RJ, Wharton AK, Anderson R, Clemmons N, Lopareva EN, Gonzalez C, Espinosa A, Probert WS, Hacker JK, Liu G, Garfin J, Strain A, Boxrud D, Bryant PW, George KS, Davis T, Griesser RH, Shult P, Bankamp B, Hickman CJ, Wroblewski K, Rota PA.

Virus Res. 2020 Mar 16:197935. doi: 10.1016/j.virusres.2020.197935. [Epub ahead of print]

PMID: 32194138

Lipopolysaccharide derived alginate coated Hepatitis B antigen loaded chitosan nanoparticles for oral mucosal immunization.

Saraf S, Jain S, Sahoo RN, Mallick S.

Int J Biol Macromol. 2020 Mar 16;154:466-476. doi: 10.1016/j.ijbiomac.2020.03.124. [Epub ahead of print]

PMID: 32194106

How Should the Rehabilitation Community Prepare for 2019-nCoV?

Koh GC, Hoenig H.

Arch Phys Med Rehabil. 2020 Mar 16. pii: S0003-9993(20)30153-2. doi: 10.1016/j.apmr.2020.03.003. [Epub ahead of print]

PMID: 32194034

Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus.

Yang F, Xiao Y, Lu R, Chen B, Liu F, Wang L, Yao H, Wu N, Wu H.

Emerg Microbes Infect. 2020 Mar 20;9(1):664-675. doi: 10.1080/22221751.2020.1742076. eCollection 2020.

PMID: 32193996

Primary and secondary dengue virus infections elicit similar memory B cell responses but breadth to other serotypes and cross-reactivity to Zika virus is higher in secondary dengue.

Andrade P, Narvekar P, Montoya M, Michlmayr D, Balmaseda A, Coloma J, Harris E.

J Infect Dis. 2020 Mar 20. pii: jiaa120. doi: 10.1093/infdis/jiaa120. [Epub ahead of print]

PMID: 32193549

Prediction of the **Vaccine**-derived Poliovirus Outbreak Incidence: A Hybrid Machine Learning Approach.

Hemedan AA, Abd Elaziz M, Jiao P, Alavi AH, Bahgat M, Ostaszewski M, Schneider R, Ghazy HA, Ewees AA, Lu S.

Sci Rep. 2020 Mar 19;10(1):5058. doi: 10.1038/s41598-020-61853-y.

PMID: 32193487

Author Correction: African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin.

Singh KS, Leu JI, Barnoud T, Vonteddu P, Gnanapradeepan K, Lin C, Liu Q, Barton JC, Kossenkov AV, George DL, Murphy ME, Dotiwala F.

Nat Commun. 2020 Mar 19;11(1):1541. doi: 10.1038/s41467-020-15366-x.

PMID: 32193389

Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus **vaccine**.

Macklin GR, O'Reilly KM, Grassly NC, Edmunds WJ, Mach O, Santhana Gopala Krishnan R, Voorman A, Vertefeuille JF, Abdelwahab J, Gumede N, Goel A, Sosler S, Sever J, Bandyopadhyay AS, Pallansch MA, Nandy R, Mkanda P, Diop OM, Sutter RW.

Science. 2020 Mar 19. pii: eaba1238. doi: 10.1126/science.aba1238. [Epub ahead of print]

PMID: 32193361

Knowledge, attitude and prevalence of hepatitis B virus among healthcare workers: a cross-sectional, hospital-based study in Bamenda Health District, NWR, Cameroon.

Akazong W E, Tume C, Njouom R, Ayong L, Fondoh V, Kuiate JR.

BMJ Open. 2020 Mar 18;10(3):e031075. doi: 10.1136/bmjopen-2019-031075.

PMID: 32193257

Diffuse cutaneous reaction following PPV-23 pneumococcal **vaccine**: an immunisation-associated hypersensitivity vasculitis.

Abdalla A, Sebaoui S, Alraqi S.

BMJ Case Rep. 2020 Mar 18;13(3). pii: e234714. doi: 10.1136/bcr-2020-234714. No abstract available.

PMID: 32193184

Optimizing the immunization activities of community chain pharmacists: Insights from a national survey.

Kulczycki A, Grubbs J, Hogue MD, Rothholz M, Shewchuk R.

J Am Pharm Assoc (2003). 2020 Mar 16. pii: S1544-3191(20)30088-1. doi: 10.1016/j.japh.2020.02.009. [Epub ahead of print]

PMID: 32192949

Pharmacist impact on pneumococcal polysaccharide vaccination rates in patients with diabetes in a national grocery chain pharmacy.

Page A, Harrison A, Nadpara P, Goode JR.

J Am Pharm Assoc (2003). 2020 Mar 16. pii: S1544-3191(20)30049-2. doi: 10.1016/j.japh.2020.02.007. [Epub ahead of print]

PMID: 32192948

Immunogenicity and safety of the RTS,S/AS01 malaria **vaccine** co-administered with measles, rubella and yellow fever **vaccines** in Ghanaian children: A phase IIIb, multi-center, non-inferiority, randomized, open, controlled trial.

Asante KP, Ansong D, Kaali S, Adjei S, Lievens M, Nana Badu L, Agyapong Darko P, Boakye Yiadom Buabeng P, Boahen O, Maria Rettig T, Agutu C, Benard Ekow Harrison S, Ntiamoah Y, Adomako Anim J, Adeniji E, Agordo Dornudo A, Gvozdenovic E, Dosoo D, Sambian D, Owusu-Boateng H, Ato Wilson E, Prempeh F, Vandoolaeghe P, Schuerman L, Owusu-Agyei S, Agbenyega T, Ofori-Anyinam O.

Vaccine. 2020 Mar 16. pii: S0264-410X(20)30358-3. doi: 10.1016/j.**vaccine**.2020.03.014. [Epub ahead of print]

PMID: 32192811

Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity.

Lai JI, Eszterhas SK, Brooks SA, Guo C, Zolla-Pazner S, Seaman MS, Bailey-Kellogg C, Griswold KE, Ackerman ME.

Vaccine. 2020 Mar 16. pii: S0264-410X(20)30354-6. doi: 10.1016/j.**vaccine**.2020.03.010. [Epub ahead of print]

PMID: 32192810

Correction to: Computational assembly of a human Cytomegalovirus **vaccine** upon experimental epitope legacy.

Quinzo MJ, Lafuente EM, Zuluaga P, Flower DR, Reche PA.

BMC Bioinformatics. 2020 Mar 19;21(1):116. doi: 10.1186/s12859-020-3452-7.

PMID: 32192427

Modeling tick **vaccines**: a key tool to improve protection efficacy.

de la Fuente J, Estrada-Peña A, Contreras M.

Expert Rev **Vaccines**. 2020 Mar 19. doi: 10.1080/14760584.2020.1745635. [Epub ahead of print]

PMID: 32192377

Free to Circulate: An Update on the Epidemiological Dynamics of Porcine Circovirus 2 (PCV-2) in Italy Reveals the Role of Local Spreading, Wild Populations, and Foreign Countries.

Franzo G, Tinello S, Grassi L, Tucciarone CM, Legnardi M, Cecchinato M, Dotto G, Mondin A, Martini M, Pasotto D, Menandro ML, Drigo M.

Pathogens. 2020 Mar 17;9(3). pii: E221. doi: 10.3390/pathogens9030221.

PMID: 32192210

Influenza Virus and Vaccination.

Nogales A, DeDiego ML.

Pathogens. 2020 Mar 17;9(3). pii: E220. doi: 10.3390/pathogens9030220.

PMID: 32192196

The Impact of Human Genetic Polymorphisms on Rotavirus Susceptibility, Epidemiology, and **Vaccine** Take.

Sharma S, Hagbom M, Svensson L, Nordgren J.

Viruses. 2020 Mar 17;12(3). pii: E324. doi: 10.3390/v12030324. Review.

PMID: 32192193

Development of Next Generation *Streptococcus pneumoniae* **Vaccines** Conferring Broad Protection.

Masomian M, Ahmad Z, Ti Gew L, Poh CL.

Vaccines (Basel). 2020 Mar 17;8(1). pii: E132. doi: 10.3390/vaccines8010132. Review.

PMID: 32192117

Immunologic Dose-Response to Adenovirus-Vectored **Vaccines** in Animals and Humans: A Systematic Review of Dose-Response Studies of Replication Incompetent Adenoviral **Vaccine** Vectors when Given via an Intramuscular or Subcutaneous Route.

Afrough S, Rhodes S, Evans T, White R, Benest J.

Vaccines (Basel). 2020 Mar 17;8(1). pii: E131. doi: 10.3390/vaccines8010131. Review.

PMID: 32192058

Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection.

Albulescu IC, White-Scholten L, Tas A, Hoornweg TE, Ferla S, Kovacikova K, Smit JM, Brancale A, Snijder EJ, van Hemert MJ.

Viruses. 2020 Mar 17;12(3). pii: E314. doi: 10.3390/v12030314.

PMID: 32191995

Identification of differential protein recognition pattern between Naegleria fowleri and Naegleria lovaniensis.

Gutiérrez-Sánchez M, Carrasco-Yepez MM, Herrera-Díaz J, Rojas-Hernández S.

Parasite Immunol. 2020 Mar 19:e12715. doi: 10.1111/pim.12715. [Epub ahead of print]

PMID: 32191816

Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.

Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro BM.

Am J Health Syst Pharm. 2020 Mar 19. pii: zxaa036. doi: 10.1093/ajhp/zxaa036. [Epub ahead of print] No abstract available.

PMID: 32191793

Prolonged inflammation leads to ongoing damage after spinal cord injury.

Kwiecien JM, Dabrowski W, Dąbrowska-Bouta B, Sulkowski G, Oakden W, Kwiecien-Delaney CJ, Yaron JR, Zhang L, Schutz L, Marzec-Kotarska B, Stanisz GJ, Karis JP, Struzynska L, Lucas AR.

PLoS One. 2020 Mar 19;15(3):e0226584. doi: 10.1371/journal.pone.0226584. eCollection 2020.

PMID: 32191733

In vitro model for the assessment of human immune responses to subunit RSV **vaccines**.

Chirkova T, Ha B, Rimawi BH, Oomens AGP, Hartert TV, Anderson LJ.

PLoS One. 2020 Mar 19;15(3):e0229660. doi: 10.1371/journal.pone.0229660. eCollection 2020.

PMID: 32191728

Knowledge gaps and acquisition about HPV and its **vaccine** among Brazilian medical students.

Costa AS, Gomes JM, Germani ACCG, da Silva MR, Santos EFS, Soares Júnior JM, Baracat EC, Sorpreso ICE.

PLoS One. 2020 Mar 19;15(3):e0230058. doi: 10.1371/journal.pone.0230058. eCollection 2020.

PMID: 32191725

Longitudinal study reveals HIV-1-infected CD4+ T cell dynamics during long-term antiretroviral therapy.

Antar AAR, Jenike KM, Jang S, Rigau DN, Reeves DB, Hoh R, Krone MR, Keruly JC, Moore RD, Schiffer JT, Nonyane BA, Hecht FM, Deeks SG, Siliciano JD, Ho YC, Siliciano RF.

J Clin Invest. 2020 Mar 19. pii: 135953. doi: 10.1172/JCI135953. [Epub ahead of print]

PMID: 32191639

Immune memory limits human longevity: The role of memory CD4+ T cells in age-related immune abnormalities.

Seledtsov VI, von Delwig AA.

Expert Rev **Vaccines**. 2020 Mar 19. doi: 10.1080/14760584.2020.1745638. [Epub ahead of print]

PMID: 32191535

Russian Twitter Accounts and the Partisan Polarization of **Vaccine** Discourse, 2015-2017.

Walter D, Ophir Y, Jamieson KH.

Am J Public Health. 2020 Mar 19:e1-e7. doi: 10.2105/AJPH.2019.305564. [Epub ahead of print]

PMID: 32191516

History of Live, Attenuated Influenza **Vaccine**.

Treanor J.

J Pediatric Infect Dis Soc. 2020 Mar 19;9(Supplement_1):S3-S9. doi: 10.1093/jpids/piz086. No abstract available.

PMID: 32191312

Nontraditional Uses of Live Attenuated Influenza **Vaccine**: School-Located Influenza Vaccination.

Weinberg GA.

J Pediatric Infect Dis Soc. 2020 Mar 19;9(Supplement_1):S19-S23. doi: 10.1093/jpids/piaa007.

PMID: 32191311

Live Attenuated Influenza **Vaccines** for Pandemic Preparedness.

Subbarao K.

J Pediatric Infect Dis Soc. 2020 Mar 19;9(Supplement_1):S15-S18. doi: 10.1093/jpids/piz073. No abstract available.

PMID: 32191310

Live, Attenuated Influenza **Vaccine**: Present and Future Roles.

Weinberg GA.

J Pediatric Infect Dis Soc. 2020 Mar 19;9(Supplement_1):S1-S2. doi: 10.1093/jpids/piz100. No abstract available.

PMID: 32191309

Is it or is it not? Lessons learned from a case of suspected **vaccine** strain measles.

Lord H, Kok J, Fletcher S, Alexander K.

Aust N Z J Public Health. 2020 Mar 19. doi: 10.1111/1753-6405.12969. [Epub ahead of print]

PMID: 32190947

SARS-CoV-2 and COVID-19: The most important research questions.

Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY.

Cell Biosci. 2020 Mar 16;10:40. doi: 10.1186/s13578-020-00404-4. eCollection 2020.

PMID: 32190290

Safety Considerations for Malaria Volunteer Infection Studies: A Mini-Review.

Odedra A, McCarthy JS.

Am J Trop Med Hyg. 2020 Mar 16. doi: 10.4269/ajtmh.19-0351. [Epub ahead of print]

PMID: 32189610

Use of Multi-Parallel Real-Time Quantitative PCR to Determine *Blastocystis* Prevalence and Association with Other Gastrointestinal Parasite Infection in a Rural Honduran Location.

Naceanceno KS, Matamoros G, Gabrie JA, Bottazzi ME, Sanchez A, Mejia R.

Am J Trop Med Hyg. 2020 Mar 16. doi: 10.4269/ajtmh.19-0876. [Epub ahead of print]

PMID: 32189609

No Correlation Between Ethical Judgment in Trolley Dilemmas and **Vaccine** Scenarios for Nurse Specialist Students.

Oftedal G, Ravn IH, Dahl FA.

J Empir Res Hum Res Ethics. 2020 Mar 19:1556264620911234. doi: 10.1177/1556264620911234. [Epub ahead of print]

PMID: 32189547

Knowledge about the human papillomavirus among high school and university students a comprehensive questionnaire study from Southeast Turkey.

Bayramoğlu Tepe N, Ozcorekci O.

J Obstet Gynaecol Res. 2020 Mar 18. doi: 10.1111/jog.14247. [Epub ahead of print]

PMID: 32189443

Prevent and Protect: A Vaccination Initiative for Uninsured Patients at a Student-Run Free Clinic.

Abuelenen T, Khalil S, Simoneit E, Palakurty SH, Hatch LA, Radisic A, Roetzheim R, Guerra L, Gonzalez E.

J Community Health. 2020 Mar 18. doi: 10.1007/s10900-020-00808-w. [Epub ahead of print]

PMID: 32189211

Towards new TB **vaccines**.

Brazier B, McShane H.

Semin Immunopathol. 2020 Mar 18. doi: 10.1007/s00281-020-00794-0. [Epub ahead of print] Review.

PMID: 32189035

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases.

Alvar J, Alves F, Bucheton B, Burrows L, Büscher P, Carrillo E, Felger I, Hübner MP, Moreno J, Pinazo MJ, Ribeiro I, Sosa-Estani S, Specht S, Tarral A, Wourgaft NS, Bilbe G.

Semin Immunopathol. 2020 Mar 18. doi: 10.1007/s00281-020-00796-y. [Epub ahead of print] Review.

PMID: 32189034

CD4/CD8 Ratio Recovery of Children and Adolescents Living With HIV With Virological Suppression: A Prospective Cohort Study.

Han WM, Apornpong T, Handoko R, Jantarabenjakul W, Gatechompol S, Ubolyam S, Kerr SJ, Avihingsanon A, Ruxrungtham K, Phanuphak P, Puthanakit T.

J Pediatric Infect Dis Soc. 2020 Mar 19. pii: piaa020. doi: 10.1093/jpids/piaa020. [Epub ahead of print]

PMID: 32188991

Burden of Adults Hospitalized with Group B Streptococcal Infection.

McLaughlin JM, Peyrani P, Furmanek S, Khan FL, Quinn A, Jodar L, Ramirez J, Swerdlow DL.

J Infect Dis. 2020 Mar 19. pii: jiaa110. doi: 10.1093/infdis/jiaa110. [Epub ahead of print]

PMID: 32188975

Prevalence of HPV infection among sexually active adolescents and young adults in Brazil: The POP-Brazil Study.

Wendland EM, Villa LL, Unger ER, Domingues CM, Benzaken AS; POP-Brazil Study Group.

Sci Rep. 2020 Mar 18;10(1):4920. doi: 10.1038/s41598-020-61582-2.

PMID: 32188884

Influenza Vaccination-associated Acute Thrombocytopenia and Diffuse Alveolar Hemorrhage: A Case Report.

Yamamoto Y, Ohara Y, Iwai A, Hara R, Matsuki T, Fukushima K, Oshitani Y, Kagawa H, Tsujino K, Yoshimura K, Miki M, Miki K, Mori M, Kida H.

Intern Med. 2020 Mar 19. doi: 10.2169/internalmedicine.3991-19. [Epub ahead of print]

PMID: 32188805

Study on the Changes of Chemical Constituents in Different Compatibilities of Ginseng-Prepared Rehmannia Root and Their Effects on Bone Marrow Inhibition after Chemotherapy.

Wang SQ, Yang X, Zhang YG, Cai EB, Zheng X, Zhao Y, Li G, Han M, Yang L.

Chem Pharm Bull (Tokyo). 2020 Mar 17. doi: 10.1248/cpb.c19-00994. [Epub ahead of print]

PMID: 32188797

mSphere of Influence: Predicting Immune Responses and Susceptibility to Influenza Virus-May the Data Be with You.

Ramos I.

mSphere. 2020 Mar 18;5(2). pii: e00085-20. doi: 10.1128/mSphere.00085-20.

PMID: 32188748

Trivalent glycoprotein subunit **vaccine** prevents neonatal herpes simplex virus mortality and morbidity.

Patel CD, Taylor SA, Mehrbach J, Awasthi S, Friedman HM, Leib DA.

J Virol. 2020 Mar 18. pii: JVI.02163-19. doi: 10.1128/JVI.02163-19. [Epub ahead of print]

PMID: 32188735

Subtype diversity of influenza A virus in North American waterfowl: a multi-decade study.

Diskin ER, Friedman K, Krauss S, Nolting JM, Poulson RL, Slemons RD, Stallknecht DE, Webster RG, Bowman AS.

J Virol. 2020 Mar 18. pii: JVI.02022-19. doi: 10.1128/JVI.02022-19. [Epub ahead of print]

PMID: 32188732

Epigenetic suppression of HIV in myeloid cells by the BRD4-selective small molecule modulator ZL0580.

Alamer E, Zhong C, Liu Z, Niu Q, Long F, Guo L, Gelman BB, Soong L, Zhou J, Hu H.

J Virol. 2020 Mar 18. pii: JVI.01880-19. doi: 10.1128/JVI.01880-19. [Epub ahead of print]

PMID: 32188727

Strong **vaccine** responses during chemotherapy are associated with prolonged cancer survival.

Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Burg SH.

Sci Transl Med. 2020 Mar 18;12(535). pii: eaaz8235. doi: 10.1126/scitranslmed.aaz8235.

PMID: 32188726

Priorities for developing respiratory syncytial virus **vaccines** in different target populations.

Drysdale SB, Barr RS, Rollier CS, Green CA, Pollard AJ, Sande CJ.

Sci Transl Med. 2020 Mar 18;12(535). pii: eaax2466. doi: 10.1126/scitranslmed.aax2466. Review.

PMID: 32188721

Genetic diversity of Plasmodium falciparum and genetic profile in children affected by uncomplicated malaria in Cameroon.

Metoh TN, Chen JH, Fon-Gah P, Zhou X, Moyou-Somo R, Zhou XN.

Malar J. 2020 Mar 18;19(1):115. doi: 10.1186/s12936-020-03161-4.

PMID: 32188442

Vaccination coverage with the pneumococcal and influenza **vaccine** among persons with chronic diseases in Shanghai, China, 2017.

Wang Y, Cheng M, Wang S, Wu F, Yan Q, Yang Q, Li Y, Guo X, Fu C, Shi Y, Wagner AL, Boulton ML.

BMC Public Health. 2020 Mar 19;20(1):359. doi: 10.1186/s12889-020-8388-3.

PMID: 32188428

Comparative studies of rubella virus immunity of immunized and non-immunized pregnant women visiting Kogi State University Teaching Hospital, Anyigba, North Central Nigeria.

O Okolo ML, Omatola CA, Ogbonnaya O, Odama LE, Bello KE, Idache BM, Ekuma OU.

J Immunoassay Immunochem. 2020 Mar 19:1-9. doi: 10.1080/15321819.2020.1741384. [Epub ahead of print]

PMID: 32188320

Outbreak of Porcine Reproductive and Respiratory Syndrome Virus 1 in Taiwan.

Lin WH, Kaewprom K, Wang SY, Lin CF, Yang CY, Chiou MT, Lin CN.

Viruses. 2020 Mar 16;12(3). pii: E316. doi: 10.3390/v12030316.

PMID: 32188123

Feline Parvovirus Seroprevalence Is High in Domestic Cats from Disease Outbreak and Non-Outbreak Regions in Australia.

Jenkins E, Davis C, Carrai M, Ward MP, O'Keeffe S, van Boeijen M, Beveridge L, Desario C, Buonavoglia C, Beatty JA, Decaro N, Barrs VR.

Viruses. 2020 Mar 16;12(3). pii: E320. doi: 10.3390/v12030320.

PMID: 32188115

Cancer **Vaccines** and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.

Schirrmacher V.

Biomedicines. 2020 Mar 16;8(3). pii: E61. doi: 10.3390/biomedicines8030061. Review.

PMID: 32188078

Design of an Epitope-Based **Vaccine** Ensemble for Animal Trypanosomiasis by Computational Methods.

Michel-Todó L, Bigey P, Reche PA, Pinazo MJ, Gascón J, Alonso-Padilla J.

Vaccines (Basel). 2020 Mar 16;8(1). pii: E130. doi: 10.3390/vaccines8010130.

PMID: 32188062

Construction and Immunogenicity of Virus-Like Particles of Feline Parvovirus from the Tiger.

Jiao C, Zhang H, Liu W, Jin H, Liu D, Zhao J, Feng N, Zhang C, Shi J.

Viruses. 2020 Mar 16;12(3). pii: E315. doi: 10.3390/v12030315.

PMID: 32188011

An Antibody Persistent and Protective Two rSsCLP-Based Subunit Cocktail **Vaccine** against *Sarcoptes scabiei* in a Rabbit Model.

Shen N, Wei W, Chen Y, Ren Y, Xiong L, Tao Y, Gu X, Xie Y, Peng X, Yang G.

Vaccines (Basel). 2020 Mar 16;8(1). pii: E129. doi: 10.3390/vaccines8010129.

PMID: 32187979

Separation of influenza virus-like particles from baculovirus by polymer grafted anion-exchanger.

Reiter K, Aguilar PP, Grammelhofer D, Joseph J, Steppert P, Jungbauer A.

J Sep Sci. 2020 Mar 18. doi: 10.1002/jssc.201901215. [Epub ahead of print]

PMID: 32187844

Genomic research delivering on promises: From rejuvenation to **vaccines** and pharmacogenetics.

Li Wan Po A.

J Clin Pharm Ther. 2020 Mar 18. doi: 10.1111/jcpt.13131. [Epub ahead of print]

PMID: 32187712

Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit **Vaccines**.

Nogal B, Bianchi M, Cottrell CA, Kirchdoerfer RN, Sewall LM, Turner HL, Zhao F, Sok D, Burton DR, Hangartner L, Ward AB.

Cell Rep. 2020 Mar 17;30(11):3755-3765.e7. doi: 10.1016/j.celrep.2020.02.061.

PMID: 32187547

Importance of epidemiological surveillance of leprosy: analysis of the occurrence of leprosy in intra-domiciliary contacts in a capital in the Brazilian northeast region.

Trindade LC, Martins LC, Marques DM, Mendes MDS, Fonseca FLA, Pereira LAA.

Rev Soc Bras Med Trop. 2020 Mar 16;53:e20190507. doi: 10.1590/0037-8682-0507-2019. eCollection 2020.

PMID: 32187344

Hepatitis B **vaccine** development and implementation.

Zhao H, Zhou X, Zhou YH.

Hum Vaccin Immunother. 2020 Mar 18:1-12. doi: 10.1080/21645515.2020.1732166. [Epub ahead of print]

PMID: 32186974

Determinants of **vaccine** hesitancy and effectiveness of vaccination counseling interventions among a sample of the general population in Palermo, Italy.

Costantino C, Caracci F, Brandi M, Bono SE, Ferro A, Sannasardo CE, Scarpitta F, Siddu A, Vella C, Ventura G, Vitale F, Casuccio A, Restivo V.

Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1728157. [Epub ahead of print]

PMID: 32186961

Study of the association of seventeen single nucleotide polymorphisms and their haplotypes in the *TNF-α, IL-2, IL-4* and *IL-10* genes with the antibody response to inactivated Japanese encephalitis **vaccine**.

Yao Y, Xu X, Li Y, Wang X, Yang H, Chen J, Liu S, Deng Y, Zhao Z, Yin Q, Sun M, Shi L.

Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1724743. [Epub ahead of print]

PMID: 32186960

Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: implications for China's expanded program on immunization.

Luo Y, He H, Tang X, Wang S, Zhang J, Wu T, Chen Z.

Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2019.1711299. [Epub ahead of print]

PMID: 32186953

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing **vaccines**, immunotherapeutics, and therapeutics.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W.

Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1735227. [Epub ahead of print]

PMID: 32186952

Safety and immunogenicity of a novel quadrivalent subunit influenza **vaccine** in animal models.

Ye H, Jia S, Zhang Y, Li J, Zhu F.

Hum Vaccin Immunother. 2020 Mar 18:1-8. doi: 10.1080/21645515.2020.1737456. [Epub ahead of print]

PMID: 32186950

Long time persistence of antibodies against Mumps in fully MMR immunized young adults: an Italian retrospective cohort study.

Bianchi FP, De Nitto S, Stefanizzi P, Larocca AMV, Germinario CA, Tafuri S.

Hum Vaccin Immunother. 2020 Mar 18:1-7. doi: 10.1080/21645515.2020.1735861. [Epub ahead of print]

PMID: 32186948

Letter to the editor concerning the article 'Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and meta-analysis' (JAMA Netw Open. 2019;2(10):e1912458).

Benninghoff B, Pereira P, Willame C.

Hum Vaccin Immunother. 2020 Mar 18:1-2. doi: 10.1080/21645515.2020.1730119. [Epub ahead of print]

PMID: 32186946

Cardiovascular Corner-Stable Coronary Artery Disease, An LDL "**Vaccine**," and Anti-inflammatories.

Abbasi J.

JAMA. 2020 Mar 18. doi: 10.1001/jama.2019.20983. [Epub ahead of print] No abstract available.

PMID: 32186687

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.

Kwok D, Okada H.

J Neurooncol. 2020 Mar 17. doi: 10.1007/s11060-020-03450-7. [Epub ahead of print] Review.

PMID: 32185647

Reporter gene knock-in into Marc-145 cells using CRISPR/Cas9-mediated homologous recombination.

Chang Y, Shao J, Gao Y, Liu W, Gao Z, Hu Y, Chang H.

Biotechnol Lett. 2020 Mar 17. doi: 10.1007/s10529-020-02860-x. [Epub ahead of print]

PMID: 32185620

Screening for efficient nitrogen sources for overproduction of the biomass of the functionally probiotic L. plantarum strain RPR42 in a cane molasses-based medium.

Papizadeh M, Rohani M, Hosseini SN, Shojaosadati SA, Nahrevanian H, Talebi M, Pourshafie MR.

AMB Express. 2020 Mar 17;10(1):53. doi: 10.1186/s13568-020-00976-x.

PMID: 32185601

Potential DNA **Vaccine** for Haemorrhagic Septiceamia Disease.

Chelliah S, Velappan RD, Lim KT, Swee CWK, Nor Rashid N, Rothan HA, Kabir N, Ismail S.

Mol Biotechnol. 2020 Mar 17. doi: 10.1007/s12033-020-00244-0. [Epub ahead of print]

PMID: 32185600

Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part II.

Moyad MA.

Curr Urol Rep. 2020 Mar 18;21(3):15. doi: 10.1007/s11934-020-0967-4. Review.

PMID: 32185555

Characteristics and function of cathepsin L3 from Schistosoma japonicum.

Huang W, Gu M, Cheng W, Zhao QP, Ming Z, Dong H.

Parasitol Res. 2020 Mar 17. doi: 10.1007/s00436-020-06647-x. [Epub ahead of print]

PMID: 32185481

Epigenetic modulation in chronic hepatitis B virus infection.

Dandri M.

Semin Immunopathol. 2020 Mar 17. doi: 10.1007/s00281-020-00780-6. [Epub ahead of print] Review.

PMID: 32185454

A live-**vaccine**-last schedule: saving an extra million lives a year?

Shann F.

Clin Infect Dis. 2020 Mar 18. pii: ciaa292. doi: 10.1093/cid/ciaa292. [Epub ahead of print] No abstract available.

PMID: 32185398

Whole-exome sequencing for the identification of rare variants in primary immunodeficiency genes in children with sepsis - a prospective population-based cohort study.

Borghesi A, Trück J, Asgari S, Sancho-Shimizu V, Agyeman PKA, Bellos E, Giannoni E, Stocker M, Posfay-Barbe KM, Heininger U, Bernhard-Stirnemann S, Niederer-Loher A, Kahlert CR, Natalucci G, Relly C, Riedel T, Kuehni CE, Thorball CW, Chaturvedi N, Martinon-Torres F, Kuijpers TW, Coin L, Wright V, Herberg J, Levin M, Aebi C, Berger C, Fellay J, Schlapbach LJ; EUCLIDS consortium and the Swiss Paediatric Sepsis Study.

Clin Infect Dis. 2020 Mar 18. pii: ciaa290. doi: 10.1093/cid/ciaa290. [Epub ahead of print]

PMID: 32185379

Out-of-sequence vaccinations with measles **vaccine** and diphtheria-tetanus-pertussis **vaccine**. A re-analysis of demographic surveillance data from rural Bangladesh.

Clipet-Jensen C, Andersen A, Jensen AKG, Aaby P, Zaman K.

Clin Infect Dis. 2020 Mar 18. pii: ciaa291. doi: 10.1093/cid/ciaa291. [Epub ahead of print]

PMID: 32185375

Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus **vaccine** trials: restoration of previously unpublished methodology.

Doshi P, Bourgeois F, Hong K, Jones M, Lee H, Shamseer L, Spence O, Jefferson T.

BMJ Evid Based Med. 2020 Mar 17. pii: bmjebm-2019-111331. doi: 10.1136/bmjebm-2019-111331. [Epub ahead of print]

PMID: 32184277

Phosphoric Metabolites Link Phosphate Import and Polysaccharide Biosynthesis for Candida albicans Cell Wall Maintenance.

Liu NN, Acosta-Zaldívar M, Qi W, Diray-Arce J, Walker LA, Kottom TJ, Kelly R, Yuan M, Asara JM, Lasky-Su JA, Levy O, Limper AH, Gow NAR, Köhler JR.

mBio. 2020 Mar 17;11(2). pii: e03225-19. doi: 10.1128/mBio.03225-19.

PMID: 32184254

Epstein-Barr Virus Epitope-Major Histocompatibility Complex Interaction Combined with Convergent Recombination Drives Selection of Diverse T Cell Receptor α and β Repertoires.

Gil A, Kamga L, Chirravuri-Venkata R, Aslan N, Clark F, Ghersi D, Luzuriaga K, Selin LK.

mBio. 2020 Mar 17;11(2). pii: e00250-20. doi: 10.1128/mBio.00250-20.

PMID: 32184241

Gamma Interferon Is Required for *Chlamydia* Clearance but Is Dispensable for T Cell Homing to the Genital Tract.

Helble JD, Gonzalez RJ, von Andrian UH, Starnbach MN.

mBio. 2020 Mar 17;11(2). pii: e00191-20. doi: 10.1128/mBio.00191-20.

PMID: 32184237

Covid-19: Trump sought to buy **vaccine** developer exclusively for US, say German officials.

Dyer O.

BMJ. 2020 Mar 17;368:m1100. doi: 10.1136/bmj.m1100. No abstract available.

PMID: 32184216

Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein.

Raghunandan R, Mayer BT, Flores-Garcia Y, Gerber MW, Gottardo R, Jhun H, Herrera SM, Perez-Ramos DW, Locke E, King CR, Zavala F.

Malar J. 2020 Mar 17;19(1):113. doi: 10.1186/s12936-020-03181-0.

PMID: 32183833

Adverse pregnancy outcomes among women presenting at antenatal clinics in Ouélessébougou, Mali.

Andemel N, Gaoussou S, Barry A, Issiaka D, Mahamar A, Traore M, Duffy PE, Dicko A, Fried M.

Reprod Health. 2020 Mar 17;17(1):39. doi: 10.1186/s12978-020-0890-7.

PMID: 32183832

Cyclosporine a directly affects human and mouse b cell migration in vitro by disrupting a hIF-1 αdependent, o_2 sensing, molecular switch.

Hilchey SP, Palshikar MG, Emo JA, Li D, Garigen J, Wang J, Mendelson ES, Cipolla V, Thakar J, Zand MS.

BMC Immunol. 2020 Mar 18;21(1):13. doi: 10.1186/s12865-020-0342-8.

PMID: 32183695

Production of Recombinant HIV-1 p24-Nef Protein in Two Forms as Potential Candidate **Vaccines** in Three Vehicles.

Larijani MS, Pouriayevali MH, Sadat SM, Ramezani A.

Curr Drug Deliv. 2020 Mar 17. doi: 10.2174/1567201817666200317121728. [Epub ahead of print]

PMID: 32183667

Awareness of HPV and drivers of HPV **vaccine** uptake among university students: A quantitative, cross-sectional study.

Cocchio S, Bertoncello C, Baldovin T, Fonzo M, Bennici SE, Buja A, Majori S, Baldo V.

Health Soc Care Community. 2020 Mar 17. doi: 10.1111/hsc.12974. [Epub ahead of print]

PMID: 32182634

Reduction of antimicrobial resistant pneumococci seven years after introduction of pneumococcal **vaccine** in Iceland.

Hjálmarsdóttir MÁ, Haraldsson G, Quirk SJ, Haraldsson Á, Erlendsdóttir H, Kristinsson KG.

PLoS One. 2020 Mar 17;15(3):e0230332. doi: 10.1371/journal.pone.0230332. eCollection 2020.

PMID: 32182260

Vaccine responses in newborns. Saso A et al. Semin Immunopathol. (2017)

On **vaccine**'s adjuvants and autoimmunity: Current evidence and future perspectives. Pellegrino P et al. Autoimmun Rev. (2015)

Addressing HPV **vaccine** myths: practical information for healthcare providers. Bednarczyk RA et al. Hum Vaccin Immunother. (2019)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound.

Cale EM, Bai H, Bose M, Messina MA, Colby D, Sanders-Buell E, Dearlove BL, Li Y, Engeman E, Silas D, O'Sullivan AM, Mann B, Pinyakorn S, Intasan J, Benjapornpong K, Sacdalan C, Kroon E, Phanuphak N, Gramzinski R, Vasan S, Robb ML, Michael NL, Lynch RM, Bailer R, Pagliuzza A, Chomont N, Pegu A, Doria-Rose NA, Trautmann L, Crowell TA, Mascola J, Ananworanich J, Tovanabutra S, Rolland M.

J Clin Invest. 2020 Mar 17. pii: 134395. doi: 10.1172/JCI134395. [Epub ahead of print]

PMID: 32182219

The potential role of using **vaccine** patches to induce immunity: platform and pathways to innovation and commercialization.

Badizadegan K, Goodson JL, Rota PA, Thompson KM.

Expert Rev **Vaccines**. 2020 Feb;19(2):175-194. doi: 10.1080/14760584.2020.1732215. Epub 2020 Mar 17.

PMID: 32182145

Epidemiology and effective pertussis vaccination of hospitalized children at Vietnam National Children's Hospital, 2015 - 2018.

Th Pham N, Nhan L, Le NT, Nguyen KD, Larsson M, Olson L, Tran DM.

Acta Paediatr. 2020 Mar 17. doi: 10.1111/apa.15259. [Epub ahead of print]

PMID: 32181924

A guideline for homology modeling of the proteins from newly discovered betacoronavirus, 2019 novel coronavirus (2019-nCoV).

Dong S, Sun J, Mao Z, Wang L, Lu YL, Li J.

J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25768. [Epub ahead of print]

PMID: 32181901

Development of hepatic pathology in GBV-B-infected red-bellied tamarins (Saguinus labiatus).

Dale JM, Hood SP, Bowen O, Bright H, Cutler KL, Berry N, Almond N, Goldin R, Karayiannis P, Rose NJ.

J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25769. [Epub ahead of print]

PMID: 32181899

Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.

Forster AH, Witham K, Depelsenaire ACI, Veitch M, Wells JW, Wheatley A, Pryor M, Lickliter JD, Francis B, Rockman S, Bodle J, Treasure P, Hickling J, Fernando GJP.

PLoS Med. 2020 Mar 17;17(3):e1003024. doi: 10.1371/journal.pmed.1003024. eCollection 2020 Mar.

PMID: 32181756

Development of mismatch amplification mutation assay (MAMA) for the rapid differentiation of *Mycoplasma gallisepticum* K **vaccine** strain from field isolates.

Bekő K, Kovács ÁB, Kreizinger Z, Marton S, Bányai K, Bánáti L, Catania S, Bradbury J, Lysnyansky I, Olaogun OM, Gyuranecz M.

Avian Pathol. 2020 Mar 17:1-24. doi: 10.1080/03079457.2020.1744523. [Epub ahead of print]

PMID: 32181698

The spread of the COVID-19 coronavirus: Health agencies worldwide prepare for the seemingly inevitability of the COVID-19 coronavirus becoming endemic.

Hunter P.

EMBO Rep. 2020 Mar 17:e50334. doi: 10.15252/embr.202050334. [Epub ahead of print]

PMID: 32181577

Bullous fixed drug eruption following Human Papilloma Virus (HPV) vaccination.

Pyl J, Aerts O, Siozopoulou V, Lambert J, Dendooven E, Poschet K, Dandelooy J.

J Eur Acad Dermatol Venereol. 2020 Mar 17. doi: 10.1111/jdv.16377. [Epub ahead of print]

PMID: 32181534

The co-administration of trehalose dibehenate and monosodium urate crystals promotes an anti-tumour phenotype in human-derived myeloid cells.

Kodar K, McConnell MJ, Harper JL, Timmer MSM, Stocker BL.

Immunol Cell Biol. 2020 Mar 17. doi: 10.1111/imcb.12329. [Epub ahead of print]

PMID: 32181513

Complement in malaria: immune evasion strategies and role in protective immunity.

Kiyuka PK, Meri S, Khattab A.

FEBS Lett. 2020 Mar 17. doi: 10.1002/1873-3468.13772. [Epub ahead of print] Review.

PMID: 32181490

Classical swine fever: challenges for the emerging swine sector in Bhutan.

Villanueva-Cabezas JP, Wangchuk J.

Trop Anim Health Prod. 2020 Mar 16. doi: 10.1007/s11250-020-02260-3. [Epub ahead of print]

PMID: 32180105

Interactions between iron and manganese in neurotoxicity.

Bjørklund G, Dadar M, Peana M, Rahaman MS, Aaseth J.

Arch Toxicol. 2020 Mar;94(3):725-734. doi: 10.1007/s00204-020-02652-2. Epub 2020 Mar 16. Review.

PMID: 32180038

Genotype-Specific Neutralization of Norovirus is Mediated by Antibodies Against the Protruding Domain of the Major Capsid Protein.

Ford-Siltz LA, Wales S, Tohma K, Gao Y, Parra GI.

J Infect Dis. 2020 Mar 17. pii: jiaa116. doi: 10.1093/infdis/jiaa116. [Epub ahead of print]

PMID: 32179892

PfCERLI1 is a conserved rhoptry associated protein essential for Plasmodium falciparum merozoite invasion of erythrocytes.

Liffner B, Frölich S, Heinemann GK, Liu B, Ralph SA, Dixon MWA, Gilberger TW, Wilson DW.

Nat Commun. 2020 Mar 16;11(1):1411. doi: 10.1038/s41467-020-15127-w.

PMID: 32179747

Comparison of LAL and recombinant Factor C endotoxin testing assays in human **vaccines** with complex matrices.

Marius M, Vacher F, Bonnevay T.

PDA J Pharm Sci Technol. 2020 Mar 16. pii: pdajpst.2019.010389. doi: 10.5731/pdajpst.2019.010389. [Epub ahead of print]

PMID: 32179709

Prevalent and diverse intratumoral oncoprotein-specific CD8+ T cells within polyoma virus-driven Merkel cell carcinomas.

Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, Afanasiev OK, Colunga A, Cook MM, Xie H, Greninger AL, Paulson KG, Chapuis AG, Bhatia S, Nghiem P, Koelle DM.

Cancer Immunol Res. 2020 Mar 16. pii: canimm.0647.2019. doi: 10.1158/2326-6066.CIR-19-0647. [Epub ahead of print]

PMID: 32179557

In Vitro and *In Vivo* Characterization of Potent Antileishmanial Methionine Aminopeptidase-1 Inhibitors.

Rodriguez F, John SF, Iniguez E, Montalvo S, Michael K, White L, Liang D, Olaleye OA, Maldonado RA.

Antimicrob Agents Chemother. 2020 Mar 16. pii: AAC.01422-19. doi: 10.1128/AAC.01422-19. [Epub ahead of print]

PMID: 32179532

Research about the optimal strategies for prevention and control of varicella outbreak in a school in a central city of China: based on an SEIR dynamic model.

Zha WT, Pang FR, Zhou N, Wu B, Liu Y, Du YB, Hong XQ, Lv Y.

Epidemiol Infect. 2020 Mar 17;148:e56. doi: 10.1017/S0950268819002188.

PMID: 32178752

Leptospira infection and shedding in dogs in Thailand.

Altheimer K, Jongwattanapisan P, Luengyosluechakul S, Pusoonthornthum R, Prapasarakul N, Kurilung A, Broens EM, Wagenaar JA, Goris MGA, Ahmed AA, Pantchev N, Reese S, Hartmann K.

BMC Vet Res. 2020 Mar 17;16(1):89. doi: 10.1186/s12917-020-2230-0.

PMID: 32178664

Antiviral drug discovery and development for Mayaro Fever - What do we have so far?

de Mello MV, Domingos TF, Ferreira D, Ribeiro M, Ribeiro T, Souza A, Rodrigues C.

Mini Rev Med Chem. 2020 Mar 16. doi: 10.2174/1389557520666200316160425. [Epub ahead of print]

PMID: 32178610

Surveillance of adverse events following immunisation in Australia: annual report, 2018.

Dey A, Wang H, Quinn H, Pillsbury A, Glover C, Hickie M, Wood N, Beard F, Macartney K.

Commun Dis Intell (2018). 2020 Mar 16;44. doi: 10.33321/cdi.2020.44.12.

PMID: 32178607

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza in 2018.

Price OH, Spirason N, Rynehart C, Brown SK, Todd A, Peck H, Patel M, Soppe S, Barr IG, Chow MK.

Commun Dis Intell (2018). 2020 Mar 16;44. doi: 10.33321/cdi.2020.44.16.

PMID: 32178606

Unsolved Problems and New Medical Approaches to Otitis Media.

Principi N, Esposito S.

Expert Opin Biol Ther. 2020 Mar 17. doi: 10.1080/14712598.2020.1740677. [Epub ahead of print]

PMID: 32178551

Oligosaccharides and Viral Infection: Human Milk Oligosaccharides versus Algal Fucan-Type Polysaccharides.

Hanisch FG, Aydogan C.

Nestle Nutr Inst Workshop Ser. 2020 Mar 16;94:124-132. doi: 10.1159/000505338. [Epub ahead of print] Review.

PMID: 32176880

The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost **vaccines** encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis.

Zhang J, He J, Li J, Zhou Q, Chen H, Zheng Z, Chen Q, Chen D, Chen J.

PLoS One. 2020 Mar 16;15(3):e0230381. doi: 10.1371/journal.pone.0230381. eCollection 2020.

PMID: 32176727

Biochemical and immunological characterization of an ETEC CFA/I adhesin cholera toxin B subunit chimera.

Jobling MG, Poole ST, Rasulova-Lewis F, O'Dowd A, McVeigh AL, Balakrishnan A, Sincock SA, Prouty MG, Holmes RK, Savarino SJ.

PLoS One. 2020 Mar 16;15(3):e0230138. doi: 10.1371/journal.pone.0230138. eCollection 2020.

PMID: 32176708

Immunogenicity of a killed bivalent whole cell oral cholera **vaccine** in forcibly displaced Myanmar nationals in Cox's Bazar, Bangladesh.

Chowdhury F, Bhuiyan TR, Akter A, Bhuiyan MS, Khan AI, Hossain M, Tauheed I, Ahmed T, Islam S, Rafique TA, Siddique SA, Harun NB, Islam K, Clemens JD, Qadri F.

PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0007989. doi: 10.1371/journal.pntd.0007989. eCollection 2020 Mar.

PMID: 32176695

Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

Hamrouni S, Bras-Gonçalves R, Kidar A, Aoun K, Chamakh-Ayari R, Petitdidier E, Messaoudi Y, Pagniez J, Lemesre JL, Meddeb-Garnaoui A.

PLoS Negl Trop Dis. 2020 Mar 16;14(3):e0008093. doi: 10.1371/journal.pntd.0008093. [Epub ahead of print]

PMID: 32176691

Mucosal immune responses to *Vibrio cholerae* O-specific polysaccharide in adults following oral vaccination not optimally assessed.

Leach S.

Hum Vaccin Immunother. 2020 Mar 16:1-2. doi: 10.1080/21645515.2020.1729029. [Epub ahead of print] No abstract available.

PMID: 32176589

Involvement of caspase-1 in inflammasomes activation and bacterial clearance in S. aureus-infected osteoblasts-like MG-63 cells.

Leite EL, Gautron A, Deplanche M, Nicolas A, Ossemond J, Nguyen MT, do Carmo FLR, Gilot D, Azevedo V, Goetz F, Le Loir Y, Otto M, Berkova N.

Cell Microbiol. 2020 Mar 16:e13204. doi: 10.1111/cmi.13204. [Epub ahead of print]

PMID: 32176433

Human Papilloma Virus Vaccination Compliance in a Military Aviation Training Community.

Porter IM, Stoker G, Seals SR, Drollinger S, Schutte HM, Bean JW, Rice GM.

Mil Med. 2020 Mar 16. pii: usaa024. doi: 10.1093/milmed/usaa024. [Epub ahead of print]

PMID: 32175587

Increasing the ratio of SID lysine to metabolizable energy improves pig performance during a viral challenge.

Jasper JE, Mendoza OF, Shull CM, Schweer WP, Schwartz KJ, Gabler NK.

J Anim Sci. 2020 Mar 16. pii: skaa082. doi: 10.1093/jas/skaa082. [Epub ahead of print]

PMID: 32175579

[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].

Wang J, Wang BJ, Yang JC, Wang MY, Chen C, Luo GX, He WF.

Zhonghua Shao Shang Za Zhi. 2020 Mar 16;36(0):E006. doi: 10.3760/cma.j.cn501120-20200307-00132. [Epub ahead of print] Chinese.

PMID: 32174095

Educating first-year medical students on inactive **vaccine** components.

Chase AJ, Heck AJ.

Med Educ. 2020 Mar 16. doi: 10.1111/medu.14111. [Epub ahead of print] No abstract available.

PMID: 32173893

Ready or Not, Patients Will Present: Improving Urban Pandemic Preparedness.

Madad S, Moskovitz J, Boyce MR, Cagliuso NV, Katz R.

Disaster Med Public Health Prep. 2020 Mar 16:1-4. doi: 10.1017/dmp.2020.7. [Epub ahead of print]

PMID: 32172715

Patient decision aid in vaccination: a systematic review of the literature.

Bruel S, Leclercq T, Ginzarly M, Botelho-Nevers E, Frappé P, Gagneux-Brunon A.

Expert Rev **Vaccines**. 2020 Mar 17:1-7. doi: 10.1080/14760584.2020.1742111. [Epub ahead of print]

PMID: 32163307

Similar articles

Select item 32161067 238.

Human Melioidosis.

Gassiep I, Armstrong M, Norton R.

Clin Microbiol Rev. 2020 Mar 11;33(2). pii: e00006-19. doi: 10.1128/CMR.00006-19. Print 2020 Mar 18. Review.

PMID: 32161067

Kinetoplastid Membrane Protein-11 Induces Pores in Anionic Phospholipid Membranes: Effect of Cholesterol.

Halder A, Sannigrahi A, De N, Chattopadhyay K, Karmakar S.

Langmuir. 2020 Mar 23. doi: 10.1021/acs.langmuir.9b03816. [Epub ahead of print]

PMID: 32160748

Vaccination with gamma radiation-attenuated *Toxoplasma gondii* protects against ovarian infiltration in mice-bearing Ehrlich ascites carcinoma.

Hafez EN, Youssef HMG, El-Kabany HA.

Int J Radiat Biol. 2020 Mar 18:1-9. doi: 10.1080/09553002.2020.1739772. [Epub ahead of print]

PMID: 32149560

Response to comment on: **Vaccine** adjuvants: Understanding the structure and mechanism of adjuvanticity.

Shi S, Liang Z, Sun B.

Vaccine. 2020 Mar 17;38(13):2759. doi: 10.1016/j.**vaccine**.2020.02.016. No abstract available.

PMID: 32145881

Reply to Shuting Shi et al., **Vaccine** adjuvants: Understanding the structure and mechanism of adjuvanticity (**Vaccine** 2019;37 (24):3167-3178).

Schuerman L.

Vaccine. 2020 Mar 17;38(13):2758. doi: 10.1016/j.**vaccine**.2019.11.036. No abstract available.

PMID: 32145880

Workshop report: Optimization of animal models to better predict influenza **vaccine** efficacy.

Lane MC, Gordon JL, Jiang C, Leitner WW, Pickett TE, Stemmy E, Bozick BA, Deckhut-Augustine A, Embry AC, Post DJ.

Vaccine. 2020 Mar 17;38(13):2751-2757. doi: 10.1016/j.**vaccine**.2020.01.101.

PMID: 32145879

Optimization of animal models to better predict influenza **vaccine** efficacy (VA).

Neumann G, Kawaoka Y.

Vaccine. 2020 Mar 17;38(13):2749-2750. doi: 10.1016/j.**vaccine**.2020.01.102. No abstract available.

PMID: 32145878

Current advances in the algae-made biopharmaceuticals field.

Rosales-Mendoza S, Solís-Andrade KI, Márquez-Escobar VA, González-Ortega O, Bañuelos-Hernandez B.

Expert Opin Biol Ther. 2020 Mar 20:1-16. doi: 10.1080/14712598.2020.1739643. [Epub ahead of print]

PMID: 32142617

Reagent controlled stereoselective synthesis of teichoic acid α-(1,2)-glucans.

Wang L, Berni F, Enotarpi J, Overkleeft HS, van der Marel G, Codée JDC.

Org Biomol Chem. 2020 Mar 18;18(11):2038-2050. doi: 10.1039/d0ob00240b.

PMID: 32141465

Oral immunization of mice with a multivalent therapeutic subunit **vaccine** protects against Helicobacter pylori infection.

Liu M, Zhong Y, Chen J, Liu Y, Tang C, Wang X, Zhang Y, Wang P, Logan SM, Chen W, Wei B.

Vaccine. 2020 Mar 23;38(14):3031-3041. doi: 10.1016/j.**vaccine**.2020.02.036. Epub 2020 Mar 2.

PMID: 32139315

Socioeconomic characteristics associated with the introduction of new **vaccines** and full childhood vaccination in Ghana, 2014.

Moran EB, Wagner AL, Asiedu-Bekoe F, Abdul-Karim A, Schroeder LF, Boulton ML.

Vaccine. 2020 Mar 23;38(14):2937-2942. doi: 10.1016/j.**vaccine**.2020.02.065. Epub 2020 Mar 2.

PMID: 32139314

Safe-by-Design of Glucan Nanoparticles: Size Matters When Assessing the Immunotoxicity.

Colaço M, Marques AP, Jesus S, Duarte A, Borges O.

Chem Res Toxicol. 2020 Mar 19. doi: 10.1021/acs.chemrestox.9b00467. [Epub ahead of print]

PMID: 32138518

Genetic engineering strategies for construction of multivalent chimeric VLPs **vaccines**.

Lei X, Cai X, Yang Y.

Expert Rev **Vaccines**. 2020 Mar 17:1-12. doi: 10.1080/14760584.2020.1738227. [Epub ahead of print]

PMID: 32133886

Immunization stress-related response - Redefining immunization anxiety-related reaction as an adverse event following immunization.

Gold MS, MacDonald NE, McMurtry CM, Balakrishnan MR, Heininger U, Menning L, Benes O, Pless R, Zuber PLF.

Vaccine. 2020 Mar 23;38(14):3015-3020. doi: 10.1016/j.**vaccine**.2020.02.046. Epub 2020 Mar 2.

PMID: 32131975

The Ebola virus glycoprotein and its immune responses across multiple **vaccine** platforms.

O'Donnell K, Marzi A.

Expert Rev **Vaccines**. 2020 Mar 16:1-11. doi: 10.1080/14760584.2020.1738225. [Epub ahead of print]

PMID: 32129120

In-situ and sensitive stability study of emulsion and aluminum adjuvanted inactivated foot-and-mouth disease virus **vaccine** by differential scanning fluorimetry analysis.

Song Y, Yang Y, Lin X, Li X, Zhang X, Ma G, Su Z, Zhang S.

Vaccine. 2020 Mar 23;38(14):2904-2912. doi: 10.1016/j.**vaccine**.2020.02.068. Epub 2020 Feb 29.

PMID: 32127228

HPV vaccination intent and willingness to pay for 2-,4-, and 9-valent HPV **vaccines**: A study of adult women aged 27-45 years in China.

Lin Y, Lin Z, He F, Chen H, Lin X, Zimet GD, Alias H, He S, Hu Z, Wong LP.

Vaccine. 2020 Mar 23;38(14):3021-3030. doi: 10.1016/j.**vaccine**.2020.02.042. Epub 2020 Feb 29.

PMID: 32127227

Measles immunity in a Czech tertiary care hospital.

Štěpánek L, Nakládalová M, Boriková A, Horáková D, Štěpánek L.

Vaccine. 2020 Mar 23;38(14):2889-2892. doi: 10.1016/j.**vaccine**.2020.02.067. Epub 2020 Feb 29.

PMID: 32127226

The immunologic dominance of an epitope within a rationally designed poly-epitope **vaccine** is influenced by multiple factors.

Shu J, Shen W, Liu H, Zhou Y, Li J, Zhuang Y, Huang Z, Yin S, Jiang L, Sun Y, Jin X, Xu J.

Vaccine. 2020 Mar 23;38(14):2913-2924. doi: 10.1016/j.**vaccine**.2020.02.069. Epub 2020 Feb 29.

PMID: 32127225

New insights about **vaccine** effectiveness: Impact of attenuated PRRS-strain vaccination on heterologous strain transmission.

Chase-Topping M, Xie J, Pooley C, Trus I, Bonckaert C, Rediger K, Bailey RI, Brown H, Bitsouni V, Barrio MB, Gueguen S, Nauwynck H, Doeschl-Wilson A.

Vaccine. 2020 Mar 23;38(14):3050-3061. doi: 10.1016/j.**vaccine**.2020.02.015. Epub 2020 Feb 29.

PMID: 32122719

Geospatial variation in measles **vaccine** coverage through routine and campaign strategies in Nigeria: Analysis of recent household surveys.

Utazi CE, Wagai J, Pannell O, Cutts FT, Rhoda DA, Ferrari MJ, Dieng B, Oteri J, Danovaro-Holliday MC, Adeniran A, Tatem AJ.

Vaccine. 2020 Mar 23;38(14):3062-3071. doi: 10.1016/j.**vaccine**.2020.02.070. Epub 2020 Feb 29.

PMID: 32122718

The adult vaccination landscape in the United States during the Affordable Care Act era: Results from a large retrospective database analysis.

Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C.

Vaccine. 2020 Mar 23;38(14):2984-2994. doi: 10.1016/j.**vaccine**.2020.02.057. Epub 2020 Feb 27.

PMID: 32115298

Potential process improvements to increase coverage of human papillomavirus **vaccine** in schools - A focus on schools with low **vaccine** uptake.

Selvey LA, Roux F, Burns S.

Vaccine. 2020 Mar 23;38(14):2971-2977. doi: 10.1016/j.**vaccine**.2020.02.047. Epub 2020 Feb 27.

PMID: 32115296

The protective efficacy of recombinant hypoxic response protein 1 of Nocardia seriolae in largemouth bass (Micropterus salmoides).

Hoang HH, Wang PC, Chen SC.

Vaccine. 2020 Mar 23;38(14):2925-2936. doi: 10.1016/j.**vaccine**.2020.02.062. Epub 2020 Feb 27.

PMID: 32115295

Meningococcal carriage in young adults six years after meningococcal C conjugate (MCC) **vaccine** catch-up campaign in Salvador, Brazil.

Ferreira VM, Ferreira ÍE, Chang HY, Nunes AMPB, Topaz N, Pimentel ER, Moura ARSS, Ribeiro GS, Feitosa CA, Reis MG, Wang X, Campos LC.

Vaccine. 2020 Mar 23;38(14):2995-3002. doi: 10.1016/j.**vaccine**.2020.02.050. Epub 2020 Feb 28.

PMID: 32115294

Influenza **vaccine** effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis.

Kalligeros M, Shehadeh F, Mylona EK, Dapaah-Afriyie C, van Aalst R, Chit A, Mylonakis E.

Vaccine. 2020 Mar 23;38(14):2893-2903. doi: 10.1016/j.**vaccine**.2020.02.049. Epub 2020 Feb 27. Review.

PMID: 32113808

Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.

Liu FJ, Shi DY, Mao YY, Xiong XH, Lu JS, Pang XB, Dong XJ, Yang ZX, Yu YZ.

Vaccine. 2020 Mar 23;38(14):2978-2983. doi: 10.1016/j.**vaccine**.2020.02.060. Epub 2020 Feb 26.

PMID: 32113807

Japanese encephalitis in the Western Pacific Region: Implication from the Republic of Korea.

Choe YJ, Jee Y, Takashima Y, Lee JK.

Vaccine. 2020 Mar 17;38(13):2760-2763. doi: 10.1016/j.**vaccine**.2020.02.061. Epub 2020 Feb 25.

PMID: 32111531

Corrigendum to "Using pneumococcal and rotavirus surveillance in **vaccine** decision-making: A series of case studies in Bangladesh, Armenia and the Gambia" [**Vaccine** 36 (2018) 4939-4943].

Hasan AZ, Saha S, Saha SK, Sahakyan G, Grigoryan S, Mwenda JM, Antonio M, Knoll MD, Nakamura T, Serhan F, Cohen AL; Pneumococcal and rotavirus surveillance case study group.

Vaccine. 2020 Mar 17;38(13):2887. doi: 10.1016/j.**vaccine**.2020.02.033. Epub 2020 Feb 25. No abstract available.

PMID: 32111529

Field challenges to measles elimination in the Democratic Republic of the Congo.

Coulborn RM, Nackers F, Bachy C, Porten K, Vochten H, Ndele E, Van Herp M, Bibala-Faray E, Cohuet S, Panunzi I.

Vaccine. 2020 Mar 17;38(13):2800-2807. doi: 10.1016/j.**vaccine**.2020.02.029. Epub 2020 Feb 25.

PMID: 32111528

Evaluation of temperature stability among different types and grades of **vaccine** storage units: Data from continuous temperature monitoring devices.

Leidner AJ, Fisun H, Trimble S, Lucas P, Noblit C, Stevenson JM.

Vaccine. 2020 Mar 23;38(14):3008-3014. doi: 10.1016/j.**vaccine**.2020.02.043. Epub 2020 Feb 25.

PMID: 32111527

Bivalent Junin & Machupo experimental **vaccine** based on alphavirus RNA replicon vector.

Johnson DM, Jokinen JD, Wang M, Pfeffer T, Tretyakova I, Carrion R Jr, Griffiths A, Pushko P, Lukashevich IS.

Vaccine. 2020 Mar 23;38(14):2949-2959. doi: 10.1016/j.**vaccine**.2020.02.053. Epub 2020 Feb 25.

PMID: 32111526

A bacterial **vaccine** polypeptide protective against nontypable Haemophilus influenzae.

Whitby PW, Morton DJ, Mussa HJ, Mirea L, Stull TL.

Vaccine. 2020 Mar 23;38(14):2960-2970. doi: 10.1016/j.**vaccine**.2020.02.054. Epub 2020 Feb 25.

PMID: 32111525

The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans.

Nguyen DN, Redman RL, Horiya S, Bailey JK, Xu B, Stanfield RL, Temme JS, LaBranche CC, Wang S, Rodal AA, Montefiori DC, Wilson IA, Krauss IJ.

ACS Chem Biol. 2020 Mar 20;15(3):789-798. doi: 10.1021/acschembio.0c00053. Epub 2020 Mar 9.

PMID: 32109354

The impact of new universal child influenza programs in Australia: **Vaccine** coverage, effectiveness and disease epidemiology in hospitalised children in 2018.

Blyth CC, Cheng AC, Crawford NW, Clark JE, Buttery JP, Marshall HS, Francis JR, McRae J, Kotsimbos T, Kelly PM, Macartney KK; Paediatric Active Enhanced Disease Surveillance (PAEDS), Influenza Complications Alert Network (FluCAN) Collaboration.

Vaccine. 2020 Mar 17;38(13):2779-2787. doi: 10.1016/j.**vaccine**.2020.02.031. Epub 2020 Feb 24.

PMID: 32107062

'Should I vaccinate my child?' comparing the displayed stances of **vaccine** information retrieved from Google, Facebook and YouTube.

Elkin LE, Pullon SRH, Stubbe MH.

Vaccine. 2020 Mar 17;38(13):2771-2778. doi: 10.1016/j.**vaccine**.2020.02.041. Epub 2020 Feb 25.

PMID: 32107061

A codon-pair deoptimized live-attenuated **vaccine** against respiratory syncytial virus is immunogenic and efficacious in non-human primates.

Mueller S, Stauft CB, Kalkeri R, Koidei F, Kushnir A, Tasker S, Coleman JR.

Vaccine. 2020 Mar 23;38(14):2943-2948. doi: 10.1016/j.**vaccine**.2020.02.056. Epub 2020 Feb 24.

PMID: 32107060

Mumps: an Update on Outbreaks, **Vaccine** Efficacy, and Genomic Diversity.

Lam E, Rosen JB, Zucker JR.

Clin Microbiol Rev. 2020 Feb 26;33(2). pii: e00151-19. doi: 10.1128/CMR.00151-19. Print 2020 Mar 18. Review.

PMID: 32102901

Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G.

Clin Microbiol Rev. 2020 Feb 26;33(2). pii: e00046-19. doi: 10.1128/CMR.00046-19. Print 2020 Mar 18. Review.

PMID: 32102898

Factors associated with referring close contacts to an app with individually-tailored **vaccine** information.

Dudley MZ, Limaye RJ, Omer SB, O'Leary ST, Ellingson MK, Spina CI, Brewer SE, Chamberlain AT, Bednarczyk RA, Malik F, Frew PM, Salmon DA.

Vaccine. 2020 Mar 17;38(13):2827-2832. doi: 10.1016/j.**vaccine**.2020.02.019. Epub 2020 Feb 22.

PMID: 32098739

Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus **vaccine** is associated with improved survival among patients with Ebolavirus infection.

Kasereka MC, Ericson AD, Conroy AL, Tumba L, Mwesha OD, Hawkes MT.

Vaccine. 2020 Mar 23;38(14):3003-3007. doi: 10.1016/j.**vaccine**.2020.02.044. Epub 2020 Feb 21.

PMID: 32093984

Evaluation of Plasmodium vivax HAP2 as a transmission-blocking **vaccine** candidate.

Qiu Y, Zhao Y, Liu F, Ye B, Zhao Z, Thongpoon S, Roobsoong W, Sattabongkot J, Cui L, Fan Q, Cao Y.

Vaccine. 2020 Mar 17;38(13):2841-2848. doi: 10.1016/j.**vaccine**.2020.02.011. Epub 2020 Feb 21.

PMID: 32093983

Chinese social media suggest decreased **vaccine** acceptance in China: An observational study on Weibo following the 2018 Changchun Changsheng **vaccine** incident.

Hu D, Martin C, Dredze M, Broniatowski DA.

Vaccine. 2020 Mar 17;38(13):2764-2770. doi: 10.1016/j.**vaccine**.2020.02.027. Epub 2020 Feb 22.

PMID: 32093982

Higher mass meningococcal group C-tetanus toxoid **vaccines** conjugated with carbodiimide correlate with greater immunogenicity.

Lockyer K, Gao F, Francis RJ, Eastwood D, Khatri B, Stebbings R, Derrick JP, Bolgiano B.

Vaccine. 2020 Mar 17;38(13):2859-2869. doi: 10.1016/j.**vaccine**.2020.02.012. Epub 2020 Feb 20.

PMID: 32089463

Neutralization capacity of highly divergent type 2 **vaccine**-derived polioviruses from immunodeficient patients.

McDonald SL, Weldon WC, Wei L, Chen Q, Shaw J, Zhao K, Jorba J, Kew OM, Pallansch MA, Burns CC, Steven Oberste M.

Vaccine. 2020 Mar 23;38(14):3042-3049. doi: 10.1016/j.**vaccine**.2020.02.035. Epub 2020 Feb 20.

PMID: 32089462

Quality and reliability of vaccination documentation in the routine childhood immunization program in Burkina Faso: Results from a cross-sectional survey.

Kaboré L, Méda CZ, Sawadogo F, Bengue MM, Kaboré WM, Essoh AT, Gervaix A, Galetto-Lacour A, Médah I, Betsem E.

Vaccine. 2020 Mar 17;38(13):2808-2815. doi: 10.1016/j.**vaccine**.2020.02.023. Epub 2020 Feb 20.

PMID: 32089461

Comparing vaccination hesitancy in Polish migrant parents who accept or refuse nasal flu vaccination for their children.

Gorman DR, Bielecki K, Larson HJ, Willocks LJ, Craig J, Pollock KG.

Vaccine. 2020 Mar 17;38(13):2795-2799. doi: 10.1016/j.**vaccine**.2020.02.028. Epub 2020 Feb 20.

PMID: 32089460

Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study.

Hvass AMF, Norredam M, Sodemann M, Thomsen MK, Christian W.

Vaccine. 2020 Mar 17;38(13):2788-2794. doi: 10.1016/j.**vaccine**.2020.02.025. Epub 2020 Feb 20.

PMID: 32089459

High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands.

Vos RA, Pasmans H, Tymchenko L, Janga-Jansen AVA, Baboe-Kalpoe S, Hulshof K, de Melker HE, van der Klis FRM.

Vaccine. 2020 Mar 17;38(13):2816-2826. doi: 10.1016/j.**vaccine**.2020.02.017. Epub 2020 Feb 19.

PMID: 32088019

Predictors of oral rotavirus **vaccine** immunogenicity in rural Zimbabwean infants.

Church JA, Chasekwa B, Rukobo S, Govha M, Lee B, Carmolli MP, Ntozini R, Mutasa K, McNeal MM, Majo FD, Tavengwa NV, Kirkpatrick BD, Moulton LH, Humphrey JH, Prendergast AJ.

Vaccine. 2020 Mar 17;38(13):2870-2878. doi: 10.1016/j.**vaccine**.2020.01.097. Epub 2020 Feb 19.

PMID: 32088018

Anal human papillomavirus among men who have sex with men in three metropolitan cities in southern China: implications for HPV vaccination.

Zhou Y, Lin YF, Meng X, Duan Q, Wang Z, Yang B, Zheng H, Li P, Li M, Lu Y, Luo Z, Zou H.

Vaccine. 2020 Mar 17;38(13):2849-2858. doi: 10.1016/j.**vaccine**.2020.02.009. Epub 2020 Feb 20.

PMID: 32088017

Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies.

Vodicka E, Zimmermann M, Lopez AL, Silva MW, Gorgolon L, Kohei T, Mooney J, Muhib F, Pecenka C, Marfin AA.

Vaccine. 2020 Mar 17;38(13):2833-2840. doi: 10.1016/j.**vaccine**.2020.02.018. Epub 2020 Feb 19.

PMID: 32085954

Acute gastroenteritis hospitalizations after implementation of universal mass vaccination against rotavirus.

Kõivumägi K, Toompere K, Soeorg H, Kallas E, Jõgeda EL, Huik K; Rotavirus Study group, Lutsar I.

Vaccine. 2020 Mar 17;38(13):2879-2886. doi: 10.1016/j.**vaccine**.2020.01.098. Epub 2020 Feb 14.

PMID: 32067818

Carcinogenesis of β-Propiolactone: A Computational Study.

Španinger E, Bren U.

Chem Res Toxicol. 2020 Mar 16;33(3):769-781. doi: 10.1021/acs.chemrestox.9b00389. Epub 2020 Feb 26.

PMID: 32056425

C-Mannosyl Lysine for Solid Phase Assembly of Mannosylated Peptide Conjugate Cancer **Vaccines**.

Hogervorst TP, Li RJE, Marino L, Bruijns SCM, Meeuwenoord NJ, Filippov DV, Overkleeft HS, van der Marel GA, van Vliet SJ, van Kooyk Y, Codée JDC.

ACS Chem Biol. 2020 Mar 20;15(3):728-739. doi: 10.1021/acschembio.9b00987. Epub 2020 Feb 20.

PMID: 32045202

Structure-based group A streptococcal **vaccine** design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.

Aranha MP, Penfound TA, Spencer JA, Agarwal R, Baudry J, Dale JB, Smith JC.

J Biol Chem. 2020 Mar 20;295(12):3826-3836. doi: 10.1074/jbc.RA119.011258. Epub 2020 Feb 6.

PMID: 32029479

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola **Vaccine** during the Sierra Leone Trial to Introduce a **Vaccine** against Ebola.

Legardy-Williams JK, Carter RJ, Goldstein ST, Jarrett OD, Szefer E, Fombah AE, Tinker SC, Samai M, Mahon BE.

Emerg Infect Dis. 2020 Mar;26(3):541-548. doi: 10.3201/eid2603.191018. Epub 2020 Mar 17.

PMID: 32017677

The Blood Stage Antigen RBP2-P1 of Plasmodium vivax Binds Reticulocytes and Is a Target of Naturally Acquired Immunity.

Chim-Ong A, Surit T, Chainarin S, Roobsoong W, Sattabongkot J, Cui L, Nguitragool W.

Infect Immun. 2020 Mar 23;88(4). pii: e00616-19. doi: 10.1128/IAI.00616-19. Print 2020 Mar 23.

PMID: 32014895

Unbiased Identification of Immunogenic Staphylococcus aureus Leukotoxin B-Cell Epitopes.

Hernandez DN, Tam K, Shopsin B, Radke EE, Kolahi P, Copin R, Stubbe FX, Cardozo T, Torres VJ, Silverman GJ.

Infect Immun. 2020 Mar 23;88(4). pii: e00785-19. doi: 10.1128/IAI.00785-19. Print 2020 Mar 23.

PMID: 32014894

Immediate Interferon Gamma Induction Determines Murine Host Compatibility Differences between Toxoplasma gondii and Neospora caninum.

Coombs RS, Blank ML, English ED, Adomako-Ankomah Y, Urama IS, Martin AT, Yarovinsky F, Boyle JP.

Infect Immun. 2020 Mar 23;88(4). pii: e00027-20. doi: 10.1128/IAI.00027-20. Print 2020 Mar 23.

PMID: 32014892

Drug treatment options for the 2019-new coronavirus (2019-nCoV).

Lu H.

Biosci Trends. 2020 Mar 16;14(1):69-71. doi: 10.5582/bst.2020.01020. Epub 2020 Jan 28.

PMID: 31996494

Modulation of immune responses with nanoparticles and reduction of their immunotoxicity.

Muhammad Q, Jang Y, Kang SH, Moon J, Kim WJ, Park H.

Biomater Sci. 2020 Mar 17;8(6):1490-1501. doi: 10.1039/c9bm01643k. Review.

PMID: 31994542

Spectroscopic characterisation of a series of Salmonella Typhi Vi-diphtheria toxoid glycoconjugate antigens differing in polysaccharide-protein ratio.

Jones C, An SJ, Yoon YK, Kothari S, Sahastrabuddhe S, Carbis R.

J Pharm Biomed Anal. 2020 Mar 20;181:113100. doi: 10.1016/j.jpba.2020.113100. Epub 2020 Jan 9.

PMID: 31991319

Development of a Highly Effective African Swine Fever Virus **Vaccine** by Deletion of the I177L Gene Results in Sterile Immunity against the Current Epidemic Eurasia Strain.

Borca MV, Ramirez-Medina E, Silva E, Vuono E, Rai A, Pruitt S, Holinka LG, Velazquez-Salinas L, Zhu J, Gladue DP.

J Virol. 2020 Mar 17;94(7). pii: e02017-19. doi: 10.1128/JVI.02017-19. Print 2020 Mar 17.

PMID: 31969432

Nasal Delivery of a Commensal *Pasteurellaceae* Species Inhibits Nontypeable Haemophilus influenzae Colonization and Delays Onset of Otitis Media in Mice.

Granland CM, Scott NM, Lauzon-Joset JF, Langereis JD, de Gier C, Sutherland KMJ, Clark SL, Pickering JL, Thornton RB, Richmond PC, Strickland DH, Kirkham LS.

Infect Immun. 2020 Mar 23;88(4). pii: e00685-19. doi: 10.1128/IAI.00685-19. Print 2020 Mar 23.

PMID: 31964748

Peripheral Merozoite Surface Proteins Are Targets of Naturally Acquired Immunity against Malaria in both India and Ghana.

Garcia-Senosiain A, Kana IH, Singh SK, Chourasia BK, Das MK, Dodoo D, Singh S, Adu B, Theisen M.

Infect Immun. 2020 Mar 23;88(4). pii: e00778-19. doi: 10.1128/IAI.00778-19. Print 2020 Mar 23.

PMID: 31964745

Live attenuated pertussis **vaccine** BPZE1 induces a broad antibody response in humans.

Lin A, Apostolovic D, Jahnmatz M, Liang F, Ols S, Tecleab T, Wu C, van Hage M, Solovay K, Rubin K, Locht C, Thorstensson R, Thalen M, Loré K.

J Clin Invest. 2020 Mar 23. pii: 135020. doi: 10.1172/JCI135020. [Epub ahead of print]

PMID: 31945015

Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.

Wong SS, Waite B, Ralston J, Wood T, Reynolds GE, Seeds R, Newbern EC, Thompson MG, Huang QS, Webby RJ; SHIVERS Investigation Team.

J Virol. 2020 Mar 17;94(7). pii: e01385-19. doi: 10.1128/JVI.01385-19. Print 2020 Mar 17.

PMID: 31941786

Sensitivity of Alphaviruses to G3BP Deletion Correlates with Efficiency of Replicase Polyprotein Processing.

Götte B, Utt A, Fragkoudis R, Merits A, McInerney GM.

J Virol. 2020 Mar 17;94(7). pii: e01681-19. doi: 10.1128/JVI.01681-19. Print 2020 Mar 17.

PMID: 31941782

Typical Stress Granule Proteins Interact with the 3' Untranslated Region of Enterovirus D68 To Inhibit Viral Replication.

Cheng J, Gao S, Zhu C, Liu S, Li J, Kang J, Wang Z, Wang T.

J Virol. 2020 Mar 17;94(7). pii: e02041-19. doi: 10.1128/JVI.02041-19. Print 2020 Mar 17.

PMID: 31941779

Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits.

Yang YR, McCoy LE, van Gils MJ, Andrabi R, Turner HL, Yuan M, Cottrell CA, Ozorowski G, Voss J, Pauthner M, Polveroni TM, Messmer T, Wilson IA, Sanders RW, Burton DR, Ward AB.

J Virol. 2020 Mar 17;94(7). pii: e01861-19. doi: 10.1128/JVI.01861-19. Print 2020 Mar 17.

PMID: 31941772

Glycan Profiles of gp120 Protein **Vaccines** from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.

Wang S, Voronin Y, Zhao P, Ishihara M, Mehta N, Porterfield M, Chen Y, Bartley C, Hu G, Han D, Wells L, Tiemeyer M, Lu S.

J Virol. 2020 Mar 17;94(7). pii: e01968-19. doi: 10.1128/JVI.01968-19. Print 2020 Mar 17.

PMID: 31941770

Improved transplant survival and long-term disease outcome in children with MHC class II deficiency.

Lum SH, Anderson C, McNaughton P, Engelhardt KR, MacKenzie B, Watson H, Al-Mousa H, Al-Herz W, Al-Saud B, Mohammed R, Al-Zahrani DM, Alghamdi HA, Goronfolah L, Nademi Z, Habibollah S, Flinn

AM, Shillitoe B, Owens S, Williams E, Emonts M, Hambleton S, Abinun M, Flood T, Cant A, Gennery AR, Slatter M.

Blood. 2020 Mar 19;135(12):954-973. doi: 10.1182/blood.2019002690.

PMID: 31932845

Broadly Protective Multivalent OspA **Vaccine** against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.

Nayak A, Schüler W, Seidel S, Gomez I, Meinke A, Comstedt P, Lundberg U.

Infect Immun. 2020 Mar 23;88(4). pii: e00917-19. doi: 10.1128/IAI.00917-19. Print 2020 Mar 23.

PMID: 31932330

Interaction of Brucella abortus with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and **Vaccine** Safety.

Khalaf OH, Chaki SP, Garcia-Gonzalez DG, Suva LJ, Gaddy D, Arenas-Gamboa AM.

Infect Immun. 2020 Mar 23;88(4). pii: e00822-19. doi: 10.1128/IAI.00822-19. Print 2020 Mar 23.

PMID: 31932325

Need for BCG Vaccination to Prevent TB in High-Incidence Countries and Populations.

Pooransingh S, Sakhamuri S.

Emerg Infect Dis. 2020 Mar;26(3):624-625. doi: 10.3201/eid2603.191232. Epub 2020 Mar 17.

PMID: 31922950

Human Epitopes Identified from Herpes Simplex Virus Tegument Protein VP11/12 (UL46) Recall Multifunctional Effector Memory $CD4^+$ T_{EM} Cells in Asymptomatic Individuals and Protect from Ocular Herpes Infection and Disease in "Humanized" HLA-DR Transgenic Mice.

Srivastava R, Coulon PA, Prakash S, Dhanushkodi NR, Roy S, Nguyen AM, Alomari NI, Mai UT, Amezquita C, Ye C, Maillère B, BenMohamed L.

J Virol. 2020 Mar 17;94(7). pii: e01991-19. doi: 10.1128/JVI.01991-19. Print 2020 Mar 17.

PMID: 31915285

Rapid Generation of Attenuated Infectious Bursal Disease Virus from Dual-Promoter Plasmids by Reduction of Viral Ribonucleoprotein Activity.

Yang H, Wang Y, Ye C.

J Virol. 2020 Mar 17;94(7). pii: e01569-19. doi: 10.1128/JVI.01569-19. Print 2020 Mar 17.

PMID: 31915284

Conserved Rotavirus NSP5 and VP2 Domains Interact and Affect Viroplasm.

Buttafuoco A, Michaelsen K, Tobler K, Ackermann M, Fraefel C, Eichwald C.

J Virol. 2020 Mar 17;94(7). pii: e01965-19. doi: 10.1128/JVI.01965-19. Print 2020 Mar 17.

PMID: 31915278

The emerging role of epigenetics in the immune response to vaccination and infection: a systematic review.

Bannister S, Messina NL, Novakovic B, Curtis N.

Epigenetics. 2020 Mar 17:1-39. doi: 10.1080/15592294.2020.1712814. [Epub ahead of print]

PMID: 31914857

Induction of Effective Immunity against Trypanosoma cruzi.

Williams T, Guerrero-Ros I, Ma Y, Matos Dos Santos F, Scherer PE, Gordillo R, Horta A, Macian F, Weiss LM, Huang H.

Infect Immun. 2020 Mar 23;88(4). pii: e00908-19. doi: 10.1128/IAI.00908-19. Print 2020 Mar 23.

PMID: 31907197

Understanding Immunity in Children Vaccinated With Live Attenuated Influenza **Vaccine**.

Shannon I, White CL, Nayak JL.

J Pediatric Infect Dis Soc. 2020 Mar 19;9(Supplement_1):S10-S14. doi: 10.1093/jpids/piz083.

PMID: 31848606

Corrigendum to: Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.

Spring MD, Sousa JC, Li Q, Darko CA, Morrison MN, Marcsisin SR, Mills KT, Potter BM, Paolino KM, Twomey PS, Moon JE, Tosh DM, Cicatelli SB, Froude JW, Pybus BS, Oliver TG, Mccarthy WF, Waters NC, Smith PL, Reichard GA, Bennett JW.

J Infect Dis. 2020 Mar 16;221(7):1204. doi: 10.1093/infdis/jiz599. No abstract available.

PMID: 31773155

Human Neonatal Rotavirus **Vaccine** (RV3-BB) Produces **Vaccine** Take Irrespective of Histo-Blood Group Antigen Status.

Boniface K, Byars SG, Cowley D, Kirkwood CD, Bines JE.

J Infect Dis. 2020 Mar 16;221(7):1070-1078. doi: 10.1093/infdis/jiz333.

PMID: 31763671

The Effects of Japanese Encephalitis **Vaccine** and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue **Vaccine**: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.

Glass A, Polhemus M, Wang D, Jarman RG, Thomas SJ, Friberg H, Currier JR, Bonaparte M, De La Barra R, Princiotta MF, Abbott M, Cuzzo B, Machabert T, Sridhar S, Endy TP.

J Infect Dis. 2020 Mar 16;221(7):1057-1069. doi: 10.1093/infdis/jiz592.

PMID: 31755526

Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus **Vaccine**.

Smith C, Moraka NO, Ibrahim M, Moyo S, Mayondi G, Kammerer B, Leidner J, Gaseitsiwe S, Li S, Shapiro R, Lockman S, Weinberg A.

J Infect Dis. 2020 Mar 16;221(7):1167-1175. doi: 10.1093/infdis/jiz590.

PMID: 31711179

Cytokine Profile Distinguishes Children With Plasmodium falciparum Malaria From Those With Bacterial Blood Stream Infections.

Struck NS, Zimmermann M, Krumkamp R, Lorenz E, Jacobs T, Rieger T, Wurr S, Günther S, Gyau Boahen K, Marks F, Sarpong N, Owusu-Dabo E, May J, Eibach D.

J Infect Dis. 2020 Mar 16;221(7):1098-1106. doi: 10.1093/infdis/jiz587.

PMID: 31701142

Cytomegalovirus Antibody Responses Associated With Increased Risk of Tuberculosis Disease in Ugandan Adults.

Stockdale L, Nash S, Farmer R, Raynes J, Mallikaarjun S, Newton R, Fletcher HA.

J Infect Dis. 2020 Mar 16;221(7):1127-1134. doi: 10.1093/infdis/jiz581.

PMID: 31689350

Antimicrobial Resistance Following Azithromycin Mass Drug Administration: Potential Surveillance Strategies to Assess Public Health Impact.

Mack I, Sharland M, Berkley JA, Klein N, Malhotra-Kumar S, Bielicki J.

Clin Infect Dis. 2020 Mar 17;70(7):1501-1508. doi: 10.1093/cid/ciz893.

PMID: 31633161

Adjuvanted Recombinant Glycoprotein E Herpes Zoster **Vaccine**.

Levin MJ, Weinberg A.

Clin Infect Dis. 2020 Mar 17;70(7):1509-1515. doi: 10.1093/cid/ciz770.

PMID: 31618437

Depletion-of-susceptibles Bias in Analyses of Intra-season Waning of Influenza **Vaccine** Effectiveness.

Ray GT, Lewis N, Klein NP, Daley MF, Lipsitch M, Fireman B.

Clin Infect Dis. 2020 Mar 17;70(7):1484-1486. doi: 10.1093/cid/ciz706.

PMID: 31351439

The Limitations of the Rheumatogenic Concept for Group A Streptococcus: Systematic Review and Genetic Analysis.

de Crombrugghe G, Baroux N, Botteaux A, Moreland NJ, Williamson DA, Steer AC, Smeesters PR.

Clin Infect Dis. 2020 Mar 17;70(7):1453-1460. doi: 10.1093/cid/ciz425.

PMID: 31334754

Antibiotic Prescribing and Respiratory Viral Testing for Acute Upper Respiratory Infections Among Adult Patients at an Ambulatory Cancer Center.

Krantz EM, Zier J, Stohs E, Ogimi C, Sweet A, Marquis S, Klaassen J, Pergam SA, Liu C.

Clin Infect Dis. 2020 Mar 17;70(7):1421-1428. doi: 10.1093/cid/ciz409.

PMID: 31095276

Early Signals of **Vaccine**-driven Perturbation Seen in Pneumococcal Carriage Population Genomic Data.

Chaguza C, Heinsbroek E, Gladstone RA, Tafatatha T, Alaerts M, Peno C, Cornick JE, Musicha P, Bar-Zeev N, Kamng'ona A, Kadioglu A, McGee L, Hanage WP, Breiman RF, Heyderman RS, French N, Everett DB, Bentley SD.

Clin Infect Dis. 2020 Mar 17;70(7):1294-1303. doi: 10.1093/cid/ciz404.

PMID: 31094423

Bacillus Calmette-Guérin Overexpressing an Endogenous Stimulator of Interferon Genes Agonist Provides Enhanced Protection Against Pulmonary Tuberculosis.

Dey RJ, Dey B, Singh AK, Praharaj M, Bishai W.

J Infect Dis. 2020 Mar 16;221(7):1048-1056. doi: 10.1093/infdis/jiz116.

PMID: 30901058

Patentes registradas en la United States Patent and Trademark Office (USPTO)

	PAT. NO.	Title
1	10,598,666	In vitro potency assay for protein-based meningococcal vaccines
2	10,597,732	Allogeneic autophagosome-enriched composition for the treatment of disease
3	10,597,731	Allogeneic autophagosome-enriched composition for the treatment of disease
4	10,597,434	Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
5	10,597,433	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
6	10,597,432	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
7	10,597,397	Adenine conjugate compounds and their use as vaccine adjuvants
8	10,596,254	Synthetic conjugate of CpG DNA and T-help/CTL peptide
9	10,596,253	Vaccines against genital herpes simplex infections
10	10,596,252	Vaccination in newborns and infants
11	10,596,251	Nanoemulsion respiratory syncytial virus (RSV) subunit vaccine
12	10,596,246	Adjuvanted combinations of meningococcal factor H binding proteins
13	10,596,243	Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
14	10,596,242	Transfected T-cells and T-cell receptors for use in immunotherapy against cancers
15	10,596,241	Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers
16	10,596,240	Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers
17	10,596,234	Compositions and methods to inhibit viral replication
18	10,596,196	Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
19	10,590,178	Chimeric vaccine against fungal infections
20	10,590,170	Vaccines and vaccine components for inhibition of microbial cells
21	10,588,964	Bacterial RNAs as vaccine adjuvants
22	10,588,962	Carbohydrate-glycolipid conjugate vaccines
23	10,588,959	Combination vaccine
24	10,588,956	Vaccine compositions
25	10,588,955	Streptococcus pneumoniae protein antigen, and preparation method and use thereof
26	10,588,857	Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix

Patentes registradas en Spacenet (European Patent Office (EPO))

1.COMBINATION VACCINE FOR SWINE
US2020085935A1 • 2020-03-19 •
INTERVET INC [US]
Earliest priority: 2016-12-23 • Earliest publication: 2018-06-28
...The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV. ...

2.ANTIGENIC THERMOSTABLE POLIO VACCINES & RELATED METHODS
US2020085941A1 • 2020-03-19 •
UNIVERSAL STABILIZATION TECH INC [US]
Earliest priority: 2017-04-28 • Earliest publication: 2018-11-01

The disclosure concerns vaccines; and more particularly, highly antigenic thermostable vaccines configured for mucosal or transdermal delivery without reconstitution. Also disclosed are methods for formulating the highly antigenic thermostable vaccines.

3.VACCINE COMPOSITION
EP3622965A1 • 2020-03-18 •
TURNSTONE LP [CA]
Earliest priority: 2013-02-21 • Earliest publication: 2014-08-28

There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus

4.PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY
US2020085931A1 • 2020-03-19 •
UNIV CALIFORNIA [US]
Earliest priority: 2018-09-19 • Earliest publication: 2020-03-19
Cancer-testis antigens were simultaneously packaged with CpG adjuvant and incorporated into an E2 nanoparticle platform to increase cancer vaccine efficacy. Also described herein is a combination of

checkpoint blockade therapy and the nanoparticle vaccine platform to deliver cancer antigens with adjuvant for treatment of tumors and prevention of future tumors. The nanoparticle vaccine platform includes a protein capsule to ...

5.Hank cetuximab combinations and methods
AU2018318125A1 • 2020-03-19 •
NANTCELL INC
Earliest priority: 2017-08-15 • Earliest publication: 2019-02-21
Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.

6.VLP-BASED BIVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
US2020085936A1 • 2020-03-19 •
CHILDRENS HOSPITAL MED CT [US]
Earliest priority: 2017-03-28 • Earliest publication: 2018-10-04
...Disclosed herein are virus-like particle (VLP)-based bivalent vaccine compositions. The compositions may comprise a spherical retroviral Group—specific... the exterior surface of the spherical Gag protein core, such that the VLP-based vaccine presents at least two Ebola ...

7.ANTIGEN FUSED WITH PORCINE FC FRAGMENT AND VACCINE COMPOSITION COMPRISING THE SAME
US2020085926A1 • 2020-03-19 •
BIOAPPLICATIONS INC [KR]
Earliest priority: 2018-09-19 • Earliest publication: 2020-03-19
Provided is an antigen fused with a porcine Fc fragment, a vaccine composition having a self-adjuvanting effect by binding...

8.NOVEL PD-L1 TARGETING DNA VACCINE FOR CANCER IMMUNOTHERAPY
US2020085928A1 • 2020-03-19 •
VAXIMM AG [CH]
Earliest priority: 2017-03-17 • Earliest publication: 2018-09-20

The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding PD-L1. In particular, the present invention relates to said attenuated strain of Salmonella for use in the treatment of cancer.

9.DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
US2020085939A1 • 2020-03-19 •
US HEALTH [US]
Earliest priority: 2001-05-22 • Earliest publication: 2002-11-28

A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.

10.METHODS FOR ENTEROVIRUS INACTIVATION, ADJUVANT ADSORPTION AND DOSE REDUCED VACCINE COMPOSITIONS OBTAINED THEREOF
US2020085940A1 • 2020-03-19 •
SERUM INST OF INDIA PVT LTD [IN]
Earliest priority: 2014-10-07 • Earliest publication: 2020-03-19

The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.

11.Aldoxorubicin combination treatments and methods
AU2018328134A1 • 2020-03-19 •
NANTCELL INC
Earliest priority: 2017-09-06 • Earliest publication: 2019-03-14

Contemplated cancer therapies use aldoxorubicin as an immunomodulator of a tumor microenvironment to increase therapeutic effects of immune therapeutic compositions.

12.PNEUMOCOCCAL FUSION PROTEIN VACCINES
US2020087361A1 • 2020-03-19 •
CHILDRENS MEDICAL CT CORP [US]
Earliest priority: 2018-09-12 • Earliest publication: 2020-03-19

Technologies for the prevention and/or treatment of pneumococcal infections.

13.METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES AGAINST CLOSTRIDIUM DIFFICILE
US2020085934A1 • 2020-03-19 •
NOVAVAX INC [US]
Earliest priority: 2017-03-15 • Earliest publication: 2018-09-20

Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.

14.RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY
US2020085944A1 • 2020-03-19 •
BOEHRINGER INGELHEIM INT [DE]
Earliest priority: 2017-03-17 • Earliest publication: 2018-09-20
... present invention provides a combination of an RNA encoding an epitope and immune checkpoint inhibitors. A pharmaceutical composition, vaccine, and kit-of-parts comprising said combination are also provided. Furthermore, the present invention relates to the combination, (pharmaceutical) composition, vaccine ...

15.VACCINE COMPOSITIONS
EP3621644A1 • 2020-03-18 •
STABILITECH BIOPHARMA LTD [GB]
Earliest priority: 2017-05-08 • Earliest publication: 2018-11-14
No abstract available

16.Virus Like Particle Compositions and Methods of Use
US2020085938A1 • 2020-03-19 •
THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES [US]
Earliest priority: 2008-11-26 • Earliest publication: 2010-06-03

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

17.Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328037A1 • 2020-03-19 •
MERCK SHARP & DOHME
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention provides capsular polysaccharides from

18.Methods and Compositions Using Highly Conserved Pneumococcal Surface Proteins
US2020085932A1 • 2020-03-19 •
BOSTON MEDICAL CT CORP [US]
Earliest priority: 2017-03-31 • Earliest publication: 2018-10-04

Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.

19.Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328038A1 • 2020-03-19 •
MERCK SHARP & DOHME
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

20.EPIDERMAL MRNA VACCINE
US2020085852A1 • 2020-03-19 •
CUREVAC AG [DE]
Earliest priority: 2015-08-05 • Earliest publication: 2017-02-09

The invention concerns the field of genetic vaccination, in particular RNA vaccines. The present invention provides an mRNA for use in the treatment and/or prevention of a disease, wherein the mRNA is administered to the epidermis. Furthermore, the invention provides compositions comprising the mRNA for epidermal administration or kits comprising the mRNA for epidermal administration. Moreover, the invention concerns the medical use of the mRNA or compositions comprising the mRNA, wherein the mRNA or compositions comprising the mRNA are administered to the epidermis.

21.Trait selection in avians
AU2018278516A1 • 2020-03-19 •
COMMW SCIENT IND RES ORG
Earliest priority: 2017-05-31 • Earliest publication: 2018-12-06

The present invention relates to transgenic avians and the eggs produced therefrom wherein the eggs comprise a genetic modification that facilitates

22.Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328036A1 • 2020-03-19 •
MERCK SHARP & DOHME
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention provides capsular polysaccharides from

23.Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
AU2018328035A1 • 2020-03-19 •
ABEYGUNAWARDANA CHITRANANDA
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention provides capsular polysaccharides from

24.Bordetella vaccines comprising LPS with reduced reactogenicity
US2020085933A1 • 2020-03-19 •
DE STAAT DER NEDERLANDEN VERT DOOR DE MINI VAN VWS MINI VAN VOLKSGEZONDHEID WELZIJN EN [NL]
Earliest priority: 2017-03-13 • Earliest publication: 2018-09-20

The current invention lies in the field of medicine and more specifically in the field of vaccinology. The current invention concerns a novel Bordetella LPS and a modified bacterium of the genus Bordetella comprising such modified LPS. The LPS of the invention has a reduced endotoxicity in comparison to an unmodified Bordetella LPS. The modified LPS of the invention is therefore particularly suitable for use in inducing or stimulating an immune response in a subject, wherein the immune response is induced or

stimulated against a Bordetella infection. The modified Bordetella LPS of the invention is obtainable by introducing in a Bordetella cell the expression of a heterologous acyl transferase. In particular, the modified Bordetella cell of the invention has an increased expression of an heterologous LpxA, LpxL or LpxD acyl transferase.

25.INFLUENZA VIRUS AND TYPE 1 DIABETES
US2020087630A1 • 2020-03-19 •
OSPEDALE SAN RAFFAELE SRL [IT]
Earliest priority: 2012-10-10 • Earliest publication: 2014-04-17

Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities.

26.NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF
US2020085756A1 • 2020-03-19 •
LA JOLLA INST FOR ALLERGY AND IMMUNOLOGY [US]
Earliest priority: 2018-09-14 • Earliest publication: 2020-03-19
... antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of...

27.Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
AU2018328040A1 • 2020-03-19 •
MERCK SHARP & DOHME
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention provides a number of process improvements related to the conjugation of capsular polysaccharides from Streptococcus pneumoniae to a carrier protein. These process are serotype specific and include acid hydrolysis, addition of sodium chloride to the reductive amination reaction, and addition of sucrose to dissolve polysaccharides. Polysaccharide-protein conjugates prepared using the processes of the invention can be included in multivalent pneumococcal conjugate vaccines.

28.IMMUNOGEN FOR BROAD-SPECTRUM INFLUENZA VACCINE AND APPLICATION THEREOF
WO2020051766A1 • 2020-03-19 •
SHANGHAI PUBLIC HEALTH CLINICAL CENTER [CN]
Earliest priority: 2018-09-11 • Earliest publication: 2020-03-19
... provides a recombinant vector vaccine utilizing the immunogen and an application of an immunization method thereof in an influenza vaccine...

29.RECOMBINANT MEASLES VACCINE EXPRESSING HTERT
EP3622078A1 • 2020-03-18 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2017-05-09 • Earliest publication: 2018-11-15

No abstract available

30.Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups
US2020087298A1 • 2020-03-19 •
3M INNOVATIVE PROPERTIES CO [US]
Earliest priority: 2017-03-01 • Earliest publication: 2018-09-07

Imidazo[4,5-c] ring compounds of formula I, (particularly imidazo4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a guanidine substituted benzamide that is attached at the N−1 position by a linking group, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed.

31.PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
US2020085874A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2018-02-21 • Earliest publication: 2019-08-22
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

32.PELLET DELIVERY MECHANISM
US2020085555A1 • 2020-03-19 •
GOVERNMENT OF THE USA AS REPRESENTED BY THE U S DEPT OF THE INTERIOR FISH AND WILDLIFE SERVICE [US]
Earliest priority: 2017-08-11 • Earliest publication: 2019-02-14

Pellet delivery systems capable of reliably and precisely delivering pellets over a large area are disclosed. In some examples, the system can deliver one or more pellets in one delivery cycle using a slide chamber. In other examples, the system can deliver one or more pellets per delivery cycle using a rotating disk comprising one or more holes. In any of these examples, the system can eject the pellets using a projector and/or gravity. The pellet delivery system can, in various examples, be utilized in conjunction with a carrier such as an airborne, terrestrial or aquatic vehicle, or in other examples with a human or animal carrier. Examples of the disclosure are also directed to precise pellet delivery based on the location of the pellet deliver system, pellet delivery tracking, adjusting pellet delivery, and determining paths for efficient pellet delivery.

33.RELAXIN1 DERIVED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS
US2020087378A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2015-03-27 • Earliest publication: 2016-09-29
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

34.EXPRESSION OF RECOMBINANT PROTEINS IN TRICHOPLUSIA NI PUPAE
US2020085022A1 • 2020-03-19 •
ALTERNATIVE GENE EXPRESSION SL [ES]
Earliest priority: 2015-09-17 • Earliest publication: 2017-03-23

The present invention covers means and methods to increase the efficiency of recombinant protein expression, in particular to optimize the industrial production of recombinant proteins in insect pupae, particularly in Trichoplusia ni (T. ni) pupae. Moreover, the present invention is also directed to the pupae itself comprising baculovirus, pupae infected, transformed, transduced or transfected with baculovirases or bacmids, as well as devices suitable for performing the methods of the present invention.

35.COMPUTER HAVING ISOLATED USER COMPUTING UNIT
EP3623978A1 • 2020-03-18 •
KIM DEOK WOO [KR]
Earliest priority: 2017-05-10 • Earliest publication: 2018-11-15

The present invention relates to a computer having an isolated user computing unit for responding to a system seizing attempt by a malicious code and minimizing damage to a system. A computer according to a feature proposed by the present invention comprises: a security management computing unit for managing connected I/O devices and auxiliary storage device unit; and a user computing unit which is isolated from the I/O devices, communicates with the I/O devices via an intercommunication unit responsible for communication between the security management computing unit and the user computing unit, has a separate CPU and memory, and is connected to the security management computing unit. The security management computing unit manages the I/O devices, monitors and restores a system, and monitors and controls the user computing unit, and the user computing unit is isolated from the security management computing unit and executes a user program and a user OS.

36.Nanoalum Particles Containing a Sizing Agent
US2020085757A1 • 2020-03-19 •
INFECTIOUS DISEASE RES INST [US]
Earliest priority: 2016-06-01 • Earliest publication: 2017-12-07

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle N ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

37.NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT
US2020085942A1 • 2020-03-19 •
CUREVAC AG [DE]
Earliest priority: 2008-01-31 • Earliest publication: 2009-08-06

... adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula....g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine ...

38.ANTIGENIC CHIMERIC POLYPEPTIDE, GENE CONSTRUCT AND ANTIGENIC COMPOSITION FOR THE IMMUNOCASTRATION OF NON-HUMAN MAMMALS
WO2020051656A1 • 2020-03-19 •
AMPLICON VACCINE LLC [US]
Earliest priority: 2018-09-12 • Earliest publication: 2020-03-19

The present invention relates to genetic constructs that encode immunogenic antigens comprising a carrier protein and inserts of the decapeptide GnrH/LHRH (gonadotropin-releasing hormone/luteinizing hormone-releasing hormone), or of an analogue thereof, forming antigenic chimeric polypeptides used in immunogenic compositions for the immunocastration of mammals, particularly pigs. The aim of the genetic construct of the present invention is the production of an antigen that is more immunogenic and efficient in terms of the production of GnrH-neutralizing antibodies and, consequently, in inhibiting synthesis of the luteinizing hormone and follicle-stimulating hormone, allowing for the immunocastration of mammals. This aim is achieved by means of genetic constructs encoding the chimeric antigen comprising the carrier protein and a sufficient number of insertions of the decapeptide GnrH or of an analogue thereof to provide a larger number of GnrH epitopes and Th cell-recruitment sequences.

39.METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS
AU2020201439A1 • 2020-03-19 •
IMMUNOLIGHT LLC
Earliest priority: 2008-04-07 • Earliest publication: 2016-08-18
... the method and a method for causing an auto vaccine effect in a subject using the method.

40.IMMUNOTHERAPY WITH A*01 RESTRICTED PEPTIDES AND COMBINATION OF PEPTIDES AGAINST CANCERS AND RELATED METHODS
US2020087364A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2018-09-18 • Earliest publication: 2020-03-19
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

41.CD40 AGONIST ANTIBODY /TYPE 1 INTERFERON SYNERGISTIC ADJUVANT COMBINATION, CONJUGATES CONTAINING AND USE THEREOF AS A THERAPEUTIC TO ENHANCE CELLULAR IMMUNITY
US2020087370A1 • 2020-03-19 •
UNIV COLORADO REGENTS [US]
Earliest priority: 2006-05-03 • Earliest publication: 2007-11-15

A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen

combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.

42.B*44 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
US2020087363A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2018-09-17 • Earliest publication: 2020-03-19
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

43.PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN
US2020085943A1 • 2020-03-19 •
CUREVAC AG [DE]
Earliest priority: 2012-01-31 • Earliest publication: 2013-08-08
... provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the...

44.PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS
US2020085930A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2016-03-16 • Earliest publication: 2017-09-21
... or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions...

45.PHOSPHODIESTERASE INHIBITORS AND METHODS OF MICROBIAL TREATMENT
US2020085828A1 • 2020-03-19 •
MAVUPHARMA INC [US]
Earliest priority: 2016-12-22 • Earliest publication: 2018-06-28

Disclosed herein are methods and compounds for treating augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, also disclosed herein include methods of activating and enhancing the cGAS-STING response and use of an inhibitor of a phosphodiesterase for the treatment of a microbial infection.

46.REPLICATION-DEFECTIVE RECOMBINANT H9N2 AVIAN INFLUENZA VIRUS EXPRESSING HA OF H5 SUBTYPE
WO2020052035A1 • 2020-03-19 •
UNIV QINGDAO AGRICULTURAL [CN]
Earliest priority: 2018-09-14 • Earliest publication: 2019-01-04
... a recombinant virus particle. The virus particle can be used to prepare an attenuated vaccine.

47.IMPROVED LAMP CONSTRUCTS COMPRISING CANCER ANTIGENS
US2020087365A1 • 2020-03-19 •
IMMUNOMIC THERAPEUTICS INC [US]
Earliest priority: 2017-05-02 • Earliest publication: 2018-11-08
... provided as part of a multivalent vaccine containing two or more LAMP Constructs. The improved LAMP Constructs as described herein...

48.SLOW-CYCLING CELL-RNA BASED NANOPARTICLE VACCINE TO TREAT CANCER
WO2020056161A1 • 2020-03-19 •
UNIV FLORIDA [US]
Earliest priority: 2018-09-12 • Earliest publication: 2020-03-19

The present disclosure provides compositions comprising a liposome comprising a cationic lipid and nucleic acid molecules comprising a sequence of a nucleic acid molecule expressed by slow-cycling cells (SCCs). The present disclosure also provides methods of preparing an anti-tumor liposome composition. In exemplary embodiments, the method comprises (a) isolating SCCs from a mixed tumor cell population in accordance with any one of the presently disclosed in vitro method of isolating SCCs from a mixed tumor cell population, (b) extracting nucleic acid molecules from the isolated SCCs, and (c) mixing the nucleic acid molecules with a cationic lipid to make an anti-tumor liposome composition. The method of preparing an anti-tumor liposome composition in alternative embodiments comprises mixing at least one SCC transcriptome nucleic acid molecule as described herein with a cationic lipid to make an anti-tumor liposome composition. Tumor treatment methods are furthermore provided by the present disclosure.

49.RECOMBINANT MUMPS VIRUS JERYL LYNN 2 BASED VACCINE
HRP20200018T1 • 2020-03-20 •
CADILA HEALTHCARE LTD [IN]
Earliest priority: 2015-03-27 • Earliest publication: 2016-10-06
No abstract available

50.ANTIBODIES TO ANDES HANTAVIRUS, AND METHODS FOR USING SAME
US2020087381A1 • 2020-03-19 •
ICHOR BIOLOGICS LLC [US]
Earliest priority: 2017-03-22 • Earliest publication: 2018-09-27

This invention provides isolated human antibodies and recombinant proteins comprising defined heavy chains and light chains, wherein the antibodies and recombinant proteins neutralize Andes Virus with defined IC50 values. This invention also provides related pharmaceutical compositions, treatment methods and kits.

51.METHOD FOR HIGH THROUGHPUT PEPTIDE-MHC AFFINITY SCREENING FOR TCR LIGANDS
US2020088726A1 • 2020-03-19 •
IMMATICS BIOTECHNOLOGIES GMBH [DE]
Earliest priority: 2018-09-14 • Earliest publication: 2019-12-05
... composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The...

52.In vivo immunoimaging of interferon-gamma
AU2018321893A1 • 2020-03-19 •
UNIV WAYNE STATE
Earliest priority: 2017-08-23 • Earliest publication: 2019-02-28

Methods for in vivo immunoimaging including: (a) administering a labeled-antibody conjugate to a subject, wherein the labeled-antibody conjugate includes: an antibody that specifically recognizes and binds to IFN-γ, and a detection label conjugated to the antibody, wherein the detection label is a radionuclide tracer or tluorophore; and (b) detecting the presence of the radiolabeled-antibody conjugate in the subject in vivo by imaging. Embodiments of the present disclosure are directed to labeled-antibody conjugates and therapeutic radionuclide- antibody conjugates.

53.ABX196 for use in the treatment of bladder cancer
AU2018332046A1 • 2020-03-19 •
ABIVAX
Earliest priority: 2017-09-13 • Earliest publication: 2019-03-21

The present invention concerns the compound ABX196 and pharmaceutical compositions comprising it for use in the treatment of bladder cancer.

54.METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY
US2020087684A1 • 2020-03-19 •
UNIV PENNSYLVANIA [US]
Earliest priority: 2001-11-13 • Earliest publication: 2003-05-13

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

55.ANTI-DENGUE VIRUS ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF
US2020087383A1 • 2020-03-19 •
DCB USA LLC [US]
Earliest priority: 2017-05-22 • Earliest publication: 2018-11-29

Disclosed herein is an anti-DENV antibody, a pharmaceutical composition comprising the same, and uses thereof. According to embodiments of the present disclosure, the anti-DENV antibody comprises a heavy chain variable region and a light chain variable region, in which the heavy chain variable region comprises amino acid sequences of SEQ ID NOs: 1-3, and the light chain variable region comprises amino acid sequences of SEQ ID NOs: 5-7.

56.Anti-HSV gB monoclonal antibody or antigen-binding fragment thereof
AU2018323503A1 • 2020-03-19 •
KM BIOLOGICS CO LTD
Earliest priority: 2017-08-30 • Earliest publication: 2019-03-07

An anti-HSV monoclonal antibody or an antigen-binding fragment thereof, which is an anti-HSV gB monoclonal antibody specifically binding to the envelope glycoprotein B (gB) of herpes simplex virus (HSV) or an antigen-binding fragment thereof, contains a heavy chain variable region comprising heavy chain CDR1 having the amino acid sequence represented by SEQ ID NO: 3, heavy chain CDR2 having the amino acid sequence represented by SEQ ID NO: 4 and heavy chain CDR3 having the amino acid sequence represented by SEQ ID NO: 5 and a light chain variable region comprising light chain CDR1 having the amino acid sequence represented by SEQ ID NO: 6, light chain CDR2 having the amino acid sequence represented by SEQ ID NO: 7 and light chain CDR3 having the amino acid sequence represented by SEQ ID NO: 8.

57.METABOLIC LABELING OF BACTERIAL TEICHOIC ACIDS CELL WALL
US2020087703A1 • 2020-03-19 •
CENTRE NAT RECH SCIENT [FR]
Earliest priority: 2017-05-22 • Earliest publication: 2018-11-28

The disclosure provides a new method for the specific metabolic labeling of bacterial teichoic acids cell wall by modified choline and click chemistry, and its use in various applications such as bio-imaging, diagnostic, vaccination or bio-materials engineering.

58.TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER
US2020085967A1 • 2020-03-19 •
PHIGENIX INC [US]
Earliest priority: 2005-10-14 • Earliest publication: 2010-08-19

The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.

59.GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY
US2020085743A1 • 2020-03-19 •
UNIV NORTH CAROLINA STATE [US]
Earliest priority: 2017-06-02 • Earliest publication: 2018-12-06

Disclosed herein are glucose-sensitive drug delivery systems including polymeric shell encapsulating an active agent. Upon exposure to a sufficient concentration of glucose, the shell is ruptured, releasing the active agent for absorption.

60.PHOSPHORYLATED HEXAACYL DISACCHARIDES (PHADS) FOR TREATING OR PREVENTING INFECTIONS
US2020085850A1 • 2020-03-19 •
UNIV VANDERBILT [US]
Earliest priority: 2017-05-01 • Earliest publication: 2018-11-08

The present disclosure relates to phosphorylated hexaacyl disaccharide (PHAD) compounds, compositions, and methods for treating or preventing infections.

61.METHOD AND SYSTEM FOR OPTIMISING THE DELIVERY OF CONTENT TO MOBILE DEVICES USING MICROZONES AND MACROZONES
US2020092389A1 • 2020-03-19 •
CONOLLY NIGEL [AU]
Earliest priority: 2018-08-30 • Earliest publication: 2020-03-19

Herein is described a method and system for optimising the delivery of content to mobile devices using microzones and macrozones and their associated methodologies. The macrozone method reduces the amount of content transferred to mobile devices. The macrozone method simplifies the determination of relevant microzones. The macrozone method also reduces the communication required between server and mobile device. The microzone method simplifies calculations for determining proximity to locations and narrows the focus for delivery of information based on proximity. The microzone method combined with the macrozone method reduces the total calculations and communications required within the total system. The system is further optimised by using microtimes and microcategories. The creation and management of content relating to microzones, microtimes and microcategories is managed through a campaign management system. Users of mobile devices receive content that is relevant geographically and contextually; with a reduced impact on the mobile device's resources.

62.T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
AU2018326875A1 • 2020-03-19 •
AGENUS INC
Earliest priority: 2017-09-04 • Earliest publication: 2019-03-07

Provided are TCRs (e.g., TCRs that bind to MLL, e.g., TCRs that bind to an MLL phosphopeptide, e.g., TCRs that bind to an MLL phosphopeptide/MHC complex), cells and pharmaceutical compositions comprising these TCRs, nucleic acids encoding these TCRs, expression vectors and host cells for making these TCRs, and methods of treating a subject using these TCRs.

63.METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
US2020085823A1 • 2020-03-19 •
TOLERO PHARMACEUTICALS INC [US]
Earliest priority: 2018-07-26 • Earliest publication: 2020-01-30

including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).

64.HIV Antigens and Antibodies
US2020087382A1 • 2020-03-19 •

THERABIOL INC [US]
Earliest priority: 2013-02-28 • Earliest publication: 2014-09-04

The present invention relates to a method for reducing the occurrence and/or severity of viral infections. The method embodies procedures for expanding HIV from the blood of HIV antibody negative donors and deriving a non-infectious virus particle product that is antigenic. The procedures for deriving the antigenic, non-infectious virus particle product are optimally designed to maintain the integrity of the envelope proteins while maximizing the depletion of capsid proteins and RNA. The resulting virus particle product, when introduced into humans or non-human animals, enables the production of antibodies that target the natural envelope macromolecular structure that is required for infectivity. The present invention can be applied to producing virus stocks from the blood of HIV-seronegative donors, for deriving non-infectious virus particles that retain intact envelope proteins, for producing anti-viral antibodies, and for administering anti-virus antibodies to patients.

65.VACCINE CONTAINING CANCER CELLS INACTIVATED BY PHOTODYNAMIC TREATMENT WITH METAL-BASED COORDINATION COMPLEXES, AND IMMUNOTHERAPY METHOD USING SAME
EP3621629A1 • 2020-03-18 •
THERALASE BIOTECH INC [US]
Earliest priority: 2017-05-11 • Earliest publication: 2018-11-15
No abstract available

66.ASSEMBLY ACTIVATING PROTEIN (AAP) AND ITS USE FOR THE MANUFACTURE OF PARVOVIRUS PARTICLES ESSENTIALLY CONSISTING OF VP3
US2020087352A1 • 2020-03-19 •
DEUTSCHES KREBSFORSCH [DE]
Earliest priority: 2009-03-04 • Earliest publication: 2010-09-10
.../or fragment Z. The present invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use.

67.METHODS FOR ISOLATING, EXPANDING AND ADMINISTERING CANCER SPECIFIC CD8+ T CELLS
US2020087625A1 • 2020-03-19 •
CARSON DENNIS A [US]
Earliest priority: 2017-03-30 • Earliest publication: 2018-10-04

Methods to isolate and expand tumor specific CD8+ T cells, and the use thereof, are provided. Also provided are method of using TLR7 agonists.

68.COMPOSITIONS AND METHODS OF ENHANCING OR AUGMENTING TYPE I IFN PRODUCTION
US2020085782A1 • 2020-03-19 •
MAVUPHARMA INC [US]
Earliest priority: 2016-12-22 • Earliest publication: 2018-06-28

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, also disclosed herein include methods of activating and enhancing the cGAS-STING response and use of an immunogenic cell death inducer with an inhibitor of a phosphodiesterase for the treatment of cancer.

69.Combination therapies of hepatitis b virus (VHB)-infected individuals using parapoxvirus ovis (PPVO) and at least one further antiviral drug
AU2018327688A1 • 2020-03-19 •
AICURIS GMBH & CO KG
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

The present invention relates to new combination therapies of HBV-infected individuals using a Parapoxvirus ovis (PPVO) and at least one further antiviral drug, e.g., nucleoside inhibitors, such as Entecavir. The methods and combination products according to the present invention are safe and suitable for the induction of a functional cure in chronically HBV-infected patients.

70.2D ORGANOID FOR INFECTION AND CULTURE OF HUMAN DIARRHEA VIRUS, AND USE OF SAID 2D ORGANOID
US2020087617A1 • 2020-03-19 •
UNIV KEIO [JP]
Earliest priority: 2016-08-24 • Earliest publication: 2018-03-01

A 2D organoid for infection and growth culture of human diarrhea virus, obtained by: (1) obtaining a 3D organoid by three-dimensionally culturing a human intestinal epithelial stem cell, a human intestinal epithelial cell, or a tissue containing at least any of those cells on an extracellular matrix; and (2) dispersing the 3D organoid to prepare a single cell, and monolayer-culturing the single cell on an extracellular matrix to obtain the 2D organoid having a monolayer structure in which epithelial cells contain differentiated trophoblastic cells and goblet cells and configured as human intestinal lumen having a monolayer structure.

71.METHODS AND APPARATUS FOR A SELF CONTAINED EXPANDABLE PET CARRIER
US2020084995A1 • 2020-03-19 •
HAZOURI YEARY KIMBERLY [US]
Earliest priority: 2017-11-02 • Earliest publication: 2020-03-19

The present disclosure provides methods and apparatus to support transport of a pet in a self-contained expandable carrier. In some examples, the carrier may be worn by a user to support the pet in a proximate location. A pet carrier which may be worn may provide comfort to pet owners while they travel.

72.RNA Formulation for Immunotherapy
US2020085974A1 • 2020-03-19 •
BIONTECH RNA PHARMACEUTICALS GMBH [DE]
Earliest priority: 2012-03-26 • Earliest publication: 2013-10-03

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as

dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

73.Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
AU2020201602A1 • 2020-03-19 •
YEDA RES & DEV
Earliest priority: 2014-03-12 • Earliest publication: 2015-09-17

A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing- remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

74.VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER
US2020085947A1 • 2020-03-19 •
DARTMOUTH COLLEGE [US]
Earliest priority: 2012-09-07 • Earliest publication: 2014-03-13

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of VISTA, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as PD-1. For example, such methods and compositions may be suitable for preventing and treating colon cancer or another cancer. An exemplary VISTA antagonist, specifically, an anti-VISTA antibody, is demonstrated herein to activate an immune response against cancer cells in vitro and in vivo, thereby conferring protective anti-tumor immunity which decreased tumor burden. Additionally, an additive benefit was observed when a VISTA antagonist was used in combination with a second checkpoint protein antagonist, specifically, an antibody against PD-1 ligand (PD-L1).

75.IgE Antibodies for the Inhibition of Tumor Metastasis
US2020087413A1 • 2020-03-19 •
UNIV LELAND STANFORD JUNIOR [US]
Earliest priority: 2013-06-12 • Earliest publication: 2014-12-18

The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.

76.USE OF A VACCINE TARGETING A CRYPTIC TERT EPITOPE, FOR TREATING CANCER IN A HLA-A*0201-POSITIVE PATIENT HAVING A NON-IMMUNOGENIC TUMOR EXPRESSING TERT

EP3621638A1 • 2020-03-18 •
VAXON BIOTECH [FR]
Earliest priority: 2017-05-09 • Earliest publication: 2018-11-14
No abstract available

77.COMPOSITIONS AND METHODS FOR TREATING NRP2-ASSOCIATED DISEASES
US2020085925A1 • 2020-03-19 •
ATYR PHARMA INC [US]
Earliest priority: 2018-07-26 • Earliest publication: 2020-01-30

Provided are therapies, including standalone and combination therapies, for treating neuropilin-2 (NRP2)-associated diseases and conditions, which include the use of at least one histidyl-tRNA synthetase (HRS) polypeptide.

78.Bacterial extracellular vesicles
AU2018330322A1 • 2020-03-19 •
EVELO BIOSCIENCES INC
Earliest priority: 2017-09-08 • Earliest publication: 2019-03-14

Provided herein are methods and compositions related to EVs useful as therapeutic agents.

79.Extracellular vesicles from Prevotella
AU2018330323A1 • 2020-03-19 •
EVELO BIOSCIENCES INC
Earliest priority: 2017-09-08 • Earliest publication: 2019-03-14

Provided herein are methods and compositions related to

80.AQUEOUS POLYGLYCIDOL SYNTHESIS WITH ULTRA-LOW BRANCHING
US2020087454A1 • 2020-03-19 •
UNIV VANDERBILT [US]
Earliest priority: 2014-01-24 • Earliest publication: 2015-07-30

Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for a variety of applications, including, but not limited to, drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

81.PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE
US2020085913A1 • 2020-03-19 •
HANMI PHARM IND CO LTD [KR]
Earliest priority: 2015-09-24 • Earliest publication: 2017-03-30

Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also

provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

82.FIBERS COMPRISING POLYESTERAMIDE COPOLYMERS FOR DRUG DELIVERY
US2020087819A1 • 2020-03-19 •
DSM IP ASSETS BV [NL]
Earliest priority: 2012-10-24 • Earliest publication: 2015-08-27

The present invention relates to fibers comprising a polyesteramide (PEA) having a chemical formula described by structural formula (iv), wherein −m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9, −m+p+q=1 whereby m or p could be 0, −n is about 5 to about 300; (pref. 50-200), -Ri in independently selected from the group consisting of (C2-C20) alkykene or (C2-C20) alkenylene and combinations thereof; —R and R in a single backbone unit m or p, respectively, are independently selected from the group consisting of hydrogen, ()alkyl, ()alkenyl, (C-C)alkynyl, (C-Cio)aryl, —(CH2)SH, —(CH2)2S(CH), —CH2OH, —CH(OH)CH, —(CH2)NH3, —(CH2)NHC(—NH2—)NH2, —CH2COOH, —(CH2)COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH—CH2—CH(CH), (CH)2—CH—CH2—, H2N—(CH2), Ph-CH2—, CH—C—CH2—, HO-p-Ph-CH2—, (CH)2—CH—, Ph-NH—, NH—(CH2)3—C—, NH—CH═N—CH═C—CH2—; —R5 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, alkyloxy or oligoethyleneglycol, —R is selected from bicyclic-fragments of 1,4,3,6-dianhydrohexitols of structural formula (III); —R is selected from the group consisting of (C6-Cio)aryl, (GCeJalkyl, —R is —(CH2)4—; whereby a is at least 0.05 and b is at least 0.05 and a+b−.

83.COMPOUND COMPRISING AN AUTOANTIGENIC PEPTIDE AND A CARRIER WITH A MHC BINDING MOTIF
US2020085927A1 • 2020-03-19 •
FRAUNHOFER GES FORSCHUNG [DE]
Earliest priority: 2005-11-17 • Earliest publication: 2007-05-24

The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.

84.SULFONAMIDE ANALOGUES OF GALIELLALACTONE
US2020087274A1 • 2020-03-19 •
GLACTONE PHARMA DEV AB [SE]
Earliest priority: 2016-12-05 • Earliest publication: 2018-05-29

Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent.

85.Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof
AU2018325445A1 • 2020-03-19 •
ABBVIE INC
Earliest priority: 2017-08-31 • Earliest publication: 2019-03-07

Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs

86.CO-DELIVERY OF NUCLEIC ACIDS FOR SIMULTANEOUS SUPPRESSION AND EXPRESSION OF TARGET GENES
US2020085758A1 • 2020-03-19 •
BRIGHAM & WOMENS HOSPITAL INC [US]
Earliest priority: 2016-12-16 • Earliest publication: 2018-06-21

Nanoparticulate pharmaceutical formulations and methods for co-delivery of two or more species of nucleic acids for simultaneous suppression and expression of target genes in a cell, are provided. The nanoparticles encapsulate two or more nucleic acid species. The first nucleic acid suppresses expression of a gene or product thereof, e.g., inhibitory nucleic acid, such as antisense, siRNA, miRNA, Dicer siRNA, piRNA, etc. The second nucleic acid increases expression of, or encodes, an endogenous or exogenous protein or polypeptide, e.g., an mRNA. The first and second nucleic acid species simultaneously target or affect the same or different cellular processes within a cell including communication, senescence, DNA repair, gene expression, metabolism, necrosis, and apoptosis.

87.Binding molecules targeting pathogens
AU2020201525A1 • 2020-03-19 •
APO T B V
Earliest priority: 2012-06-26 • Earliest publication: 2014-01-03

Abstract A first aspect of the invention relates to the field of binding molecules targeted at pathogens. The present invention further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with 5 or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins. 12155998_1 (GHMatters) P98972.AU.2

88.PUMP SPRAY OR PRESSURIZED AEROSOL DEVICE WITH APPLICATOR ARM
US2020086097A1 • 2020-03-19 •
NANOMETICS LLC [US]
Earliest priority: 2016-12-19 • Earliest publication: 2020-03-19

A spray device for dispensing a product includes a canister, a wand attached to the canister by a ball joint, a manually actuatable valve connecting the canister to the wand for dispensing a product through a nozzle at a free end of the valve. The wand may be telescoping. Applicator attachments are provided for securing to the free end of the wand for varying the delivery.

89.DEVICE FOR TRANSDERMAL DELIVERY OF ACTIVE MOLECULES, USES OF THE DEVICE AND METHODS FOR PRODUCING THE DEVICE AND ITS COMPONENTS
US2020086102A1 • 2020-03-19 •
ALTERGON SA [CH]
Earliest priority: 2017-05-04 • Earliest publication: 2018-11-04

The object of the present invention is a device (1) for the transdermal delivery of active molecules. The device (1) comprises a support element (8) and a plurality of micro-needles (10) that protrude from a first surface of the support element (8), the support element (8) and the micro-needles (10) being both permeable to the active molecules. The device (1) further comprises a porous membrane (7) configured to be loaded with said active molecules, which lies on a second surface of the support element (8). Characteristically, the porous membrane (7) is configured to behave, from an optical viewpoint, as a Bragg mirror. Further objects of the present invention are the following uses of the device (1): for monitoring the release and/or the decay of the active molecules, for the optical control of the release of the active molecules and for the thermal control of the release of the active molecules. Lastly, an object of the present invention is the method for producing the device (1) for transdermal delivery of active molecules.

90.Compositions and methods for inducing apoptosis in anaerobic cells and related clinical methods for treating cancer and pathogenic infections
AU2018313719A1 • 2020-03-19 •
BROWN JOE
Earliest priority: 2017-08-07 • Earliest publication: 2019-02-14

The invention provides potent anti-cancer methods and compositions that employ novel glycome compounds exemplified by glyco-benzaldehydes that disrupt anaerobic respiration and trigger apoptosis in cancer cells. Additionally, the invention provides useful compositions and methods to treat viral and microbial infections, and for enhancing suppressed immune systems, including by disrupting alpha-N-acetylgalactosaminidase (nagalase) function and lov/ering circulating nagalase blood levels. In certain anti-cancer and immune enhancing methods and compositions of the invention glyco-benzaldehyde compounds, such as the plant-deri ved glyco- benzaldehyde helicidum, are employed, alone or in combination, to potently destroy tumors and c irculating cancer cells, and significantly prolong survival of cancer patients, including treatment-resistant Stage III and Stage IV cancer patients.

91.Crystalline forms
AU2018348161A1 • 2020-03-19 •
ARRAY BIOPHARMA INC
Earliest priority: 2017-10-10 • Earliest publication: 2019-04-18

Provided herein are compound of Formula I-IV and pharmaceutically acceptable salts thereof which exhibit rearranged during transfection (RET) kinase inhibition. In particular, provided herein are novel crystalline

forms of 4-(6-(4-((6-methoxypyridin-3-yl)methyl)piperazin-1-yl)pyridin-3-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula I), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula II), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-(6-methoxynicotinoyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula III), 6-(2-hydroxy-2-methylpropoxy)-4-(6-(4-hydroxy-4-(pyridin-2-ylmethyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Formula IV), and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, processes for making the compounds, and the use of the compounds in therapy. More particularly, the application relates to novel crystalline forms of Formula I-IV and pharmaceutically acceptable salts thereof useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

92.Antibodies to programmed cell death protein 1
AU2018330180A1 • 2020-03-19 •
AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC
Earliest priority: 2017-09-07 • Earliest publication: 2019-03-14

Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell.

93.METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA+ T CELLS
EP3623468A1 • 2020-03-18 •
LYMPHACT LYMPHOCYTE ACTIVATION TECH S A [PT]
Earliest priority: 2015-06-09 • Earliest publication: 2016-12-15

The present invention relates to novel methods for the isolation and the selective ex vivo expansion of Vδ2-TCRγδ+ T cells and to their clinical application.

94.USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS
US2020085892A1 • 2020-03-19 •
GUANGZHOU VIROTECH PHARMACEUTICAL CO LTD [CN]
Earliest priority: 2014-08-26 • Earliest publication: 2015-08-05

Disclosed is use of alphavirus in preparation of antitumor drugs. The alphavirus is M1 virus or Getah virus. In addition, the specific tumor types sensitive to abovementioned alphavirus treatment are further determined, so as to provide a safe and effective solution for antitumor drug administering schemes.

95.Heterocyclic compound and use thereof
AU2018312326A1 • 2020-03-19 •
TAKEDA PHARMACEUTICALS CO
Earliest priority: 2017-08-03 • Earliest publication: 2019-02-07

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I) : wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis treatment of narcolepsy.

96.Unmanned aircraft system with swappable components
AU2018308963A1 • 2020-03-19 •
ZIPLINE INT INC
Earliest priority: 2017-08-01 • Earliest publication: 2019-02-07

An unmanned aerial vehicle may include a fuselage and an anchor structure coupled to the fuselage and including a wing retention structure and a power module retention structure. The unmanned aerial vehicle may also include a wing releasably coupled to the wing retention structure, thereby coupling the wing to the fuselage, and a power module releasably coupled to the power module retention structure, thereby coupling the power module to the fuselage.

97.BEARING FOR A PISTON ROD BODY FOR A DRUG DELIVERY DEVICE, A PISTON ROD ARRANGEMENT AND A PISTON ROD BODY
EP3622988A1 • 2020-03-18 •
SANOFI AVENTIS DEUTSCHLAND [DE]
Earliest priority: 2012-05-30 • Earliest publication: 2013-12-05

The present disclosure concerns a bearing (18) for a piston rod body (19) for a drug delivery device (1). The bearing (18) has an axis (46) and comprises a first and a second surface (39, 20) which are spaced apart in the direction of the axis (46) and a third surface (40), wherein the third surface (40) connects the first and the second surface (39, 20), wherein an opening (41, 42) is provided in each of the first and the third surface (39, 40), and wherein the opening (41) in the first surface (39) is connected to the opening (42) in the third surface (40). Further, the present disclosure concerns a piston rod body (19) and a piston rod arrangement (12) comprising said bearing (18) and the piston rod body (19).

98.GRIFFITHSIN MUTANTS
US2020087359A1 • 2020-03-19 •
UNIV LOUISVILLE RES FOUND INC [US]
Earliest priority: 2015-02-10 • Earliest publication: 2016-08-18

The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.

99.SWELLABLE ADHESIVE NEEDLES
US2020086101A1 • 2020-03-19 •

BRIGHAM & WOMENS HOSPITAL INC [US]
Earliest priority: 2013-02-01 • Earliest publication: 2014-08-07

This disclosure relates to swellable needles that include a proximal end portion and a swellable distal end portion. Upon exposure to a liquid, the needles are configured to undergo a shape change from a first configuration in which the width of the needle is tapered from the proximal end portion to the distal end portion to a second configuration in which the distal end portion is more swollen than the proximal end portion. The swellable needles can be double layer swellable needles or single material swellable needles.

100.NOVEL PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES COMPRISING A COMPLEX OF A DOUBLE-STRANDED POLYRIBONUCLEOTIDE AND A POLYALKYLENEIMINE
AU2020201605A1 • 2020-03-19 •
BIONCOTECH THERAPEUTICS S L
Earliest priority: 2015-11-17 • Earliest publication: 2017-05-26

The present invention relates to compositions comprising particles, each of said particles comprising a complex of at least one double-stranded polyribonucleotide, such as polyinosinic-polycytidylic acid 5 [poly(:C)], and at least one linear polyalkyleneimine. The particles are also characterized by their monomodal diameter distribution and z-average diameter within specific ranges. The present invention additionally relates to use of said compositions as medicaments, in particular for the treatment of a cell growth disorder characterized by abnormal growth of human or animal cells, as well as to processes for the preparation of said compositions.

101.Method For Treating Cancer
US2020085868A1 • 2020-03-19 •
CHINA MEDICAL UNIV HOSPITAL [CN]
Earliest priority: 2018-09-17 • Earliest publication: 2020-02-26

The present disclosure relates to a method for treating cancer including steps as follows. A chemotherapy drug is administered to a subject in need for a treatment of cancer. Then a composition containing a plurality of chimeric antigen receptor expressing cells is administered to the subject, wherein the chimeric antigen receptor expressing cells expresses a chimeric antigen receptor specific to human leukocyte antigen G (HLA-G).

102.ANIMAL MODELS AND THERAPEUTIC MOLECULES
EP3622813A1 • 2020-03-18 •
KYMAB LTD [GB]
Earliest priority: 2009-07-08 • Earliest publication: 2011-01-13

The invention discloses methods for the generation of chimaeric human - non human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

103.Melanin antibodies and uses thereof

AU2018331430A1 • 2020-03-19 •
RADIMMUNE THERAPEUTICS INC
Earliest priority: 2017-09-13 • Earliest publication: 2019-03-21

Provided herein are monoclonal antibodies that specifically bind to melanin. The antibodies may be chimeric or humanized. Also provided herein are methods of use and methods of making the antibodies described. For example, the melanin antibodies may be used therapeutically to treat or prevent melanoma.

104.Thiazolopyridine derivatives as adenosine receptor antagonists
AU2018309265A1 • 2020-03-19 •
MERCK PATENT GMBH
Earliest priority: 2017-08-01 • Earliest publication: 2019-02-07

The invention relates to thiazolopyridine derivatives of the general formula I, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative or infectious diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.

105.MUTANTS DU VIRUS DE LA VACCINE UTILES POUR L'IMMUNOTHÉRAPIE ANTICANCÉREUSE
EP3621646A1 • 2020-03-18 •
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
Earliest priority: 2017-05-12 • Earliest publication: 2018-11-15
No abstract available

106.INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF
US2020085822A1 • 2020-03-19 •
NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LTD [HK]
Earliest priority: 2016-12-15 • Earliest publication: 2018-06-21

The invention provides a class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.

107.Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
AU2018345652A1 • 2020-03-19 •
CRITITECH INC
Earliest priority: 2017-10-03 • Earliest publication: 2019-04-11

Disclosed are combination therapy methods useful for the therapeutic treatment of cancer by combining local administration of compositions containing antineoplastic particles, such as taxane particles, with systemic administration of compositions containing immunotherapeutic agents. Local administration methods include topical application, pulmonary administration, intratumoral injection, intraperitoneal injection, arid intracystic injection.

108.ANTI-GARP PROTEIN AND USES THEREOF
US2020087404A1 • 2020-03-19 •
UNIV LOUVAIN [BE]
Earliest priority: 2013-08-01 • Earliest publication: 2015-02-05

The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.

109.LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS
EP3623361A1 • 2020-03-18 •
NOVARTIS AG [CH]
Earliest priority: 2013-12-19 • Earliest publication: 2015-06-25

This invention provides for a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein R1-R4, n and p are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

110.RNA ENGINEERED T CELLS FOR THE TREATMENT OF CANCER
US2020087659A1 • 2020-03-19 •
UNIV PENNSYLVANIA [US]
Earliest priority: 2011-09-16 • Earliest publication: 2013-03-21

The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.

111.COMBINATION OF IMMUNOTHERAPEUTICS AND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR TREATING LYMPHOMAS
US2020085839A1 • 2020-03-19 •
AYALA PHARMACEUTICALS INC [US]
Earliest priority: 2018-05-24 • Earliest publication: 2019-11-28

for treating lymphomas.

112.METHODS, APPARATUSES, AND SYSTEMS FOR CONTINUOUSLY INACTIVATING A VIRUS DURING MANUFACTURE OF A BIOLOGICAL PRODUCT
US2020087632A1 • 2020-03-19 •
BOEHRINGER INGELHEIM INT [DE]
Earliest priority: 2014-04-15 • Earliest publication: 2015-10-22

Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet,

an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.

113.INDIRECT HOMOGENEOUS MOBILITY SHIFT ASSAYS FOR THE DETECTION OF BIOLOGICS IN PATIENT SAMPLES
US2020088749A1 • 2020-03-19 •
PREC IBD INC [US]
Earliest priority: 2014-12-05 • Earliest publication: 2016-06-09

The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.

114.OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE
US2020087646A1 • 2020-03-19 •
UNIV NORTH CAROLINA CHAPEL HILL [US]
Earliest priority: 2017-05-31 • Earliest publication: 2018-12-06

The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to optimized polynucleotide sequences encoding Factor IX proteins, vector comprising the same, and methods of using these compositions to treat a bleeding disorder.

115.MEANS AND METHODS FOR PREVENTING AND/OR TREATING CARIES
US2020085727A1 • 2020-03-19 •
BASF SE [DE]
Earliest priority: 2004-09-10 • Earliest publication: 2006-03-15

Another aspect of the present invention is an analog or fragment of said microorganism which is thermally inactivated or lyophilized, wherein said analog or fragment retains the capability of specifically binding to Streptococcus mutans. In addition, the present invention encompasses compositions and additives for food, feed or drinks comprising the microorganism belonging to the group of lactic acid bacteria which specifically bind to Streptococcus mutans or an analog or fragment thereof. Moreover, uses of said microorganism or said analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing said compositions or food or feedstuff are provided by the present invention.

116.METHODS AND COMPOSITIONS FOR TREATMENT OF ZIKA VIRUS INFECTION
US2020085830A1 • 2020-03-19 •
BIOCRYST PHARM INC [US]
Earliest priority: 2016-03-06 • Earliest publication: 2017-09-14

The present disclosure is directed to methods and compositions that are useful in combating the spread of Zika virus infections, such as, but not limited to, methods and compositions for treating, preventing or suppressing a Zika virus infection in a subject. The methods comprise administering to the subject an effective amount of a compound of the disclosure, or a composition (such as a pharmaceutical composition) comprising a compound of the disclosure.

117.PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES
US2020085745A1 • 2020-03-19 •
TRANSLATE BIO INC [US]
Earliest priority: 2018-08-29 • Earliest publication: 2020-03-05

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.

118.COMBINATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA
US2020086139A1 • 2020-03-19 •
GENENTECH INC [US]
Earliest priority: 2012-08-07 • Earliest publication: 2014-02-13

This invention concerns methods of treating a patient diagnosed with glioblastoma comprising administering to said patient a therapy comprising an effective amount of an anti-VEGF antibody and a chemotherapeutic.

119.Anti-mesothelin antibody and antibody-drug conjugate thereof
AU2019272250A1 • 2020-03-19 •
REMEGEN LTD
Earliest priority: 2018-05-21 • Earliest publication: 2019-11-21

Disclosed is an MSLN-targeted antibody-drug conjugate (ADC). Also disclosed is a method for preparing the ADC. Also disclosed is a novel MSLN antibody or a functional fragment thereof, comprising an engineered heavy chain and light chain.

120.DATA MANAGEMENT UNIT FOR SUPPORTING HEALTH CONTROL
US2020090798A1 • 2020-03-19 •
SANOFI AVENTIS DEUTSCHLAND [DE]
Earliest priority: 2016-12-23 • Earliest publication: 2018-06-28

A data management unit for supporting health control and avoiding wrong dose suggestion, the unit including: a processor to provide a dose helper functionality with regard to a predefined medicament, a display, a data

input unit, a data storage, a clock unit adapted to determine the absolute time of a dose helper request received by the data input. The processor is adapted to initiate storing at least the time of a dose helper request that is outside the time range around the usual dose time in the data storage. The processor is further adapted to execute the dose helper functionality only if the time of the most recent dose helper request is within the dose time window around the usual dose time. The processor is further adapted to initiate sending a recommendation message for change of usual dose time and/or dose time window to the display.

121.DRUG DELIVERY DEVICE WITH DOSE KNOB CLUTCH
US2020086060A1 • 2020-03-19 •
SANOFI AVENTIS DEUTSCHLAND [DE]
Earliest priority: 2013-11-22 • Earliest publication: 2015-05-28

An assembly for a drug delivery device and an associated drug delivery device are provided. The device has a drug delivery device housing and a medicament contained in the drug delivery device housing. A clutch is established between the dose knob and the dial link to prevent inadvertent proximal axial movement of the lead screw away from the cartridge piston, which can lead to dosing inaccuracies.

122.EXPRESSION OF PTEN-LONG WITH OCOLYTIC VIRUSES
US2020085890A1 • 2020-03-19 •
OHIO STATE INNOVATION FOUNDATION [US]
Earliest priority: 2016-07-29 • Earliest publication: 2018-02-01

Disclosed are novel modified viruses comprising recombinant PTEN-Long and methods of using the same for treating cancer.

123.THERMALLY-POWERED COILED POLYMER FIBER TENSILE ACTUATOR SYSTEM AND METHOD
US2020088175A1 • 2020-03-19 •
UNIV TEXAS [US]
Earliest priority: 2012-08-01 • Earliest publication: 2014-02-06

Actuators (artificial muscles) comprising twist-spun nanofiber twist-inserted polymer fibers generate tensile actuation when powered electrically, photonically, chemically, thermally, by absorption, or by other means. These artificial muscles utilize coiled polymer fibers and can be either neat or comprising a guest. In some embodiments, the coiled polymer fibers actuator can be incorporated into an article, such as a textile, braid, clothing, smart packaging, or a mechanical system, and the coiled polymer fiber in the coiled polymer fiber actuator can have a stroke amplification factor of 5 or greater.

124.ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY
US2020085891A1 • 2020-03-19 •
SILLAJEN INC [KR]
Earliest priority: 2017-04-21 • Earliest publication: 2018-10-25

A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer.

125.METHODS FOR THE PROGNOSIS OF HIV-INFECTED SUBJECTS
EP3623813A1 • 2020-03-18 •
INST DINVESTIGACIO SANITARIA PERE VIRGILI [ES]
Earliest priority: 2018-09-17 • Earliest publication: 2020-03-18

The invention provides an in vitro method, kits, uses of said kits and of reagents, for determining the prognosis of an HIV-infected subject having an undetectable viral load in the absence of antiretroviral treatment (or of an Ellite Controler HIV-infected subject) by determining the expression level of at least one biomarker selected from the group consisting of Galectin-3-binding protein (LG3BP), α-1-antichymotrypsin (AACT), Ficolin-2 (FCN2), 14-3-3 protein zeta/delta (1433Z) and coagulation factor XI (FA11) in a sample from said subject, and comparing the expression level of said at least one biomarker with a reference value.

126.COMPOSITE BODY, pH-SENSITIVE COMPOSITION CONTAINING COMPOSITE BODY, AND METHOD FOR PRODUCING COMPOSITE BODY
EP3622967A1 • 2020-03-18 •
TERUMO CORP [JP]
Earliest priority: 2017-05-11 • Earliest publication: 2018-11-15

According to the present invention, there is provided a complex in which a carrier and a physiologically active substance are integrated, the complex being conveniently obtainable, having excellent efficiency for the integration of a physiologically active substance, and having a satisfactory membrane disruptive function promoting effect. The complex according to the present invention is formed by supporting a physiologically active substance on an aggregate of a pH sensitive carrier, wherein the aggregate is formed by aggregating under acidic conditions.

127.PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-I AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY
US2020085734A1 • 2020-03-19 •
BAYER PHARMA AG [DE]
Earliest priority: 2016-12-21 • Earliest publication: 2018-06-28

The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

128.CONSTRUCTS TARGETING PSA PEPTIDE/MHC COMPLEXES AND USES THEREOF
US2020087400A1 • 2020-03-19 •
EUREKA THERAPEUTICS INC
Earliest priority: 2015-07-22 • Earliest publication: 2017-01-26

The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a PSA peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

129.RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY
WO2020056424A1 • 2020-03-19 •
MEMORIAL SLOAN KETTERING CANCER CENTER [US]
Earliest priority: 2018-09-15 • Earliest publication: 2020-03-19
... modifiés ou recombinants, comprenant un virus de la vaccine Ankara modifiée (MVA) comprenant une délétion de E3L (MVAΔE3L) modifiée pour...), un MVA comprenant une délétion de E5R (MVAΔE5R), un virus de la vaccine comprenant une délétion de C7L (VACVΔC7L) modifiée ...

130.COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT, AND HIGH VISCOSITY LIQUID CARRIER MATERIAL
US2020085829A1 • 2020-03-19 •
DURECT CORP [US]
Earliest priority: 2013-03-11 • Earliest publication: 2014-10-16

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.

131.Methods of Treating Palmoplantar Pustular Psoriasis (PPP) Using IL-17 Antagonists
US2020085945A1 • 2020-03-19 •
NOVARTIS AG [CH]
Earliest priority: 2013-08-15 • Earliest publication: 2015-02-19

The disclosure is directed to methods, treatment regimens, uses, kits and therapies for treating Generalized Pustular Psoriasis (GPP). These methods, treatment regimens, uses, kits and therapies utilize, inter cilia, administration of an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. Additionally disclosed are improved methods for treating plaque-type psoriasis that utilize up-titration and down-titration of the IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, as well as modification of dose frequency. Further disclosed are methods of treating palmoplantar pustular psoriasis using the disclosed IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab.

132.METHODS OF DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE
US2020088724A1 • 2020-03-19 •
UNIV CALIFORNIA [US]
Earliest priority: 2016-10-25 • Earliest publication: 2018-05-03

Provided are methods of mitigating, reversing or eliminating in a subject one or more symptoms associated with cognitive impairment associated with amyloid deposits in the brain (e.g., olfactory dysfunction as a risk factor of dementia, mild cognitive impairment, Alzheimer's Disease) by detecting and targeting gram negative bacteria in the brain.

133.COMPOSITION COMPRISING B REGULATORY CELLS

US2020087624A1 • 2020-03-19 •
UNIV OXFORD INNOVATION LTD [GB]
Earliest priority: 2017-05-05 • Earliest publication: 2018-11-08

The present invention relates to an expanded population of human Breg cells having the phenotype CD19+CD73−CD71+CD25+TIM-1+ and methods for producing the cell population of the invention. The invention also relates to pharmaceutical compositions comprising the cell populations of the invention and their use in the treatment of immune-mediated disorders.

134.NOVEL TRF1 MODULATORS AND ANALOGUES THEREOF
EP3623370A1 • 2020-03-18 •
FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO [ES]
Earliest priority: 2018-09-13 • Earliest publication: 2020-03-18

Novel TRF1 modulators and analogues thereof.

There is provided compounds of Formula I, wherein R, R1, R2 and X have meanings written in the description. Such compounds are useful as TRF1 inhibitors and, for that reason, as medicaments, in the treatment of cancer, particularly high cancer stem cell cancer like glioblastoma and lung cancer, and can be also useful for the development of additional TRF1 inhibitors and increasing knowledge about TRF1 activity.

135.Methods for determining selectivity of test compounds
AU2018359500A1 • 2020-03-19 •
CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBH
Earliest priority: 2017-10-31 • Earliest publication: 2019-05-09

The invention relates to methods for determining the selectivity of a test compound and related methods such as methods for determining whether a subject suffering from cancer will respond or is responsive to treatment with a test compound or compositions comprising more than one test compound.

136.THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES
US2020085869A1 • 2020-03-19 •
NOVARTIS AG [CH]
Earliest priority: 2018-05-16 • Earliest publication: 2020-03-19

The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.

137.BIODEGRADABLE DRUG DELIVERY FOR HYDROPHOBIC COMPOSITIONS
US2020085958A1 • 2020-03-19 •
MEDINCELL [FR]
Earliest priority: 2012-06-27 • Earliest publication: 2014-01-02

A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

138.METHODS OF USING CYTOTOXIC T CELLS FOR TREATMENT OF AUTOIMMUNE DISEASES
US2020085871A1 • 2020-03-19 •
UNIV TENNESSEE RES FOUND [US]
Earliest priority: 2017-03-17 • Earliest publication: 2018-09-20

The present disclosure relates to methods of using engineered cytotoxic T cells comprising a recombinant vector construct that expresses a chimeric antigen receptor to reduce and/or deplete the number of B cells in a subject in order to treat autoimmune diseases, such as lupus.

139.MODULATION OF TRF1 FOR BRAIN CANCER TREATMENT
EP3623009A1 • 2020-03-18 •
FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO [ES]
Earliest priority: 2018-09-13 • Earliest publication: 2020-03-18

The invention provides TRF1 inhibitors and compositions comprising them for the treatment of a brain cancer, such as a glioblastoma, and particularly a glioblastoma multiforme (GBM). PI3K inhibitors can be among the TRF1 inhibitors used. The compositions can comprise more than one TRF1 inhibitor, being particularly advantageous that at least one of the inhibitors is a PI3K inhibitor and that at least a second possible TRF1 inhibitor present is selected from the group an RTK inhibitor, a MEK inhibitor, an ERK inhibitor, an HSP90 inhibitor, docetaxel and gemcitabine, because such compositions show a synergic effect. The invention also relates to a method for identifying compounds candidates to be used for treating glioblastoma or other cancers, which method is based on the identification of the compound as a TRF1 inhibitor.

140.Substituted imidazoquinolines
AU2018327414A1 • 2020-03-19 •
BIONTECH SE
Earliest priority: 2017-09-06 • Earliest publication: 2019-03-14

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

141.METHODS OF TREATING DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE WITH PROTECTIVE PROTEIN/CATHEPSIN A (PPCA)
US2020087704A1 • 2020-03-19 •
ST JUDE CHILDRENS RES HOSPITAL [US]
Earliest priority: 2011-08-31 • Earliest publication: 2013-03-07

Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with Alzheimer's disease. Such methods provide a lysosomal exocytosis activity profile comprising one or more values representing lysosomal exocytosis activity. Also provided herein, is the discovery that low lysosomal sialidase activity is associated with various pathological states. Thus, the methods also provide a lysosomal sialidase activity profile, comprising one or more values representing lysosomal sialidase activity. A lysosomal sialidase activity profile is one example of a lysosomal exocytosis activity profile.

142.IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS
US2020085872A1 • 2020-03-19 •
UNIV TEXAS [US]
Earliest priority: 2017-04-19 • Earliest publication: 2018-10-25

Provided herein are immune cells expressing antigenic receptors, such as a chimeric antigen receptor and a T cell receptor. Further provided herein are methods of treating immune-related disorder by administering the antigen-specific immune cells.

143.ANTI-TRANSTHYRETIN ANTIBODIES
US2020087386A1 • 2020-03-19 •
PROTHENA BIOSCIENCES LTD [IE]
Earliest priority: 2015-01-28 • Earliest publication: 2017-03-02

The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

144.ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF
WO2020052581A1 • 2020-03-19 •
EUCURE BEIJING BIOPHARMA CO LTD [CN]
Earliest priority: 2018-09-12 • Earliest publication: 2020-03-19

This disclosure provides an anti-TNFRSF9 (tumor necrosis factor receptor superfamily member 9) antibody, antigen-binding fragment, and the uses thereof.

145.2'-CHLORO AMINOPYRIMIDINONE AND PYRIMIDINE DIONE NUCLEOSIDES
US2020087337A1 • 2020-03-19 •
GILEAD SCIENCES INC [US]
Earliest priority: 2014-08-21 • Earliest publication: 2016-02-25

Provided herein are formulations, methods and substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus

infections, as well as methods and intermediates for synthesis of substituted 2′-chloro aminopyrimidinone and pyrimidine dione compounds.

146.End-to-end cell therapy automation
AU2018324180A1 • 2020-03-19 •
LONZA COLOGNE GMBH
Earliest priority: 2017-09-01 • Earliest publication: 2019-03-07

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

147.IMMUNOMODULATING CELL CIRCUITS
US2020085876A1 • 2020-03-19 •
SENTI BIOSCIENCES INC [US]
Earliest priority: 2017-03-17 • Earliest publication: 2018-09-20

Provided herein are methods and compositions for dynamically controlling and targeting multiple arms of the immune system. Some aspects provide mesenchymal stem cells (MSCs) engineered to produce multiple effector molecules. In some instances, each effector molecule modulates a different cell type of the immune system or different functions of a cell. Also provided herein are methods of using the MSCs to treat or alleviate symptoms of inflammatory bowel disease (IBD), for example.

148.ANTIBODIES TO IL-6 AND USE THEREOF
US2020087391A1 • 2020-03-19 •
ALDERBIO HOLDINGS LLC [US]
Earliest priority: 2007-05-21 • Earliest publication: 2009-12-03

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

149.Substituted imidazoquinolines as agonists of TLR7
AU2018329152A1 • 2020-03-19 •
BIONTECH SE
Earliest priority: 2017-09-06 • Earliest publication: 2019-03-14

The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

150.RESIDENCE STRUCTURES AND RELATED METHODS
US2020085736A1 • 2020-03-19 •
BRIGHAM & WOMENS HOSPITAL INC [US]
Earliest priority: 2014-06-11 • Earliest publication: 2015-12-17

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

151.Amylases, Nucleic Acids Encoding Them and Methods for Making and Using Them
US2020085070A1 • 2020-03-19 •
BASF ENZYMES LLC [US]
Earliest priority: 2003-03-06 • Earliest publication: 2004-10-28

In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars. In one aspect, the invention provides delayed release compositions comprising a desired ingredient coated by a latex polymer coating.

152.Ectonucleotidase Inhibitors and Methods of Use Thereof
US2020087310A1 • 2020-03-19 •
CALITHERA BIOSCIENCES INC [US]
Earliest priority: 2016-09-09 • Earliest publication: 2018-03-15

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

153.TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY
EP3623380A1 • 2020-03-18 •
MILONE MICHAEL C [US]
Earliest priority: 2013-03-15 • Earliest publication: 2014-09-18

The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a "KIR-CAR" which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

154.Cyclic di-nucleotides as stimulator of interferon genes modulators
AU2018323053A1 • 2020-03-19 •
BEIJING XUANYI PHARMASCIENCES CO LTD
Earliest priority: 2017-08-30 • Earliest publication: 2019-03-07

The present disclosure relates to a compound of formulae (I) or (II), or a pharmaceutically acceptable salt, a solvate, a hydrate thereof, a pharmaceutical composition comprising a compound of formulae (I) or (II), and use thereof, wherein various Markush groups are as described herein.

155.TREATING AND PREVENTING MICROBIAL INFECTIONS
US2020087660A1 • 2020-03-19 •
SNIPR BIOME APS [DK]
Earliest priority: 2018-04-30 • Earliest publication: 2018-09-27

The invention provides methods for treating or preventing microbial (eg, bacterial) infections and means for performing these methods. In particular, treatment of infections requiring rapid and durable therapy is made possible, such as for treating acute conditions such as septicemia, sepsis, SIRS or septic shock. The invention is particularly useful, for example, for treatment of microbes such as for environmental, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system. The invention also useful for the treatment of pathogenic bacterial infections in subjects receiving a treatment for a disease or condition, such as a transplant or a treatment for cancer, a viral infection or an autoimmune disease.

156.AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
US2020087296A1 • 2020-03-19 •
BEIJING ADAMADLE BIOTECHNOLOGY LLC [CN]
Earliest priority: 2017-06-13 • Earliest publication: 2018-10-26

the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

157.BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY
US2020087376A1 • 2020-03-19 •
NOVARTIS AG [CH]
Earliest priority: 2017-03-22 • Earliest publication: 2018-09-27

The invention provides compositions and methods improved CAR T cell therapies. Specifically, the invention provides cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CAR T cells.

158.Methods for inhibiting angiogenesis in a subject in need thereof
AU2020201633A1 • 2020-03-19 •
OMEROS CORP
Earliest priority: 2016-03-31 • Earliest publication: 2017-10-05

Abstract In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.

159.HDAC inhibitor in combination with immune checkpoint modulator for cancer therapy
AU2018330492A1 • 2020-03-19 •
4SC AG
Earliest priority: 2017-09-08 • Earliest publication: 2019-03-14

The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.

160.ANTIBODY-DRUG CONJUGATES AND USES THEREOF
US2020085968A1 • 2020-03-19 •
IMMUNOMEDICS INC [US]
Earliest priority: 2012-12-13 • Earliest publication: 2015-12-24

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard

therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.

161.Anti-TM4SF1 antibodies and methods of using same
AU2018323470A1 • 2020-03-19 •
ANGIEX INC
Earliest priority: 2017-08-28 • Earliest publication: 2019-03-07

Anti-TM4SF1 antibodies, and antigen-binding fragments thereof, are described that bind to an epitope on the ECL2 loop of human TM4SF1. Methods of use of said antibodies and fragments are also described, including for the inhibition of metastasis.

162.CBLB ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
US2020087653A1 • 2020-03-19 •
BLUEBIRD BIO INC [US]
Earliest priority: 2017-05-25 • Earliest publication: 2018-11-29

The present disclosure provides improved genome editing compositions and methods for editing a CBLB gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.

163.BROAD-SPECTRUM ANTI-INFECTIVE PEPTIDES
US2020087349A1 • 2020-03-19 •
UNIV NANYANG TECH [SG]
Earliest priority: 2015-06-25 • Earliest publication: 2016-12-29

Provided herein are anti-infective peptides and uses thereof. Such anti-infective peptides are useful against bacteria and viruses. Also provided herein are compositions comprising said anti-infective peptides.

164.Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
AU2018329741A1 • 2020-03-19 •
POSEIDA THERAPEUTICS INC
Earliest priority: 2017-09-08 • Earliest publication: 2019-03-14

Disclosed are composition comprising (a) an inducible transgene construct, comprising a sequence encoding an inducible promoter and a sequence encoding a transgene, and (b) a receptor construct, comprising a sequence encoding a constitutive promoter and a sequence encoding an exogenous receptor, wherein, upon integration of the construct of (a) and the construct of (b) into a genomic sequence of a cell, the exogenous reporter is expressed, and wherein the exogenous reporter, upon binding a ligand, transduces an intracellular signal that targets the inducible promoter of (a) to modify gene expression. Methods for introducing compositions into cells and the use of the resultant cells in adoptive cell therapies are also provided.

165.AFFINITY-OLIGONUCLEOTIDE CONJUGATES AND USES THEREOF
US2020088725A1 • 2020-03-19 •

ABVITRO LLC [US]
Earliest priority: 2015-09-24 • Earliest publication: 2017-03-30

Provided herein are methods and compositions for single cell characterization using affinity-oligonucleotide conjugates. Provided herein are methods and compositions for single cell charaterization using tetramer-oligonucleotide conjugates.

166.NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
US2020087313A1 • 2020-03-19 •
KARYOPHARM THERAPEUTICS INC [US]
Earliest priority: 2011-07-29 • Earliest publication: 2013-02-07

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I:

or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

167.PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
US2020087301A1 • 2020-03-19 •
INCYTE CORP [US]
Earliest priority: 2016-09-09 • Earliest publication: 2018-03-15

Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

168.ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
US2020085066A1 • 2020-03-19 •
SNIPR TECH LIMITED [GB]
Earliest priority: 2015-05-06 • Earliest publication: 2016-11-10

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

169.Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
AU2018318982A1 • 2020-03-19 •
OMEROS CORP

Earliest priority: 2017-08-15 • Earliest publication: 2019-02-21

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft- versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

170.Methods for treating conditions associated with MASP-2 dependent complement activation
AU2020201500A1 • 2020-03-19 •
OMEROS CORP
Earliest priority: 2015-11-09 • Earliest publication: 2017-05-18

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.

171.FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
US2020087379A1 • 2020-03-19 •
BIOVERATIV THERAPEUTICS INC [US]
Earliest priority: 2012-02-15 • Earliest publication: 2013-08-22

The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

172.Compounds for the Treatment of Bovine or Swine Respiratory Disease
US2020085779A1 • 2020-03-19 •
INTERVET INC [US]
Earliest priority: 2016-12-23 • Earliest publication: 2018-06-28

The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Ma. Victoria Guzmán Sánchez mguzman@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu
Rolando Ochoa Azze ochoa@finlay.edu.cu

FINLAY
EDICIONES